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Abstract 
Pressure to conduct off-label, unlicensed and compassionate use, which are 
hereafter summarized under the term nonlicensed drug use (NDU) is exerted 
onto health care professionals (HCPs) in times of situational therapeutic impasse. 
Liability, contractual and penal risks are present when treating a patient in a non-
licensed was. There is a gap of knowledge about institutional and governmental 
methods of resolution concerning off-label, unlicensed and compassionate use. 
Hypothesize is however, that strategies to manage off-label, unlicensed and 
compassionate use have evolved in different countries. The research problem of 
this thesis is thus to compare the effects of NDU on pharmaceutical legislation in 
selected industrial countries and to determine strategies brought forth by NDU. 
Furthermore, the development of a general regulatory approach to the manage-
ment of NDU is sought. A regulatory approach shall consider existing conven-
tions and means already available in the present regulatory world. 
Semi-structured qualitative interviews, comparison of laws, and literature re-
search i.e. triangulation, was the scientific methodology chosen to address the 
research problem. The study was undertaken in Canada, the U.S., U.K., Japan, 
France, Germany, Switzerland, Austria and the transnational E.U. 44 semi-
structured qualitative interviews were conducted with 47 selected representatives 
of different roles from five areas of interests and in each country. The emphasis 
of this comparison of the impact of NDU laid on terminology for NDU, supply and 
necessity of NDU, pharmaceutical promotion of NDU, legal responsibility for NDU 
and public policies related to NDU. Social legislation was not considered. 
Key findings from the survey included miscellaneous synonyms for NDU, multiple 
definitions for NDU and different classes of off-label, unlicensed and compassio-
nate use. Two important results from the current literature on supply and neces-
sity derived: There is a circumstantial need for off-label, unlicensed and compas-
sionate use, but isolated evidence suggested non-rational NDU intermittently. 
Furthermore, the comparison of laws showed legal obligations of physicians to 
perform off-label, unlicensed and compassionate use. Another outcome was 
proof of inappropriate off-label marketing on the part of MA holders (MAH). On 
the other hand, a demand for information on NDU on behalf of HCPs was 
present. Obtained results illustrated cross-liability for HCPs and MAH. Special 
use authorizations, which were recommended by interviewed representatives, 
were found. Pharmacovigilance in NDU was seen to be either intensified in the 
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scope of special use authorizations or else relied on routine adverse drug 
reaction (ADR) reporting. Finally, results demonstrated regulatory strategies of 
different efficiencies: In the E.U. for instance, incentives for new indications were 
(a) limited to one year or (b) restricted to (i) pediatrics or (ii) rare disorders. This 
was found to probably be insufficient, because a drug may be appropriate for 
multiple indications or much-needed in fields of medicine other than pediatrics or 
rare disorders.  
The absence of statutory terminology causes incoherent interpretation of NDU 
across the researched nations; harmonization is crucial for an effective concept 
development. There is a situational need for early access to unapproved treat-
ments. Denial of (nonlicensed) treatment is considered unethical. Databases to 
combat data shortage about NDU are operated intermittently in different settings. 
On the other hand, isolated evidence also highlights inappropriate marketing of 
NDU, which perhaps causes irrational NDU. Different effective regulatory strate-
gies are at hand for patient access to off-label, unlicensed and compassionate 
use of medications in the short term. If present, these so-called special use au-
thorizations are accompanied by drug safety measures exceeding customary 
ADR reporting and providing for pharmacovigilance, which otherwise would be 
absent. Special use authorizations define the liability and provide legal certainty. 
In the long term however, demand-driven approach to marketing authorization 
(MA), not neglecting the fact that a single drug may be appropriate in many indi-
cations, is crucial. Proposed solutions for an enduring management of NDU are 
firstly, the amendments of templates by competent authorities to include appro-
priate off-label use, secondly full MA of innovative MPs used compassionately 
and thirdly an amended German standard MA for essential unlicensed drugs.  
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1. Introduction 
The term ‘off label use’ is first mentioned by Higgins et al. in 1988.1 The concept 
of using a drug in a way different from the stated method on the label is however, 
long-established: On June 1st 1961 the first oral contraceptive, Anovlar®, is mar-
keted in Germany.2 An approved indication for application is menstrual dysfunc-
tion. It was if used for contraception, only to be prescribed to married women ac-
cording to the marketing authorization holder’s (MAH’s) information. To prescribe 
Enovid® only to married women is medically implausible. The drug’s marketing 
authorization (MA) did not correspond to science. 
Equal mechanisms of action can be effective in managing different conditions, 
i.e. menstrual dysfunction and contraception in the example given above. This 
leads to use of one drug in different therapeutic areas. MA need not have been 
granted. In our time the vascular endothelial growth factor inhibitor bevacizumabi 
for treatment of colon cancer is widely used “off label” in the treatment of wet 
age-related macular degeneration (AMD). Often, drugs are approved for a limited 
indication, while a wide range of possible indications is apparent. This is particu-
larly the case for newly approved drugs with a very limited approved indication. 
Use beyond a label becomes common practice and is subject to criticism. Com-
mon keywords of disapproval are: corporate responsibility of the MAH to apply for 
an MA, circumvention of the licensing process by the MAH through marketing 
methods, liability of health care professionals (HCPs) and patient safety. Sup-
porters of drug use beyond the product label presently bring forward ethical ar-
guments of situational drug supply gaps and medical assistance for patients 
without adequate treatment options.  
Lack of treatment options has led to emergency drug release long before off label 
use is first mentioned: The FDA is believed to have a compassionate use policy 
in place since the 1970s or before.3 The areas of controversy at that time were 
and still are patient exploitation and live-saving therapy in cases involving inves-
tigational AIDS drugs. There is, even nowadays, a circumstantial need for 
nonlicensed drug uses, such as in patients with diseases for which therapeutic 
options are exhausted or unavailable. On the other hand, compassionate use is 
dismissed as experiments in humans. 
MA is meant to ensure evidenced-based pharmacotherapy; absence of MA did 
however, not hinder use of drugs in the past: Records mentioning unlicensed use 
are found as early as 1975.4 Therapeutic approaches or medicinal products un-
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available in a patient’s country of residency are nowadays widely acknowledged 
through international media, targeting both HCPs and patients. Demand for a 
specific medicinal product (MP), which has not received MA in a certain country, 
is therefore stimulated more easily today than it was in the pre-internet era.N.16  
All three drug uses have been subject to thorough quantitative investigation: The 
research field of off-label, unlicensed and compassionate use, after this summa-
rized under the term nonlicensed drug use (NDU), is yet relatively new. It is also 
growing, as evidenced by the increasing number of papers on the subject. NDU 
has attracted much attention in pediatrics, oncology and neurology with regard to 
prospective and retrospective cohort studies. Research on NDU is focused on 
the incidences of NDUs and does not examine the impact on legislation. It is un-
explored as far as institutional and governmental strategies of resolution are con-
cerned. Legislation affecting decisions related to NDU has not been reviewed in a 
cross-national survey. Transnational laws regulating NDU of MPs and assuring 
drug safety and supply have not been compared and contrasted. Regarding 
NDU, regulation for product liability for the MAH has also not been compared 
internationally. Means of preventing circumventions of the licensing process have 
not been subject to scientific investigation. Neither legal definition for NDU has 
been searched for worldwide. Nor have experiences by authorities, societies and 
organizations with making rules regulating NDU been evaluated across national 
boundaries. A stocktaking of laws applying to physicians, hospitals, pharmacists, 
authorities and MAHs has not yet been performed. An assessment of the short-
falls in legislation and solutions for such has not been presented. Surveys into (a) 
deficiencies concerning drug supply in different therapeutic areas, the (b) neces-
sity and (c) conduct of NDU are absent. Criteria by which is it possible to extend 
indications in a simplified process have not been analyzed in the past. However, 
evidence from France and the U.S. suggests processes to be present. 
Hypothesize is set that strategies to manage off-label, unlicensed and compas-
sionate use have evolved and contribute to a safe and effective management of 
NDU. The research problem is therefore to compare different, national regulatory 
solutions brought forth by off-label, unlicensed and compassionate use. The main 
research aim is to develop a general regulatory approach to the management of 
NDU. The study focuses on nonlicensed use of human MPs. Veterinary MPs, 
medical devices, food supplements and cosmetics and their unauthorized use 
are not the subject of this study. The term “off label use” is assigned to a medica-
tion practice not indicated in the SmPC and prescribed as such by a physician. 
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Abusive misuse and unintentional, incorrect use were not regarded as off label 
use and therefore not assessed. It was necessary to not only pay attention to the 
terms and their synonyms, but also for similar concepts. Sources were only ex-
amined closely when associated with unlabeled drug use, which is anticipated to 
treat, identify or prevent disease or when conceptualizing off label use else wise. 
The term “unlicensed use” was assigned to the use of any product as a medicine 
that does not have a legitimate MA in the country considered, irrespective of the 
registration requirements in the country of origin. “Compassionate use” was also 
related to the use of active treatment investigational new drugs (INDs) in individu-
als or groups of patients not participating in a clinical trial. Compassionate und 
unlicensed use are also not restricted to the proposed area of application of a 
product. The primary focus of this study is health legislation affecting NDU. 
Health care law is defined as any pharmaceutical legislation and statutory provi-
sions on MPs and the following of regulations such as directives or guidelines. 
Selected aspects of medical law and professional codes of conduct were taken 
into consideration. Social legislation is not covered and the researched countries 
are U.S., Canada, U.K., France, Germany, Austria, Switzerland, Japan and the 
E.U. 
CURRENT STATE OF SCIENCE: RATES OF NONLICENSED DRUG USE The following 
review of the state-of-the-art of science aims at giving an updated overview of the 
multinational situation of nonlicensed drug use in different settings. There are 
conflicts in the literature concerning the percentage of NDU. Another major 
problem to overcome, when developing a general regulatory approach to the 
management of NDU, is its commonness in certain medical fields. The summary 
looks at off label, unlicensed and compassionate use, pediatric and oncological 
NDU in out- and inpatient care. 
Bücheler et al. finds off label use in Germany to account for 13.2% of 1.74 m pre-
scriptions by pediatricians from Baden-Württemberg, general practitioners and 
internal specialists in the first quarter of 1999.5 In some medical sectors, how-
ever, he finds off label use rates of up to 64%. Results by Schütz indicate that 
misoprostoli is used for induction of labor by 42% of researched physicians, and 
82.1% used misoprostoli for a practice period of more than two years. Nearly half 
(44.8%) prefer misoprostoli for induction of labor6 (N.B. oxytocin is licensed for 
induction of labor in Germany). A survey by Conroy et al. suggests that off label 
use is common in specialized pediatric care. Her results show that 41% of the 
patients in Germany did not receive prescriptions in accordance with the MA.7 
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Questioning an E.U. expert revealed that three compassionate use programs 
took place in Germany in 2007.8 Unlicensed use is partially measurable by the 
rate of MPs imported to Germany: Results from 1064 community pharmacies in 
19 out of 54 districts and cities in North Rhine-Westphalia for the second half of 
2003 reveal 10,729 import transactions (19,193 packages).9 In oncology care, the 
federal government suggests that 70%–80% of cases involve off label use.10 Esti-
mations (without empiric survey) imply rates of 56% and 90% for off label pre-
scriptions in pediatric inpatient and neonatal care, respectively.11 Results in psy-
chiatric hospitals confirm 20% off label prescriptions (additional 19% off label use 
probable) for 2001–2002 and 2% (additional 26% off label use probable) in 
2003–2004.12 SmPCs of some drugs require extra qualifications of the physician 
prescribing the MP, and so prescriptions issued by physicians without advanced 
training can be considered off-label: Lauktien reports that in an analysis of pre-
scriptions for controlled drugs, 17% of methylphenidatei scripts are prescribed by 
physicians who did not qualify.13  
Off label prescriptions occur at a rate of 20% to 50% in the E.U.14 An up-to-date 
list of compassionate use products15 is not yet available according to information 
provided by the EMEA, because surprisingly no decisions have been taken.16 
Data on unlicensed use in general in the E.U. is not available. In oncology units 
33% off label and 19% unlicensed use takes place according to European stu-
dies.17 In line with an announcement in 2005 by the European Commission, more 
than 50% of all drugs are prescribed to children on an off label basis.18  
There are no data in Japan on the incidence of off label use, compassionate use 
or pediatric NDU. A study by the Division of Clinical Trial Design & Management 
in the Translational Research Center of the Kyoto University Hospital in 2003 
reveal that 30% of anti-cancer treatments and 40% of the products of comple-
mentary oncology, standard products for American physicians according to ‘Cur-
rent Medical Diagnosis and Treatment – an easy-to-read Manual’, are not li-
censed in Japan.19  
The British Drug Safety Research Unit, a registered independent charity, finds a 
rate of 22% off label use in children.20 Their study on Foradil® (formoteroli) sug-
gests that 258 children, or 4.5% of the cohort, received the drug on an off label 
basis.21 Data on compassionate use in the U.K. is unavailable (as of 2007). An 
inquiry of the regulatory agency on January 25th 2008 revealed 704,812 notifica-
tions on record since January 2002.22 Data by Conroy et al. demonstrate that in 
pediatric oncology, every child was treated at least once in a way not in accor-
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dance with the drug’s license.23 A further study by Conroy et al. in children’s 
wards suggests that 109 out of 192 patients (84.5%) were assigned drugs not 
meeting licensing specifications.24 Of 205 prescriptions dispensed, 66 cases 
(32%) involve patients receiving a diverging dose or doses at diverging intervals, 
79 prescriptions (39%) are not suited for the patient with regard to his or her age, 
36 (17%) are used in another indication, and 24 (12%) are given via another 
route of application.  
In France, off label use is as frequent as 25% to 40% of the prescriptions in spe-
cific medical areas (not representative).25 The French expert N.34 (see Table 29) 
stated that each year, 200 products are granted an ATU (temporary use authori-
zation) by the AFSSAPS (agence française de sécurité sanitaire des produits de 
santé), and 20,000 nominative ATUs are issued every year. Temporary use au-
thorizations are ascertained statistically since 1994. From 1994 until 2006, 781 
drugs were used on ATU basis in oncology, infectious diseases, endocrinology 
and neurology. By February 1st 2008, eleven valid ‚ATU de cohorte’ were 
present.26 Data on unlicensed use is absent in France as of 2008. In 2001, a 
scientific analysis of the Vidal formulary (French National Formulary) 2000 ex-
plored pediatric information with regard to cytotoxic chemotherapy. At comple-
tion, 416 products qualified for cancer therapy; however, only 76 MPs remained 
after a) “drugs not to be used in children” and b) “drugs available on an ATU ba-
sis” had been excluded. As few as 20 out of 76 drugs were seen to provide pe-
diatric information classified as “satisfying”, 37 MPs were found to provide 
moderate information, and 19 unsatisfactory information. Out of 48 drugs pre-
scribed only to pediatric patients, only 14 are seen to have distinct pediatric 
indications. Pediatric information is found to be available for dosing in 27 cases 
and contraindications are available in 8 cases. Pediatric information for drugs 
commonly used in children is seen to be satisfactory in 23% of the cases, poor 
for 38% and unsatisfactory for 30% of all cases.27 In outpatient care, off label use 
in French children is estimated at 20%-30%; for inpatient care the rate is 67% 
and in neonatal and intensive care it is 90%.28 29 30 
As early as 1980, Erickson et al. published an analysis of the proportion of drugs 
that are “used in an unlabelled way” in the U.S. i.e. 46 out of 500 drugs in an 
outpatient clinic.31 Thompson et al. report an incidence of 7% (62 out of 951) off 
label use in a survey of drug orders from 1987 in university teaching hospitals.32 
Results of a Delphi-analysis judge 24 (39%) drug orders as reasonable and 10 
(16%) unsuitable. Consensus was not possible for 45% of the orders. Raybourn 
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et al. report a survey of women who were examined before the 14th week of 
pregnancy and who then gave birth to their child at a university hospital in 
Oklahoma: 22.6% (165 out of 731) women are found to have been treated off 
label in terms of the drug’s indication.33 In 2001, an estimated 150 m (95% 
confidence interval, 127-173 m) off-label mentions (21% of overall use) are 
present in the U.S.34 The Association of Community Cancer Centers report very 
frequent off label uses in the eighties.35 Another study at the same point in time 
reveals that one third of all patients in oncology receive a drug off-label. Another 
scientific investigation reports that 44 out of 46 drugs licensed for cancer 
treatment are prescribed off label at least once and more than half of all cancer 
patients (56%) receive an off label prescription at least once.36 Albuterol (a selec-
tive beta-2-adrenergic agonist) is an example of a commonly used off label drug 
for children that has pediatric disclaimers stating that “safety and efficacy has not 
been studied in children”.37 Three out of four prescription drugs marketed in the 
U.S. lack full pediatric approval in 1996.38 During the period 1997 through 2005, 
the FDA receives an average of 4.6 treatment INDs per year and approximately 
659 emergency INDs (INDs) per year.39 
In Canada, statistics on off label use, unlicensed use or NDUs in pediatrics or 
oncology are absent as well. A Canadian expert estimates that on average 300 
off label prescriptions are issued per year.40 30,000 special access requests per 
year are processed by Health Canada; thousands of requests are authorized per 
year.41 
A telephone survey in Austria finds that 115 (66.5%) patients receive a psycho-
tropic agent for an off label indication between 1996 and 1997.42 Quantitative 
studies on the incidence of compassionate use and NDU in oncology care are 
found neither for the inpatient nor the outpatient sector. According to the Austrian 
Society for Child and Adolescent Care, 50% of all drugs used in children’s wards 
(general medicine) and 90% of drugs in neonatal care are not licensed.43 Al-
though these figures may by careful judgment originally derive from the U.K. As 
to the import fraction of unlicensed use: 925 import declarations were registered 
at AGES PharmMed for 2006.44 
In a prospective study about unlicensed and off label prescriptions Di Paolo et al. 
provide evidence over a period of six months in Swiss university hospitals and 
the Children’s Hospital of Lausanne. Sixty patients aged 3 days to 14 years were 
included in the study, and 483 prescriptions were analyzed. More than half of the 
prescriptions (247; 51%) met licensing criteria, while 114 (24%) are classified as 
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unlicensed use, and 122 (25%) as off label use.45 Approximately 4500 requests 
and 3000 inquiries for special dispensation (“Sonderbewilligung”) led to an ap-
proval of 3197 requests in 2002 by Swissmedic with a view to compassionate 
use.46 Lambert’s study assessing the prescription behavior in a pediatric hospital 
in Basel in 251 pediatric patients analyzed 1,339 prescriptions and finds rates of 
46% off label and 10% unlicensed use. In summary, 79% of the children are 
treated in an off label or unlicensed way. There is no information available on 
NDU in Swiss oncology. Another study analyzes 1,033 drugs used in 2002-2003 
at the University Children’s Hospital of Basel, the Island Hospital of Bern, and the 
Children’s Hospital of Zurich; 296 active ingredients with pediatric information are 
found in the SmPCs.47 48 For 187 active substances (63.2%) a need for action is 
postulated by the authors, and 95 active pharmaceutical ingredients (APIs) 
(32.1%) require updates or further specifications of the SmPC in the Swiss For-
mulary. Eight active ingredients (2.7%) had claims for dosages in children but a 
pediatric pharmaceutical form is still crucial and 114 active substances (38.5%) 
require clinical trials on the safety and efficacy of age appropriate formulations by 
opinion of the researchers. 
Data are also available for countries that are not focus of this thesis: In the Neth-
erlands Schirm et al. finds a rate of 22.7% off label drug use in pediatric outpa-
tient care.49 The extent of off label and unlicensed use depends on the patients 
and the supply area.50 O’Donell et al. finds 58% of all Australian pediatric 
prescriptions are NDU.51  
This summary with a focus on the afore mentioned medical areas underlines the 
presumption that selected medical sectors are affected by NDU. However, re-
search activities have merely focused heavily on the incidence of NDUs espe-
cially in pediatrics and oncology. In fact, NDUs are assumed to also be common 
in other areas of expertise.52 More research is needed. 
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OBJECTIVE AND RESEARCH QUESTIONS Due to the commonness of NDU, its impact 
on legislation is expected to be considerable. The key objective of this study is 
therefore to contrast different regulatory strategies brought forth by off-label, unli-
censed and compassionate use. Another key aim is to design an approach to the 
management of NDU.  
The following key research questions are pursued in order to contrast legislative 
management in different countries: What are the legal definitions for NDU? 
Which surveys of deficiencies concerning first the drug supply in different thera-
peutic areas, second the necessity and finally conduct of NDU exist? Which laws 
regulate NDU in terms of drug safety and supply of MPs? Which laws apply to 
HCPs, hospitals, authorities and MAHs? What experiences with rules for NDU 
were made by authorities, societies and other organizations? How is liability for 
NDU regulated to the MAH? What legislation affects therapeutic decisions related 
to NDU? How can circumvention of the MA be prevented? Which criteria allow 
indications to be extended in a simplified application process while assuring drug 
safety? Which shortfalls in legislation are in place and how can they be over-
come? 
The purpose of this project extends beyond recording the current state of affairs, 
to suggesting a procedure as a proposal for solution. Information on off-label, 
unlicensed and compassionate use is reported to often be insufficient; risk for 
patients due to a lack of data are described. Rules for rational, well-founded 
pharmacotherapy outside or without product licenses are said to be crucial. The 
review, analysis and documentation of firstly the legal state in bordering coun-
tries, secondly literature research and finally qualitative research shall contribute 
to identification of solutions.  
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2. Methodology and Materials 
Triangulation i.e. use of two or more research methods in one study was 
achieved by using a combination of literate research, comparison of laws and 
qualitative research. While literature research and comparison of laws provides 
unrestricted information, new theories, confidential information and data that are 
either unpublished or inaccessible to the public could not be captured by a simple 
subject matter search. Reliance on qualitative research alone to identify strate-
gies was judged to be error prone. Data collection, research into legislative provi-
sions as well as qualitative interviewing and its analysis thus were combined to 
answer the research questions effectively. Triangulation ensured comprehen-
siveness and encouraged a reflexive analysis of the data.53  
2.1. Literature Research  
Literature on NDU was available from an in-house database (Reference 
Manager®) managed since November 2005. The data provided for derived from 
Medline®, HealthStar® and PsycInfo® by OVID, Embase® and SciSearch® (ISI 
Web of Knowledge).  
Medline® was found to be a National Library of Medicine (NLM, U.S.) database. 
It was seen to contain bibliographic details and abstracts of papers from more 
than 4600 medical journals in 70 countries. Subject areas were said to include 
medicine, dentistry, veterinary medicine, psychology, public health, biology, che-
mistry, biomedicine and biophysics. Medline® was estimated to be one of the 
largest literature databases in the world. HealthStar® by Ovid was seen to be 
loaded with literature from Medline® but was shown to contain own citations. 
HealthStar® was noted to specialize in public health, technology, administra-
tion/politics and scientific research in inpatient and outpatient care. For the in-
house database, papers from 1966 onward were selected from both Ovid-Med-
line® and HealthStar®. PsycInfo® was designed to locate 2000 journals and 
covers psychology, neuroscience, law, medicine and service to the community. 
Its searches were observed to cover the period from 1967 until today. Embase® 
by Elsevier (Amsterdam/The Netherlands) was found to retrieve 9.5 m publica-
tions (mostly European journals) and provide coverage of human medicine and 
biological sciences, focusing on drugs, active substances (pharmacology, effi-
cacy and adverse reactions), health economics and hospital affairs, environ-
mental medicine, ecology, forensic science and drug addiction. SciSearch® (ISI 
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Thomson Scientific, U.S.) was estimated to be the source for 23 m documents 
from 5900 international journals covering applied sciences, technology and medi-
cine.  
The MeSH®-Thesaurus (MeSH® = Medical Subject Heading) was the descriptor 
for Medline® and HealthStar®. The search strategy used to build the in-house 
database consisted of a search method by NLM (National Library of Medicine) in 
1992 termed ‘off label use of prescription drugs’. This method was outdated and 
was therefore changed. Keywords (a) “off-label”, “unlicensed use” and “compas-
sionate use” were consequently used. These keywords produced results specific 
to documents using the terms. In order to also identify documents not using the 
term “off label use”, yet referring to the same concept, (b) unlabel$i, unapprov$, 
nonapprov$, non-approv$ and in Medline from 2006 onward “not approv$” and 
(c) selected expressions from the MeSH®-Thesaurus were used. Results (b) and 
(c) were merged to (d). (a) and (d) were pooled and duplicates removed.  
The search strategy was adapted for use with other databases. Psycinfo offered 
a thesaurus from which further terms were included in the search. The search of 
Embase® allowed entry of only one keyword, therefore „off-label“, „unlicensed“ 
and „compassionate use“ were employed to locate relevant studies. SciSearch® 
was also subjected to this search strategy and further terms.  
The descriptors “off label use”, “unlicensed use” and “compassionate use”, “inpa-
tient”, “outpatient”, “language”, “country”, “full text” and “source of origin” were 
assigned to the record as a presentation of contents.  
2.2.  Research into legislative provisions 
Regulation on NDU was identified from in-house country reports. A systematic 
study of internet sources was carried out to determine relevant literature and 
other sources of information (surveys and studies on NDU regulation) for the 
country reports. Scientific, legal and administrative information was obtained in 
order to compare legislative frameworks and to provide an overview of concepts 
in each country. The possibilities and limitations of incentives as well as enforcing 
measures were acknowledged.  
Evaluation grids, a procedure in place for drafting laws, were used to classify 
approaches to unlicensed use of medications (see 3.6 Liability for nonlicensed 
                                                            
i $ stands for masking of terms to increase hits by including all grammatical forms and endings 
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drug use) [prohibition with an obligation to obtain a permit, obligation of notifica-
tion (general authorization, where necessary, subject to prohibition) (relatively 
autonomous legal framework) and prohibition (restrictive rules), subject to the 
possibility of authorization]. 
2.3.  Qualitative research in Regulatory Affairs 
Qualitative research was historically a research instrument in social and geo-
graphical sciences. In health research, qualitative questioning of patients was 
seen to be common. In recent times, it was introduced to pharmaceutical 
sciences.54 55 56 57 Qualitative approaches have until now, not taken into account 
regulatory requirements. In this thesis, methods in qualitative health research 
were adapted to the exigencies of the regulatory field (see 2.3.1 Experimental 
design).  
Qualitative research provided the interviewer with internal and otherwise inac-
cessible information. Nonlicensed drug use was seen to be a delicate topic e.g. 
for MAH due to liability issues and physicians because of the risk of recourse. 
Qualitative interviews were a valuable source of information for confidential data 
or intelligence not available in literature or else not accessible to the public. Un-
published information became accessible, reported or even provided directly to 
the researcher by the expert. Internal data and the level of knowledge and 
awareness in circles of experts was presented. 
The absence of legal definitions has caused available studies to be 
incomparable. Research nevertheless highlighted the extent of NDU in discip-
lines such as pediatrics, but failed to compare cross-national conventions, phar-
maceutical legislation and handling of risks. Qualitative methods served as a 
technique for describing law in comparison to effective practice. Experience from 
regulatory bodies, societies and associations, and hence shortfalls in practice, 
were surveyed with qualitative methods so as to overcome information difficulties 
and find lowest common denominators for definitions.  
Qualitative research was seen to be able to contribute to measurement through 
the construction of simple scales and aggregate measures (typologies and 
taxonomies, see figure 7)58 as well as the understanding of the reasons behind 
NDU. Qualitative interviews were described to be a precise source for description 
and explanation. Interviews supplied information on the national options and 
needs. Primary, practical perspectives were captured. Qualitative research was 
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found to provide a more rich and deep understanding of a situation.59 Descriptive 
statistics were judged to illustrate procedures accurately and to capture 
attributes. Everyday situations, daily practices and real life conditions can be re-
vealed.60 In particular, HCPs’ experience with present procedures provided an 
insight into the success or failure of solutions. Findings in literature and law were 
confirmed or disproved. Qualitative interviewing allowed for continued reviewing 
of the in-house country reports during the data collection period. This detail was 
particularly important for the determination of conventions for informal 
proceedings.  
A response to shifts and new questions is feasible in qualitative research.61 Pre-
vious knowledge gained during literature research allowed the interviewer to take 
up national subjects and discuss them in greater detail. Recent incidents were 
addressed, and it was possible to re-sequence interview topics and omit ques-
tions to avoid termination of an interview.  
A qualitative study design is generally explorative and based on multiple case 
reports. Research participants were seen to not be obligated to check boxes and 
select answers that may not represent their response adequately.62 Qualitative 
research met the requirement of a timesaving technique that persuaded chief 
executives to participate in the survey. Interviewees were found to be allowed to 
talk at length and think about items in their own terms.63 This explorative ap-
proach was essential to discover new theories and unpublished approaches to a 
problem. As a result of the qualitative survey, theories were developed from the 
observations.  
2.3.1. Experimental design 
Semi-structured interviews were selected due to their circumstantial flexibility 
whilst enabling comparison of covered topics. Yet, three major forms of inter-
viewing were seen to be known to qualitative research: structured, unstructured 
and semi-structured64 (see figure 1). Structured interviews were found to require 
the researcher to repeatedly ask the interviewee the same set of questions. With 
this form of interviewing issues identified after the interview topic guide was 
passed, were likely to not be picked up and in-depth discussion of a topic is not 
stimulated. Furthermore, response categories were proved to be limited. Struc-
tured interviews were best to be used when literature in a subject area is highly 
developed.65  
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Figure 1 Types of interviewing (University of the West of England Research Observatory66) 
Unstructured interviews did not require preset questions. They were predicted to 
be difficult to replicate (see section ‘Reliability’) and they have a greater potential 
for bias. Unstructured interviews were rejected because of the risk of poor com-
parability of findings.  
Semi-structured interviews were conducted using an interview topic guide that 
suggests questions to be covered by the researcher. Excursions were acceptable 
according to the researcher’s discretion. 16 in-depth, semi-structured interviews 
involved face-to-face interviews, and 28 were conducted by telephone (see Table 
30). Sturges et al. found that face-to-face and telephone interviews yielded simi-
lar information and depth provided that immersion in the environment is not ne-
cessary.67 Up to two interviewers questioned one expert. In other cases inter-
views were scheduled with two participants or an expert decided to consult a 
colleague, who then joined the interview. This multi-method approach was found 
to be admissible.68  
A semi-structured interview was seen to be best used when repeated interview-
ing is difficult and when there is more than one interviewer. Semi-structured inter-
viewing was chosen because a completely pre-designed questionnaire as in 
structured interviewing would have limited the in-depth discussion of topics. 
Semi-structured interviews were also used because they allowed probing and 
clarification, thus preserving standardization and comparison in contrast to un-
structured interviews. Interviewing was preceded by country reports to develop 
an understanding of NDU. An interview topic guide was developed following 
country reports based on research questions stated in the synopsis of the dis-
sertation. Semi-structured interviews allowed participants to raise issues and 
concerns.  
SELECTING PARTICIPANTS Six candidate roles were subject to recruitment in the 
eight countries and E.U.  
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Figure 2 Researched countries (black) and E.U. member states (dark grey) 
Representative roles from medical and pharmaceutical “societies”, industry, 
regulatory agencies, academia, and health insurance companies involved with 
NDU were invited to participate. Data collection was performed by in-depth inter-
views (t = 9 to 180 minutes) either face-to-face or by telephone survey at study 
sites in Germany, the U.K. and Austria. Qualitative sampling was meant to be 
purposive. Inclusion criteria for participation in this survey were (a) affiliation to a 
stakeholder, (b) point of contact to NDUs, and (c) willingness to provide insightful 
information.  
A wide range of interests and stakeholders was selected in order to represent 
possibly all current opinions. Six categories were chosen: (a) medical or 
pharmaceutical societies, self help groups, HCP associations, federations and 
confederations, (b) “regulatory” bodies, either a supreme or higher federal au-
thority and federal state authorities, (c) “MAH”s denoting pharmaceutical compa-
nies or enterprises or their federal associations, (d) health technology assess-
ment (“HTA”) bodies including institutes for cost benefit analysis, (e) “coverage” 
including health care insurance companies and services, and (f) “academia” in-
cluding research professors, lawyers and authors of scientific papers. Table 1 
was set up to illustrate the organizations wherefrom research participants were 
recruited. In “academia”, participants were authors of publications, which were 
identified in an interoffice database and contacted directly. All other organizations 
were first contacted not addressing a specific person. If two such approaches 
failed, publications on NDU by the institutions were checked for authors, who 
were then addressed personally in correspondence.  
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Category
 
COUNTRY  
Society Regulatory MAH HTA Coverage Academia 
Medical Pharmaceutical
GERMANY DLH AMK BfArM VfA, BAH IQWIG MDK University of Berlin 
AUSTRIA ÄKW AKW AGES PharmMed Pharmig HEK HV University of Innsbruck 
SWITZERLAND FMH Pharma Forum Swissmedic Interpharma BAG Santé Suisse University of Basel 
GB RCPLondon, BMA RPSGB MHRA ABPI NICE HCC University of London 
JAPAN JMA JPA PDMA JPMA NIPH NHI Keio University 
U.S. AMA APhA FDA PhRMA PCMA CMS Columbia University 
CANADA CPSO CPA Health Canada Rx&D CADTH CLHIA Dalhousie University 
FRANCE CNOM CNOP ASSFAPS LEEM HAS UNCAM Institut Gustave-Roussy 
E.U. EMA PGEU EC EFPIA EUnetHTA ESIP Not applicable 
Table 1 Recruitment by candidate roles and country of employment (see list of abbreviations for written out words) 
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Call 
 
COUNTRY  
Initial [N] Response [N] Appointments [N]
JAPAN  7 1 2  
CANADA 10  8  2  
U.S.  68  13 7 
E.U. 9  6 5  
SWITZERLAND 7  7  4  
U.K.  13  13  10  
GERMANY 31  15 9 
AUSTRIA 7  5  4  
FRANCE 9  4  2  
TOTAL [N] (%) 161 (100) 98 (61) 45 (28) 
Table 2 Participation 
Table 2 was created to illustrate the call report. In Japan, two acceptances but 
only one response was the result of a primary request for information on com-
passionate use in Germany to the department of Drug Regulatory Affairs at the 
School of Pharmacy of the University of Bonn by a Japanese delegation. This 
delegation was in return asked to participate in the qualitative interview in return. 
In North America, eleven written inquiries were forwarded to their destination via 
the U.S. Embassy in Frankfurt; only one letter was acknowledged in the tele-
phone follow-up. Two appointments for interviews were arranged in the follow up 
period. After this unsatisfying follow-up in North America, publications of the 
interoffice database were searched for experts, who were contacted by email if 
an academical directory provided contact information. A total of 119 publications 
were identified from the interoffice database for Canada and the U.S. For 57 ex-
perts, contact information was available in an academical directory. Eleven ad-
dresses were invalid. Three experts referred to other specialists. Five denied par-
ticipation. Five additional appointments were made. In the E.U., six experts re-
sponded to the initial inquiry, five participated. All experts responded in the U.K. 
und Switzerland; participation was good or sufficient respectively. Germany pro-
duced mediocre reaction and satisfying contribution. In Austria, six experts were 
interviewed on four occasions. A low rate of participation was obtained in France. 
A total of 47 experts was interviewed at 44 appointments (see Table 30).  
Countries cited in 3 Results and onward not being subject to the survey (i.e., Bel-
gium, Ireland and the Netherlands) originated from interviews with representa-
tives from the E.U. or research scientists working abroad who were referring to 
specific measures in their home countries.  
INTERVIEW TOPIC GUIDE The interview guide consisted of two sections (pharma-
ceutical and social law) and 15 domains of inquiry on the basis of research ques-
Methodology and Materials 
19 
 
tions: Determination of terms, reasons for off-label, compassionate and unli-
censed use, functional implementation, relevance, necessity, adequacy, regula-
tion, liability policies, scientific analysis, pharmacovigilance, scientific informa-
tion/continuous training, ruling/legislature, transparency/nescience, reality of 
health care and references/recommended further reading. 
The sequence of questions was conditional on the course of conversation. Inter-
views were conducted in German or English. 
RECRUITING PARTICIPANTS Participants were contacted by mail, email or tele-
phone (see Table 3).   
CALL 
COUNTRY  Initial consultation Follow up 1 Follow up 2 
AUSTRIA Email Telephone – 
U.K.  Email Telephone Telephone 
U.S.  Mail Telephone Email 
CANADA Mail Telephone Email 
FRANCE Mail Email – 
E.U. Mail Email Telephone 
JAPAN  Email – – 
SWITZERLAND Telephone – – 
GERMANY Mail Telephone Email 
Table 3 In the order in which interviewed: Contact to organizations and experts  
To increase participation, an allowance for special expenditures was offered; only 
one participant demanded remuneration for his efforts.  
2.3.2. Composition of focus groups 
Sixth parts of experts spoke per category, but a forth on behalf of academia (see 
figure 3). However, experts fitting two categories were assigned to the category 
matching the organization by which they had been contacted and whose views 
they were asked to take. 
 
Figure 3 Absolute values of candidates per category 
The category “coverage” includes “HTA” to merge pharmaco-economic interests.  
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SAMPLE SIZE AND NUMBER OF GROUPS The researched countries were selected 
based on available language skills and the official language in addition to the 
country’s membership in the E.U. or its status as an observer in the International 
Conference of Harmonization of principles as a minimum. Japan was exempted 
from the language criteria and included for attainment of scientific knowledge as 
few differences were expected within the E.U. Greater differences were expected 
trans-continentally. For similarity reason, Belgium and Ireland were excluded 
from the survey for identical reasons despite meeting language criteria, but Bel-
gian and Irish people interviewed on behalf of the E.U. and U.S. addressed Bel-
gian and Irish issues. Table 29, Appendix was set up to illustrate the distribution 
of experts per country. It is also the key to the lower index citations.  
 
Guidelines for sample sizes in applied research were found to be absent.69 Sam-
ple size in qualitative research was seen to depend on the homogeneity of the 
group, data quality and the accuracy of the area of inquiry. An assessment of a 
variation for instance was observed to require larger groups. On the other hand, if 
a population is homogeneous, objectives are narrow and a similar set of interview 
questions is asked, as few as 12 interviews may provide data saturation.70 In this 
study, the participants were homogenous: All had a university degree, filled simi-
lar positions and were acquainted with the subject of NDU; diversity in terms of 
genders and professions (physicians, pharmacists, chemists and attorneys 
amongst others) nevertheless led to desire for a larger sample. Sampling of one 
interview per category i.e. five per country was aimed at (Σ=45). Data saturation 
was calculated to prove the chosen sample size to be sufficient (Figure 2). 
The number of individuals expressing the same idea, content driven codesii and 
novel insights were exhaustive. This leads to data saturation. Guest et al. 
measured data saturation at the point from where no or little change to the codes 
was produced. Most of the hither codes were developed in the initial coding 
(British interviews); few new codes derived later on. Codes typically evolved at 
the beginning of a new country set due to national features. Guest et al. confirms 
that important codes in the early stage of analysis remain essential. Figure 2 was 
created to illustrate the code changes during analysis of the interviews within this 
study (for interview numbers see Table 29, Appendix). No changes to data-de-
                                                            
ii Keywords are applied to the textual data to dissect text into segments. Coding is naming 
segments of data with a label that categorizes, summarizes or accounts for a piece of data. 
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rived codes occurred after five out of nine i.e. British, Canadian, Japanese, Swiss 
and Austrian sets had been coded.  
 
Figure 4 Fifteen out of 47 interviews were accompanied by code changes 
Data quality was also related to the depth of information, the duration of the inter-
view and the purpose of participation. Depth of information was directly propor-
tional to the duration of an interview. Although two interviews continued for less 
than 20 minutes, but the content was included into the study, because, upon 
consideration, both interviewees made invaluable statements, which contributed 
to the understanding of NDU. Interviews lasted 50 minutes on average.  
The professional identity of the researcher was observed to play an important 
part and may provide for richer and more personal accounts.71 In the present 
study, interviews in company of a physician took the longest, followed by inter-
views in company of an approved drug information pharmacist, and sole ques-
tioning by the research pharmacist. Thus presence of higher professional identity 
lengthened interviews. Chew-Graham et al. confirms that interviewing GPs 
(general practitioners) is easier when a GP researcher is known to the respon-
dent.  
The purpose of participation was an expectation on the behalf of the interviewees 
to contribute to future legislation, especially in Germany. Despite single inter-
views possibly aimed at exerting influence, the sample is nonetheless broad 
enough to counterbalance interests. The data quality was additionally assured by 
careful standardization (see 2.3.1 Experimental design). 
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ENSURING RIGOR A scientifically accepted research protocol allowed multiple case 
studies, assuring (a) currency of information; (b) data reliability (see next section) 
and (c) validity (see section thereafter). Data collection for descriptive purposes 
and theory construction was reported to have to be possible.72  
Currency of information: All interviews were completed within a time frame of 19 
months. During the survey period, the important issue of bevacizumabi and rani-
bizumabi 73 moved into the center of attention of media. Interviews in Austria were 
completed before the topic became subject to daily press; the remaining inter-
views were completed after the controversy.  
After data retrieval with MAXQDA 2007 R270608-ENG (for Windows 2000, Win-
dows XP, Windows Vista). Belous, I., n.p., data description and theory building 
were accomplished by interpretation. Reoccurring themes were identified and 
analyzed. A topic was elaborated if it was not a direct subject of the question or 
project description but emphasized or represented a novel consideration. Certain 
patterns, such as approval procedures, notification requirements, etc., were 
searched for. Differences in country-specific attitudes were explored and con-
trasted (see Table 22). Descriptive processes contributed to the constructing of 
theories.  
RELIABILITY The semi-structured interview topic guide (see Appendix) assured 
standardized data collection; it was newly developed, piloted in Austria and vali-
dated by peers. Data collection was achieved by intensive questioning; audio 
records were transcribed verbatim using Transcriber 1.5.1 (for Unix systems (Li-
nux, Sun Solaris, Silicon Graphics) and Windows NT). Geoffrois, E; Libermann, 
M; Wu, Z., n.p. (see section ‘Validity’).  
However, reliability was seen to be the extent to which the investigation is free 
from unsystematic error. Reproducibility of results and freedom from bias was 
found to be crucial in qualitative research and best achieved by retesting and 
reassessing. The limited availability of representative roles in this research field, 
however, caused repeated questioning by a second observer to be unfeasible. 
Also, the rapid development of the NDU field (e.g., new sentences or amend-
ments to regulations in the area of interest or the NDU of bevacizumabi) did not 
allow assumption of consistency of opinion. The survey was therefore determined 
to be a current summary and can only provide an insight into strategies and opi-
nions of 2009.  
Because reliability was found to be defined as the likelihood of achieving consis-
tency of measurement, it is dependent on data collection methods and settings, 
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techniques of the data collectors, and interpretation of the data collection instru-
ments by respondents.74 Three data collectors performed the interviews, which 
were scheduled face-to-face or conducted via teleconference. The interviewer 
refocused the interview on the intention of a question if the participants’ interpre-
tation of the questions diverged from the preset purpose. Reliability was ob-
tained, established and maintained by increased training, multiparty modification 
of the interview topic guide, and a system of consultation for all scientists. 
VALIDITY, the extent to which qualities are captured, was tested by (a) face vali-
dation, (b) piloting of the interview topic guide, and (c) content validation. It 
should be pointed out here that structured interviews have been found to have 
higher validity than unstructured interviews.75 A semi-structured interview guide 
was described to provide a clear set of topics to be covered for interviewers while 
presenting reliable and comparable qualitative data.76 Nonetheless: 
(a) Face validity was shown to be measurable through research participants 
recycling the analysis and then refining it according to their reactions.77 
This process was piloted in Austria but then discarded due to 
confidentiality, intellectual property and secrecy concerns.  
(b) During piloting of the interview topic guide in Austria, qualities already 
identified in the country report were verified. For this reason the interviews 
were hereafter used to confirm or disprove literature findings.  
(c) Content validity was seen to be assessed by presenting the interview 
topic guide to peers for rating its validity. Nine lecturers were contacted 
and provided with a rating form (see Appendix). It was predetermined that 
a low rating would require amendments to the interview topic guide. 
These lecturers represented a cross-section of disciplines, and included a 
judge, a psychiatrist, a stakeholder (MAH), an oncologist, an executive 
(G-BA), a senior manager (CRO), a lawyer, a patient representative and a 
director (VDAK). Seven out of nine experts responded. Three assigned a 
high validity to the topic guide, three a satisfactory validity, and one a par-
tial satisfactory and partial low validity to the interview topic guide. 
RECORDING Written notes, minutes from memory and audio recordings were 
found to be the options for recording qualitative observations. In this study, all 
interviews were audio recorded with a Philips Digital Voice Tracer 7680 in order 
to reduce interview interference and to avoid loss of details. Written notes were 
kept to obviate data loss. The file format *.zvr was convertible to *.wav and ma-
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naged with Voice Tracer 2.2. Philips, n.p. Interviewees gave their oral consent 
prior to recording.  
TRANSCRIPTION All interviews were transcribed verbatim with Transcriber 1.5.1 
(for Unix systems (Linux, Sun Solaris, Silicon Graphics) and Windows NT). Geof-
frois, E; Libermann, M; Wu, Z., n.p. as well as proofheared with f4 3.0.3. dr. 
dresing & pehl GmbH, n.p. and USB-Footswitch f-pro. Interjections, repetitions 
and verbal errors were replaced by three full stops in squared brackets. All inter-
views were proofheared at least once by a second listener and forwarded to the 
interviewee to ensure correctness. Red highlighting marked words, which were 
not understood and, which required special attention. In three cases the record 
broke off and the interview was completed by minutes from memory. As a seen to 
be a standard procedure in qualitative research participants were sent a tran-
script of their interview, to amend within a given time frame. One participant ans-
wered questions in written form beforehand. Both the interview and written reply 
became subject to analysis.  
PRIVACY AND CONFIDENTIALITY Ethics of qualitative research deserved special 
attention. As the representative roles in this survey at the time occupied major 
positions, their identities should not be revealed. Numbers were assigned to all 
interviews. The experts’ organization was replaced by a corresponding ‘category’. 
The country of residence is assigned to each expert, rather than his home coun-
try. Passages in which experts declared statements to be off-record were unac-
counted for.  
QUALITATIVE CONTENT ANALYSIS Content analysis was performed for evaluation. 
Mention of legislation, preambles and publications was assessed in order to 
identify effects and to learn about their as-is state in a country. There, Interviews 
produced invaluable information, genuine insight into strategies and views from 
key decision makers and industry experts.  
Content analysis was seen to be a qualified methodology for drawing valid 
meaning from qualitative data and involves interpreting texts through coding (in-
dexing), classification and categories. It was found to allow comparative enume-
ration of reoccurring themes and evaluation as well as correlation of elements. 
Qualitative data analysis was performed in three steps: 
1. Data reduction, 
2. Data display and 
3. Conclusion drawing and verification. 
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Conventional, directed and summative content analysis were shown to be three 
research techniques used to interpret qualitative texts.78 Inductive analysis was 
observed to be used when no previous studies have dealt with the event. The 
researcher allows the data to define results without the use of predefined para-
meters or a pre-existing coding frame (ad-hoc codes). Deduction was to be used 
when the structure of analysis is parameterized on the basis of previous know-
ledge (conceptual codes). Summative analysis was designed to identify and 
quantify words and content of texts. All three techniques were combined to ana-
lyse the interview protocols.  
CAQDA (COMPUTER-AIDED QUALITATIVE DATA ANALYSIS) Graphical analysis was 
found to be time consuming when handling large quantities of data. With graphi-
cal procedures, a clear cut display of data was seen to be a challenge; retrieval is 
error-prone. Therefore, use of software to accomplish analysis was preferred. 
With computer-aided qualitative data analysis software (CAQDAS), text material 
was coded electronically allowing for fast coding, undemanding display and 
sound scientific retrieval of all statements on a subject and thus an overview. 
MAXQDA 2007 R270608-ENG (for Windows 2000, Windows XP, Windows 
Vista). Belous, I., n.p. was used to perform computer analysis. MAXQDA is a 
means for making the analysis process easier in terms of data management, and 
is indicated when dealing with large amounts of material.  
FEATURE
ENTITY  Quantity [N]
TEXTS  45  
N° OF EXPERTS  47 
CODES (CREATIONS) 191  
CODING (ASSIGNMENTS) 11364  
CODE SETS  31  
COUNTRIES  9  
CONTINENT SETS 3  
Table 4 Key parameters of the MAXQDA project 
In this study, 191 codes were developed. 11,364 assignments were made to 45 
texts from 44 interviews with 47 experts. Three sets of countries were built (North 
America, Europe and Japan), and 31 code sets were analyzed (see Table 4). 
The interviews were coded by one assessor between 16th and 31st of July 2008. 
Data retrieval was completed by August 22nd 2008. 
To assess the effects of identified laws in 3.5 Operating experience with 
provisions for nonlicensed drug use, segments coded “law” NEAR “feasibility” 
and “positive” as well as “negative” were retrieved for all countries (N=310). The 
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statements were narrated and verified or disproved with literature data and 
wording of law. 
The offer of information was put through a sub-investigation in 3.7 Circumvention 
of drug approval: Law on advertising. The code set “information” („second opi-
nion“, „initiatives“, „evidence“, “data”, “documentation”, “compendia” und “circula-
tion”) was analyzed. Commercial (e.g., „off-label.com“) and non-commercial as 
well as public and offers of information with restricted access were identified. 
2.3.3. Limitations to qualitative regulatory research 
The limitations of qualitative research were found to be well recognized. Amongst 
other potential nonconformities investigators’ internal persuasion was seen to 
possibly falsify conclusions. Integrity and criticality were therefore described to be 
represented through recursive and repetitive checks of interpretations and a re-
served presentation of findings.79 Good practice was seen to dictate that subjec-
tive processes be shared with the reader.80 Conflicts of interests, expected find-
ings, the process of forming outcomes, material provided to the interviewees and 
influence of the media on the investigator were therefore illustrated below: 
Conflicts of interests were not present with the investigator. She had no financial 
affiliations to pressure groups.  
EXPECTED FINDINGS Preceding knowledge on NDU was gained during a sympo-
sium in the spring of 2006 at the Bonn School of Pharmacy by the chair for Drug 
Regulatory Affairs. The researcher hence did not expect to find incoherent termi-
nology.  
PROCESS OF FORMING OUTCOMES British institutional guidelines, problem solving 
strategy for quality assurance beared problems of decentralized assessment and 
unequal management of patients, which led to early dismissal of this strategy. 
Second opinion procedures were not pursued due to time-intensity, problems of 
unequal treatment and high expenses. Research was soon focused on a) CPs, 
ensuring equal access for all patients and b) on the national management of 
risks, because problems for decentralized management of NDU were identified 
(DHCP-letters, batch recalls and important notification). Limitations of suggested 
improvements will also be discussed in 4 Discussion. 
MATERIAL PROVIDED TO THE INTERVIEWEES The interview topic guide was given to 
the interviewees with a letter of inquiry and the project description (see Appendix) 
enclosed in order to improve participation and demonstrate integrity. Only one 
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interviewee in Germany strongly referred to the project description. Citations of 
the project description were excluded from the analysis. 
INFLUENCE OF THE MEDIA ON THE INVESTIGATOR Recent topics e.g., bevacizumabi 
and ranibizumabi or the U.S. “Draft Guidance for the Distribution of Medical Jour-
nal Articles and Medical or Scientific Reference Publications on Unapproved New 
Uses of Approved Drugs and Approved or Cleared Medical Devices” were dis-
cussed in accordance with the methodology.  
Further common errors of qualitative research apart from subjectivity were found 
to include (a) the failure to legitimize research findings, (b) the generalization of 
findings beyond the sample and (c) failure to estimate and interpret effect sizes.81 
Techniques to avoid these errors were seen to include review, reclassification 
and reassessment by other members of the research group. Subjectivity was 
thus leveled in an interdisciplinary team. The presentation of two independent 
analyses anchors the discussion in an evaluation of the objectivity and reliability 
of actual qualitative findings.82 All interviews were presented to Dr. med. Christian 
Behles and Drug information pharmacist Petra Nies for independent evaluation. 
This final analysis of the impact of NDU on pharmaceutical law was presented to 
Dr. Christian Behles and Petra Nies for review and comparison. Discrepancies 
were discussed within the team.  
Furthermore, the validity of the results is limited to the researched countries. To-
tal response in the qualitative survey remained poor in Canada, France and Ja-
pan, with overrepresentation of the remaining countries. Grounds for underrepre-
sentation of countries were possible linguistic barriers or administrative hurdles. 
Misrepresentation as discussed in 2.3.2 Composition of focus groups may have 
caused academic issues such as patient supply, therapeutic freedom, research 
and access to treatment to have headed findings. Reason for overrepresentation 
of interest groups were probably a greater time-based flexibility along with an 
interest in research. However, interests and problems of all groups were dis-
cussed well-balanced. Two U.S. and one British expert assigned to the “aca-
demic” group had previously worked for the regulatory agency and discussed 
regulatory concerns in detail. Many experts from academia, especially in the 
U.K., also acted for societies, representing its interests and cooperating with the 
industry. All arguments were also assumed to be identifiable in counter-argu-
ments. Multi-professionalism and the interdisciplinary nature outweighed potential 
overrepresentation.  
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The methodology was standardized by the interview topic guide; however, 
presence of professional experience correlated, as shown in 2 Methodology and 
Materials, with prolonged interviews. Interview lengths were proportional to the 
interviewer’s previous knowledge. Legislation in all German speaking countries 
had unexpected similarities to each other and across the E.U. had unexpected 
differences; basic principles in all German speaking countries were particularly 
well known to the investigators. These analogies simplified but also lengthened 
discussion. In other countries, information content was always counterbalanced 
by triangulation. Taken together, potential limitations are minor.  
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3. Results 
3.1. Terminology 
Medication not licensed for use in humans (unlicensed use), drugs used outside 
the terms of their product license (off label use)83 or INDs used outside of clinical 
trials (compassionate use)84 are expressions, which are together referred to as 
‘nonlicensed drug uses’ (NDU) in this thesis. Double meaning, ambiguous no-
menclature and their spreading through international journals were assumed to 
cause complications in the (a) understanding across the world and (b) correct 
adherence of guidance. To give an example: Patients with brain metastases not 
participating in a trial give their informed consent for “off label use” of an IND to 
be designated for the “off-label” indication. Such drug use was more often re-
ferred to as compassionate use in this study, while off label use regularly was 
assumed to be the unlicensed use of a licensed medicine. Compassionate use is 
subject to more far-reaching measures than off label use in Germany. BfArM’s 
proposed requirements for compassionate use may have not be met by clini-
cians. Patient’s informed consent may be invalid. Therefore explicit and – in the 
internet era – internationally harmonized definition of technical terms is important 
for the effective development of guidance. Definitions must also be designed 
carefully, because they determine the extent of NDU that is regulated. For this 
reason this chapter is devoted to terminology, to attribution, and to itemization. 
Recurring patterns were identified and the suitability of the definitions was tested 
by applying the definitions to national conventions. A variance of understanding 
and a desire for an umbrella term were found. 
Use of an MP outside the terms of its license85 was only one of many possible 
definitions for off label use. Compassionate use was said to be the use of an IND 
in patients not participating in a clinical trial,86 while other authors said 
compassionate use was “widely understood to be the accepted use of a medicine 
either outside its license or before it is licensed by authorities for compassionate 
reasons”.87 Several authors regarded unlicensed use as the use of biological ac-
tive substances as MPs, the modifications of proprietary MPs88 or the use of pro-
prietary MPs without an MA valid in the country of consideration. Not only under-
standing but also designation of NDU varies. Table 5 displays designations, col-
lected throughout the three year period of the project, which conceptualize NDU 
(sorted by languages). There was no consistent terminology. 
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Types of Nonlicensed drug use 
Off label use Unlicensed 
use/medicines 
Compassionate use/access 
Nicht lizensierter Gebrauch Named patient use 
Nicht zertifizierter Gebrauch Single patient useiii 
Unapproved use Special access program 
(SAP) 
Usage out of labeling Extra-label 
(drug) use 
(ELDU) 
Parallel track/trial 
Extended Access Program 
(EAP) 
Off license use Individual patient use 
Not registered indications Named patient supplies 
Beyond label use Expanded/Early/Emergency 
access  
Non approved use Named patient pro-
gram/project 
Out of label use No label use 
Unlabelled use Unauthorized 
products 
Emergency drug release 
program (EDRP) 
Not in accordance with 
designation 
Use of MPs not 
(yet) licensed 
compassionate use pathway 
l’utilisation hors AMM médicaments 
sans AMM 
Usage compassionnel 
Table 5 German, English and French terms with similar concepts (not comprehensive) 
For off label use, three major definitions were present: post-licensing drug use 
outside the terms of the a) license89, b) labeliv 90 91 92, and c) indication93 94 95 96 97 
98. The “beyond label” definition was seen to be competitive with unlicensed use, 
as extemporaneous products and imported MPs also carry labels. The “not 
registered indication” perspective did not explain prominent off label uses e.g. (a) 
of iloprosti inhalation used in registered indication or (b) off label use in pediatrics 
but adult indication. Moreover, authors long have categorized off label use into 
indication, dose, age, route and contraindication levels.99 For these reasons the 
label and indication definition failed verification tests.  
Seven categories of off label use were identified in this study:  
1. Indication100 
2. Population101 
                                                            
iii ≠ single‐use instruments 
iv The term “labeling'” means all labels and other written, printed, or graphic matter (1) upon any 
article or any of its containers or wrappers, or (2) accompanying such article 
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3. Dose102 
4. Application103 
5. Contraindication104 
6. Qualification105 
7. Generic106 
Subtypes of off label use were distinguished (Table 7). Indication-based off label 
use was the use of a licensed drug to treat a different disease107 108 109 110 111 112 113 
114 115 116, entity 117 118 119 or stage (early, advanced/extensive, end/late). Popula-
tion-based off label use was in different gender-120 or age-groups121 122 123 124. Do-
sage-based off label use occurred in terms of different intervals,125 overdose/sub 
therapeutic doses and defiant duration (short- or long-term treatment). Off label 
use in contraindications126 included going against warnings and interactions.127 
Qualification-based off label use was where a drug should be prescribed by a 
specialist but was not.128 Generic off label use129 was again a result of cost 
saving attempts or mandatory generic substitution. Application-based off label 
use was the irregular administration of a licensed drug. Specifically, the “method 
of application” was seen changed, for example, suppositories applied re-
versely.130 Moreover, the “way of application” was observed to be altered, i.e. 
iloprosti inhaled as opposed to injected.131 132 Finally, the “type of application” was 
detected to have been changed, i.e., while iloprosti was systemically effective by 
both ways of application, intravitreal bevacizumabi suddenly had local action. 
Routes of application were therefore additionally subdivided by (a) the site of 
pharmacological action e.g. systemic or local and (b) site of administration for 
instance pulmonary, intravenously or rectal (Table 6). The mode of application is 
mentioned for completeness, but was not of importance for NDU.  
Site 
TERM of effect*
of 
application example 
METHOD OF 
APPLICATION  Identical Identical 
Reversed suppositories (systemic 
effect) 
MODE OF 
ADMINISTRATION Dissimilar Identical 
Hormone (systemic effect) vs. 
copper releasing IUD (local effect) 
WAY OF 
APPLICATION  Dissimilar Dissimilar 
Intravitreal (local effect) vs. 
intravenous (systemic effect) 
TYPE OF 
ADMINISTRATION Identical Dissimilar 
Inhalation vs. injection 
(systemically effective) 
Table 6 Application techniques (*systemic or local, IUD= intrauterine device) 
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It was detected that there are blurred boundaries between off label administration 
by a different route and unlicensed use. Galenic manipulation to an MP for it to 
be administered by a different route is legally judged to be “manufacture” e.g. in 
Germany according to § 4 para. 14 German Drug Act (AMG) and classified as 
unlicensed use in the U.K. Unlicensed use was often used synonymously with off 
label use. Iloprosti solution for example though not reformulated, was used pul-
monary as an inhalation; bevacizumabi injection solution was used intra-vitreally 
after dilution and refilling,133 thus affecting the product’s quality. Quality is deter-
mined by physical properties of a drug e.g. (§ 4 (15) AMG). Osmolarity and os-
molality of a medicine for instance was most probably not adequate for applica-
tion of the medicine into a different compartment. Also, bioavailability is untested 
in extemporaneous preparations.N.24 These observations led different ways and 
types of application to be assigned to unlicensed use, because off label use 
falsely leads to the assumption that a licensed pharmaceutical form will be used, 
of which quality is secured.  
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CLASS Variance  
MP/ active ingredient/ 
formulation MA Off label use 
INDICATION (ALSO 
DIFFERENT 
CLINICAL STAGE, 
ENTITY, 
TREATMENT 
REGIMEN) 
Disease Sandoglobulin® 
Guillain-Barré-Syndrome, Kawasaki Syn-
drome or idiopathic thrombopenic purpura 
with a high risk of bleeding 
Primary chronic-progres-
sive multiple sclerosis 
Form  
Genotropin®, 
Humatrope®  
Microsomia due to insufficient endogenic 
growth hormone production and children 
with microsomia due to Ullrich-Turner-
Syndrome or chronic kidney failure 
Microsomia due to Silver-
Russell-Syndrome or 
idiopathic microsomia 
POPULATION 
Age Sotaloli Adults Children 
Gender Duloxetini Women Men 
DOSE 
Interval Valette® 21 days + 7 day pause Continuous  
Excess/under usage Gentamycini Every 8 to 12 hours Once-daily 
Duration of treatment Dona® Six weeks Long term 
ROUTE 
Way*  Avastin® Systemic application Local application 
Method  Suppository Headlong Contrary wise 
Type*  Proleukin® i.v. Inhalative 
CONTRAINDICATED
Also warnings, interac-
tions Dobutaminei Heart failure Stress echocardiography 
QUALIFICATION No variance Methylphenidatei Specialist General practitioner 
GENERIC 
Cost saving/ mandatory 
generic substitution 
Omeprazoli 20mg 
Ratiopharm Antacid 
Eradication of 
helicobacter pylori 
Table 7 Examples of off label use (not comprehensive) *application in a different compartment represented a new dosage form and for this reason unlicensed use
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It was not only off label use that was understood miscellaneously or for which 
several circumscriptions were found. Compassionate use was found to be a term 
historically used by physicians to refer to the use of investigational drugs outside 
formal trial.134 N.40 On the other hand, two German authors argued that 
compassionate use was an individual treatment attempt, that expanded access 
was to be distinguished from compassionate use and that named patient use was 
related to the importation of MPs.135 Attorney N.46 stated that “in Germany, com-
passionate use is featured as (a) off label use, (b) unlicensed use and (c) state of 
emergency.” Originally, it was the supply of an IND by a sponsor for compassio-
nate reasons to responding, former participants after completion of RCTs says 
expert N.39. Expert N.41 verified that compassionate use bridges the supply gap 
for patients eligible for the new drug after positive outcomes in RCT and before 
MA. So far compassionate zse was seen to be unrestricted or performed post-
licensing, pre-licensing or else post-RCT. To further clarify this issue, programs 
meeting the compassionate principle were investigated more closely: In figure 5 
the special access program in Canada (SAP, sections C.08.010 and C.08.011 
Food and Drug Regulations) formerly known as emergency drug release program 
(EDRP), the ATU in France, U.S. treatment-, emergency- and single patient IND 
(regulated by 21 CFR 312.34 and 312.35), the E.U. compassionate use proce-
dure and the Swiss special dispensation are arranged on a regulatory timescale 
to depict at what point of time of drug development compassionate access has 
been granted in the past.  
Figure 5 Drug Release Programs on a regulatory timescale 
Simultaneously, the product’s identity and the number of patients were frequent 
criteria for compassionate use. In the US and France for instance, 
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compassionate treatment INDs and ATUs can be filed for a single patient, not 
eligible to the RCT or group of patients e.g. former participants in an RCT. Some 
compassionate use programs provide access to INDs, while others also regulate 
access prior to clinical investigation. Briefly, compassionate use was seen to be 
medication of active investigational treatment or unlicensed products and was 
broken down into: (a) the number of concerned patients, i.e., individuals (hence-
forth named patient use) and groups (hereafter referred to as expanded access), 
(b) the point of regulatory progress, i.e., as early as pre-CTA, post-CTA or post-
Phase-III etc. and (c) off-protocol (patients do not meet RCT inclusion criteria)136 
or in-protocol (patients meet RCT inclusion criteria). This parameterization was 
tested and verified with off label and unlicensed use.  
“Unlicensed use” means ‘all uses of a drug, which has never received a Euro-
pean Marketing Authorisation as medicinal for human use in either adults or 
children’.137 Expert N.7 reports that “the entire class of herbal remedies is unregu-
lated and therefore unlicensed by the FDA”. Unlicensed use was also said to be 
a synonym for off label use.138 139 The Guideline on conduct of 
Pharmacovigilance for Medicines used by the Paediatric Population was found to 
conceptualize unlicensed use, excluding extemporaneous products and including 
imported MPs.140 Choonara, Conroy and other authors gave (a) modifications to 
licensed MPs, (b) reformulated MPs, (c) biological active substances used as 
MPs, (d) novel MPs available as specials (see 3.2 Investigations into supply 
shortages of drugs and the necessity as well as procedure of nonlicensed drug 
use) and (e) imported MPs as examples of unlicensed drug use in the U.K.141 142 
143 Taken together, unlicensed use was predominantly separated from off label 
use and subdivided into the use of MPs, which were  
(a) formerly licensed (expiry, suspension or waiver),  
(b) seemingly licensed (extemporaneous products, shortage/supply shortfall) 
or  
(c) not yet licensed (imported MPs, biological active substances [BAS]).  
The definitions included MPs requiring registration, such as imported MPs and 
BAS, and even extended to extemporaneous products needing no approval. 
NDU statements from literature, legislation and expert questioning of different 
countries are summarized in Table 31 depicting criteria assigned to the expres-
sions. Where no definition was evident, “undefined” was assigned to a segment. 
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One concept of law was identified for compassionate use in the E.U. Though one 
intervieweeN.40 claimed that in the E.U. a legal concept was also passed for off 
label use. The guideline144 in question however, has no force of law and solely 
addressed pediatric pharmacy. Though compassionate use was undoubtedly 
regulated in European legislation, it was yet unknown to a number of intervie-
wees in the MSs (member states). To improve awareness of NDU, expert N.43 
suggested definition in professional codes of conducts; whereof HCPs are more 
conscious than of state law.  
In total, uniform international concepts were absent for all NDU. Mutual agree-
ment was present that off label use concerns licensed MPs and occurs post-li-
censing. No predominance was observed across the countries as to whether 
compassionate use is more associated with groups or individuals. For this reason 
both were assumed to apply. Compassionate use served as a superordinate 
concept for use of an active investigational treatment or unlicensed product be-
tween pre-CTA and pre-MA as well as off-protocol (patient[s] do not meet inclu-
sion criteria) and in-protocol (patient[s] admitted after recruitment closed). No 
consensus was seen in unlicensed use with regard to its validity only for MPs 
requiring registration or also for seemingly licensed products. Therefore it was 
implied that both was effective practice.  
The overall trends hence were: Off label use was described post-NOC and is 
limited to the point of variation of MA. In most cases, compassionate use was 
detected in parallel to clinical trials in a research setting. Unlicensed use was 
majorly associated with pre-RCT medication. All types of NDU have a predomi-
nant regulatory time segment in common. The legal impact of misunderstanding 
NDU and its legal consequences for medical practice suggested an accurate se-
paration of compassionate and unlicensed use. Unlicensed use was therefore 
assigned to any use of an MP prior to clinical investigation or any use for which 
MA was withdrawn, renounced or suspended. Compassionate use most likely 
displayed the use of ‘active treatment’ INDs while clinical trials take place or 
when a new drug application (NDA) was filed. These outcomes were plotted on a 
product life cycle (Figure 6). 
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Figure 6 A regulatory lifecycle  
As mentioned before, there was also a general tendency for all expressions to be 
assigned to certain patients, products and reasons. These designations are 
hereafter referred to as dimensions of NDU. The four dimensions of NDU were 
the  
(a) regulatory point of time (pre-RCT, post-RCT/pre-NDA, pre-NOC/post-
NDA),  
(b) addressees (e.g. groups, individuals or severely ill patients),  
(c) product classification (investigational, extemporaneous or proprietary) and  
(d) cause (e.g. lack of licensed options, intolerance of alternative products).  
To a certain extent, all NDUs were argued to apply to (c) severely ill patients and 
(d) by reason of inadequate alternatives. Off label use primarily had time (post-
NOC) and product (liable to labeling, licensing or indication) dimensions. For 
closer examination, it has to be repeated that off label use was interpreted nar-
rowly as ‘every prescription outside the label’ or read more broadly as off-license 
use (requiring authorization from the regulatory authority for the amendment by 
the MAH). Other authors merely interpreted any breaches of preset indication as 
off label use.145 The label, license and indication interpretations presupposed that 
labels, MAs and a field of indication are present with the product used off label. In 
Germany, if limited to indications off label use only referred to proprietary medical 
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products. Avastin® however, was reformulated to an extemporaneous product 
when used to treat age-related macular degeneration. The “indication interpreta-
tion” did not classify intravitreal bevacizumabi as an off label use, because ex-
temporaneous preparations have no range of application. Assuming “out of label 
use” as a legal concept in future, rules would be valid for large scale products, 
“chemists’ nostrums”, proprietary products, German standard admissions, INDs, 
extemporaneous formulations and small industrial scale products. Here, bevaci-
zumabi in wet AMD was an off label use. In contrast, “off-license” use does not 
relate to extemporaneous or small industrial scale products, but affects large 
scale products, “chemists’ nostrums”, proprietary products and German standard 
admissions. Thereby nomenclature became fail-safe.  
Compassionate use had time, addressee, product, and cause146 dimensions. It 
was frequently related to a period during or before drug development. Terminally 
or seriously ill groups of patients or individuals resistant to licensed treatment 
were commonly named as subjects for compassionate use. In association with 
cohorts, either (a) former volunteers who are supplied with the IND after the end 
of the clinical trial or (b) even new patients before licensure were compassionate 
cases. Individual patients are treated with INDs on a compassionate use basis, 
either because they are eligible for a RCT but recruitment is closed, or patients 
are treated outside the protocol because they do not meet inclusion criteria. The 
MPs used were active treatment forms of INDs or imported MPs. An overlap with 
regard to unlicensed and off label use was observed. Imported MPs were also 
used or severely ill patients were treated for lack of adequate treatment before a 
medicine was approved for a purpose in unlicensed use. The greatest bandwidth 
of understanding was detected for compassionate use across all countries. On 
the other hand, written down definition was obtained most often within temporary 
use procedures.  
Unlicensed use primarily had time and product dimensions. It was the use of me-
dication in the absence or presence of clinical investigation and product license. 
The MP did not have an MA and was (as in the case of imported MPs) or was not 
(with extemporaneous products) liable to registration. Jassal et al. reported that 
“[…] palliative care uses a number of drugs for indications or by routes that are 
not licensed by the manufacturer. In the U.K. such unlicensed use is allowed 
[…]”.147 The term unlicensed use was also assigned to the use of 
extemporaneous products,148 imported MPs149 and INDs.150 Twice in Germany 
and Switzerland, imported MPs were subdivided by origin, e.g., E.U. and third 
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party country or countries with similar versus incomparable pharmaceutical law 
(EEA, New Zealand, Australia, U.S. and Canada). Extemporaneous formulations 
sometimes included reformulated proprietary MPs and BAS. The superordinate 
concept unlicensed use was used to address issues common to all NDU.151 152 153 
Figure 7 gives a forecast for a potential consensus understanding of NDU, which 
was used as common denominator in the following chapters. 
Figure 7 Fragmentation of NDU into macro-, meso-, micro- and submicrostructure  
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3.2. Investigations into supply shortages of drugs and 
the necessity as well as procedure of nonlicensed 
drug use 
Methodical investigations into the supply shortages of MPs for the treatment of 
specific clinical pictures were not present in scientific literature. Nevertheless, 
there were reports on orphan MPs (OMPs), extemporaneous products and single 
APIs showing under-supply that has been present.  
Findings suggested a circumstantial need for off-label, unlicensed or compassio-
nate use under certain conditions.154 155 The aim of two studies, identified in the 
course of this project, was to determine whether NDU prescriptions were neces-
sary. According to a case presentation by Blumer, off label use of drugs in chil-
dren was appropriate and was suggested to may be necessary.156 Hanna et al. 
found that based on guideline definitions, appropriate off label use of IVIG was 
89% in Canada.157 In the opinion of the experts polled within this thesis, off label 
and unlicensed use were found to be necessary in children,N.6 N.9 N.21 N.23 N.24 N.28 
sometimes in cancer patientsN.26 and on occasion in adults with chronic 
diseases.N.27 Off label use was said to be beneficial and in the patient’s best in-
terest in child psychiatry.N.8 NDU were said to be required in obstetrics; the ne-
cessity of NDU was stated to be population-N.5 and case-dependent.N.32 In general 
practice, off-license use was judged to usually not be regarded as necessary.N.25 
Countries with a small population like Canada or Ireland were shown to not see 
all licensed products marketed and HCPs hence regarded NDU as necessary.N.2 
N.32 
Real patient access to OMPs was reported to be unsatisfactory in Europe in 
2007.158 A survey covered 22 OMPs authorized before the first of January 2006. 
Most OMPs (20 or 21 OMPs) had been available to patients in Finland, France, 
Germany, and Sweden. Between 15 and 19 OMPs had been obtainable in Aus-
tria, the Czech Republic, Denmark, Italy, the Netherlands, Norway, Spain, Swit-
zerland, and the United Kingdom. Iceland, Latvia, and Lithuania only had up to 
four OMPs accessible. According to the authors, the 180 day legal delay for 
placing orphan MPs (OMPs) on the market was not followed frequently. Inci-
dences of rare disorders per country did not correlate with the availability of 
OMPs. Unfortunately, the authors did not publish or explore whether and how 
OMP deficiency was overcome.  
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EFPIA also showed that MPs accessible to patients did not correlate with the 
number of MPs with MA in all countries, with the exception of Germany. EFPIA 
also reported several cases of reimbursement denied for new MPs licensed be-
tween January 1st and December 31st 2006 in its survey, though again none 
were reported for Germany.  
A number of non-OMPs have been reported to be unobtainable: Shortages of 
injectable furosemide and injectable prochlorperazine have been identified in the 
U.S. when marketing was discontinued.159 Intravenous immunoglobulin has been 
out of stock in the past.160 A shortage of urokinase developed in the U.S. in early 
1999.161 A shortage of raw materials in 2002 had a considerable impact on the 
availability of isoproterenol hydrochloride in the U.K.162 Recently (January 2009), 
a shortage of acetonitrile affected U.K. drug manufacture.163 There were, how-
ever, no accompanying surveys into how many patients required each MP or into 
how shortages were managed by HCPs. One therapeutic area was seen to be 
permanently affected by a lack of suitable medication: drugs of proven quality as 
well as adequate license were detected to be infrequent for pediatric patients.164 
Various drugs used in children were reported not to be offered in suitable liquid 
dosage forms.165 Liquid dosage forms were confirmed to have to be prepared 
extemporaneously using child-appropriate excipients. 
Undersupply of age appropriate MPs and necessity of age related NDU is there-
fore explored further. Using drugs developed for adults in children was observed 
to be challenging because formulations and dosages often were not suitable for 
young patients, though the development of age-based MPs for children was per-
ceived to be encouraged. Similar to children, seniors were classified heteroge-
neously. Age restrictions (for taxonomy see Table 8) and a lack of fluid prepara-
tions were reported to be major difficulties in pediatrics and gerontology. Elderly 
people were also said to require liquid formulations because of swallowing diffi-
culties and gavages. Until now, however, their need has only been discussed in 
terms of divisibility of tablets and handling of primary, secondary and tertiary 
packaging. Attempts to raise awareness in wards that solid preparations may not 
be mortared together and prepared for liquid administration illustrated further ge-
riatric needs. Pientka et al. suggested that physicians should determine the 
pharmacokinetic status of seniors individually and classify resilient (go-go), co-
morbid (slow go) and elderly who must receive customized treatment according 
to a physician’s professional judgment (no go).166 167 Lack of age-specific studies 
has caused MPs to have age restrictions both for young and elderly patients. The 
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elderly were also shown to make up the majority of carcinoma patients, but were 
proven to be a minority in clinical trials for cytostatic drugs.168  
Body 
 
MINORS 
ZAK 
medicines 
for 
children 
database 
ICH 
E11 FDA EMEA
Age
 
 
MAJORS [y] 
PRETERM n/a Preterm n/a <36w SENIORS 65- 74 
NEW BORN ≤ 27d 0-27d 
birth-
1m 0-27d ELDERLY 75- 79 
BABY 28d-11m 
28d-
23m 
1m-
2y 
28d-
23m 
AGED 80- 89  
INFANT 12-23m 
HIGHLY 
AGED 90- 99 
PRESCHOOLER 2-5y LONG LIVED ≥100 
CHILD 6-11y 2-11y 
2-
12y 2-11y 
ADOLESCENT  <12y 
12-
16/18y 
12-
16y 
12-
17y 
Table 8 Classification of infancy & seniority (d=days, m=months, y=years, n/a=not available) 
Among other causes, drug information and high insurance premiums were said to 
account for NDU: In the qualitative survey, expert N.37 claimed that 30%-40% of 
physicians used drugs off label because they did not know that a licensed alter-
native was available. This presumption was also the reason behind creating an 
approved children’s medicines database (ZAK) in Germany. The reverse case of 
licensed MPs being extrapolated to untested populations was seen to be met by 
the Beer’s listv in gerontology. However, only 51 out of 975169 MAH contributed to 
ZAK as of June 28th, 2008. Due to insufficient contributions, the database was 
confirmed to be no reliable source of information for the availability or absence of 
drugs licensed for use in children.170 Child protection and high insurance pre-
miums for pediatric studies were evidenced to be causal for the supply shortage 
despite maximum fixed sums, e.g., setting an upper limit to indemnifiability in 
Germany (§§ 86-89 AMG). Another cause or reason for the small number of 
children’s MPs in Europe was indicated to be the posterior registration process. 
Posterior registration caused licenses for treatments for the management of 
colds, herbal MPs, antibiotics, antihelminthic therapies and beta-sympatholytic 
suppositories to be cancelled. A sample survey, however, showed no intersection 
with an essential medicines list for children (EML-C) as listed by the WHO.  
                                                            
v list of agents to be avoided or used with extreme caution in elderly patients 
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On the other hand, MPs that are currently licensed for use in children were sug-
gested not to necessarily be suitable for the target group. For example, U.S. ex-
perts stated that certain drugs (e.g., ketorolaci) are licensed for use in newborns, 
although studies had never been conducted in the age group. Earlier period 
extrapolations did not mirror current levels of knowledge of these drugs and re-
quire reassessment. MA renewal was explained to be excellent: MA is valid for 
five years in the E.U. (article 24 Directive 2001/83/EC) and becomes invalid if the 
product is not marketed within the three years after approval or if the produce is 
not marketed for three consecutive years. However, there is only one renewal in 
the E.U. that is followed by, given periodic safety update reports (PSURs) and 
far-reaching no risk event, unlimited validity.  
Aside from these age groups another population, women of child-bearing age 
were said to have access to hardly any treatments which are demonstrably 
harmless in pregnancy. Even when licensed MPs are available, physicians and 
midwives were sometimes confirmed to use nonlicensed drugs (see 1 
Introduction). Although oxytocini is licensed for induction of labor, misoprostoli or 
a mixture of ricinus oil, apricot juice and sparkling wine were also being used to 
induce labor in addition to a number of methods assigned to drug misuse. While 
data to license misoprostoli for this indication was suggested to be promising, 
pharmaceutical companies were said to resent licensure because misoprostoli is 
known to be misused for abortion. A reluctance to license MP to use during preg-
nancy was reported even for essential drugs. Until May 2009, Tamiflu® and Re-
lenza® had not been licensed for use in pregnant women and nursing mothers. 
The literature hence gave evidence for the circumstantial absence of specific 
MPs. Several publications additional gave evidence for strategies to circumvent a 
lack of suitable MPs. Guidance supported importation (e.g., of Ritalin SR®)171 
and extemporaneous preparations as possible solutions for supply shortages. In 
Germany, extemporaneous formulations were associated with compassionate 
use and OMPs.172 Continued use of biological active substances or 
extemporaneous products was reported because of the costs of licensed, OMPs 
in the U.K. by Nunn.173 However, extemporaneous preparations (N.B. 
bioavailability untested) were exclaimed to only be used if no alternative option is 
present.174 In the long term and in order for patients to benefit from R&D, MA was 
explained to be necessary.175 Furthermore, chances to overcome the shortage of 
drugs were firstly incentives and duties present for orphan or pediatric MPs and a 
supplementary indication (see 3.8 Criteria for simplified variation while assuring 
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drug safety: Incentives and duties), secondly the much-discussed compulsive MA 
(not discussed for property right reasons) and finally this thesis identified the 
German standardized MA (§ 36 AMG Standardzulassung)176. Standardized MA 
was suggested as a way to overcome refusals of licensing by Zapf.177 While 
forfeiting a patent and meeting formal requirements are preconditions, the MPs 
were indicated to be available cost effectively and at a high quality standard. 
Negative assessment reports could potentially suspend unsafe medications in 
the long term. 
In absence of a systematic, cross-country research into the strategies to over-
come situations when patients are requiring MPs missing an MA, legislation af-
fecting nonlicensed drug use in the selected countries was identified in this 
chapter:  
U.K. “Except in accordance with a license […] no person shall […] (a) sell, supply 
or export any MP […]” (§ 7 (b) Medicines Act 1968) in the U.K. § 13 gave an ex-
emption for “the importation of a medicinal product where it is specially imported 
by or to the order of a doctor or dentist for administration to a particular patient of 
his” and § 10 (extemporaneous products) from these requirements. The importa-
tion of MPs was seen to be subject to an obligation of notification by wholesalers 
in accordance with the Medicines for Human Use (Manufacturing, Wholesale 
Dealing and Miscellaneous Amendments) Regulations (SI 2005/2789) in the U.K. 
The importation was to proceed unless the MHRA informs the wholesaler within 
28 days that it objects to importation. MHRA informs if there were concerns about 
the safety or quality of the product, or when an equivalent licensed MP was 
available and no 'special need' for the supply to an individual patient was 
apparent. Schedule 1 of the 1994/SI 3144 provided details on the exceptions for 
„named patient use“. The MHRA also published a guidance note on the supply of 
unlicensed medicines.178 Standard 12 of the Department of Health Medicines 
Management in the National Health Service (NHS) hospitals framework specified 
that guidelines should […] be in place for unlicensed medicines use […].179 
Examples of these guidelines are outlined in the following paragraph.  
Off label and unlicensed use was managed variably from trust to trust within the 
NHS.N.22 180 181 182 183 Extra quality assurance procedures on unlicensed products 
were present in secondary care;N.21 the Royal College of Paediatrics and Child 
Health provided the model patient information leaflets (PILs) (not restricted to 
inpatient use).N.24 Some trusts published internal request forms.184 185 186 Others 
categorized unlicensed MPs or off label use of licensed MPs,187 e.g., as a traffic 
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light scheme.188 189 The Liverpool Women’s NHS Foundation Trust also published 
decision trees, PILs and a documentation system190 as suggested by medical 
societies such as the RPSGB,191 who issued legal considerations.192 A list of MPs 
and established off label uses was enclosed in some guidelines193 and the NHS 
Fife published an online database amounting to 246 unlicensed MPs on May 6th 
2009.194 Formalized collection of information on NDU was also conducted (a) in 
the Birmingham Hospital’s Database to Manage Use of Unlicensed Medicines195 
and (b) nationwide in the BNF-C (British National Formulary for Children).N.21 
Table 9 summarizes the cited guidance’s properties.  
 
CONTENT 
 
 
 
 
NHS TRUST E
xp
la
na
to
ry
 
no
te
s 
R
eq
ue
st
 fo
rm
 
C
at
eg
or
iz
at
io
n 
D
ec
is
io
n 
tr
ee
 
Le
ga
l 
co
ns
id
er
at
io
ns
 
Li
st
 o
f 
ap
pr
ov
ed
 
m
ed
ic
in
es
 
PI
L 
FIFE X X X* - X - - 
GREENWICH X - X - X - - 
MORECAMBE X - - - - - - 
SOMERSET X - - - - - - 
PENNINE X - X - - X - 
YORKSHIRE X X - - X X - 
DUDLEY 
GROUP X X - - - - - 
SCOTTISH 
QUALITY 
GROUP X X X - X - - 
BRIGHTON 
AND HOVE X - - - X - - 
LOTHIAN X - X* - X - - 
LIVERPOOL X X X X X - X 
LONDON X X X - - X - 
Table 9 Details of selected British guidance (*traffic light scheme, x= present, –= absent) 
CANADA MA was seen to be regulated in C.01.014 [Drug Identification Number 
(DIN)], with the importation of MPs being subject to C.01.014.1 FDR: “[…] in the 
case of a drug to be imported into Canada, the importer of the drug may make an 
application for a drug identification number (DIN) for that drug […]”. Once a drug 
has been approved, the Therapeutic Products Directorate issues a notice of 
compliance (NOC), which permits the manufacturer to market the drug in 
Canada. Several countries as we will see later, insist on an MA before importa-
tion of MPs. 
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The Special Access Program (SAP), originating from the emergency drug release 
program (EDRP), was seen to allow access to non-marketed drugs in Canada.196 
As early as 1996, Food and Drug Regulations (Sections C.08.010 [permission] 
and C.08.011 [dispensing] FDR) enabled access to unapproved drugs in cases of 
emergency. The Therapeutic Product Directorate was observed to handle the 
Special Access Requests (SAR); 197 198 an application form of two pages was 
identified. The physician was documented to remain responsible for the (a) the-
rapeutic decision, (b) proof of efficacy and (c) patient information.199 A Special 
Access Management System (SAMS) was found to administer all dispensed 
products.200 Health Canada was also discovered to encourage MAHs to perform 
open label studies with patients not meeting inclusion criteria of an RCT.201 Drugs 
were recognized to be provided free of charge.202 Temporary (restricted treat-
ment period), emergency (urgent situation) and future uses (case by case) were 
shown to be distinguished.203 Future use was found to require justification beyond 
the singular case.204  
Compassionate use programs were in place for certain Canadian provinces or 
areas of supply; for example, the British Columbia Cancer Agency (BCCA) sup-
ported a compassionate access program (CAP). It enabled evidence-based 
treatment in unusual or uncommon clinical circumstances or during the imple-
mentation phase of an MP. A Tumour Group and Systemic Therapy Program was 
described to file CAPs on a case by case basis. It was found to uphold the fol-
lowing clinical goals: (a) best practice and safe application of anti-cancer agents, 
(b) evidence-based selection of MPs, (c) financial coverage and (d) report to a 
Provincial Systemic Therapy Drug Database. The applying physician was seen to 
have to support his request with references. If requests were shown to be fre-
quent (> 5 requests), either a formal application to a Priority and Evaluation 
Committee of the BCCA was mandatory or a treatment strategy, protocol, Provin-
cial Pre-Printed Order and patient information was to be presented. Periodically 
updated reports including publications, presentations and patient data were found 
to be solicited throughout the term of the program.  
SWITZERLAND MPs were reported to have to be approved according to article 9 
HMG and the VAM (Swiss Ordinance on Drugs). HCPs were shown to be al-
lowed to import proprietary MPs on a small scale if authorized or exempt from 
authorization and a need to treat specific patients was evident. Article 10 HMG 
was observed to regulate the importation of MPs. The Swiss regulatory office was 
said to be allowed to license foreign drugs immediately in the case of a supply 
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shortage and when the manufacturing process is true to the originalN.13 (Art. 9 
Abs. 4 and Art 18 – 23 HMG as well as VAZV [Swiss Ordinance on the simplified 
approval of drugs]205).206 207 An applicant is charged 3,000 CHF (HGebV, Anhang I 
Abs. 2 Bst. k) at the time of this study. A list of admitted MPs was found pub-
lished online.208 As many as 23 temporary licenses were issued in 2005.209 
Extemporaneous formulation were seen to be regulated in article 9 (b) HMG. 
Furthermore, GMP rules were identified for small scale extemporaneous prepa-
ration in accordance with Swiss pharmacopoeia.N.12 210 Whenever MPs are judged 
to be unavailable in Switzerland, patients suffering from life threatening or serious 
disease may be treated after so-called ‘special authorization’ (Sonderbewilli-
gung). This mechanism was shown to also be applicable if a product license is 
withdrawn or cancelled. Six preconditions were observed to be compulsory: 
a) the disease to either be treated had to be fatal or lead to 
incapacitation,  
b) a licensed, acceptable, alternative MP of Switzerland 
I. was to be unavailable or  
II. its risk/chance-ratios were judged to be poorer or  
III. it had not achieved satisfying therapeutic results 
c) the intervention was to be 
I. an emergency or  
II. a last treatment option 
d) the MP 
I. was found to be licensed in a third party country or  
II. had a license applied for.  
III. If neither is the case, solid scientific evidence from clinical 
trials and quality product information on efficacy, safety and 
quality of the drug was to be presented in the application 
e) the MP was to be used in a single named patient 
An opinion from a local IRB (institutional review board) was uncalled for. The 
authorization was found to be issued to a single physician who must then keep a 
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record of all required data. He was also seen to be responsible for first docu-
menting each case (history) and then issuing a report to the Swiss Medic when a 
therapy ends. Adverse drug reaction (ADR) reporting was observed to be subject 
to the customary system. The patient was to be informed about the special regu-
latory circumstances and was seen to have to give his or her consent for the 
pharmacotherapy prior to prescription. The physician was explained to have to 
ensure that his liability insurance covers harm that may result from such therapy. 
Swissmedic may set further preconditions. The request form211 212 was to be for-
warded by a licensed physician in primary care or a medical director in secondary 
care. Authorizations which were issued by the provinces before the HMG had 
come into force in 2002 remained valid until the expiration or ended in 2007. Sta-
tistics for 2008 reported: 1927 requests for special dispensation for human MPs, 
thereof 107 needlessly submitted (cases, where applications were withdrawn or 
special dispensation is not required by Art. 36 Abs. 3 of the Arzneimittelbewilli-
gungsverordnung), 40 were denied and 1770 were approved.213 
Further mechanisms for NDU identified in Switzerland were first parallel trials and 
second extended access214. A special authorization for a parallel trial was shown 
to be permissible for an investigator of a clinical trial or physician currently trea-
ting the patient. The authorization was seen to apply to patients who were not 
eligible to the corresponding clinical trial. Excluded patients could be treated “in 
parallel”. The patient must suffer from a fatal disease or a disease causing inca-
pacitation. Alternative MPs must be unavailable, second-rate or not achieve ex-
pected therapeutic results. Again, the permission was described to be reserved 
for emergencies and as a final treatment option. The MP was to either be li-
censed abroad or subject to clinical investigation in Switzerland. The patient was 
to be named and an opinion from the IRB is compulsory in this case. The spon-
sor was to provide a parallel investigation plan. The authorization was to be 
granted to a physician who holds the required data, keeps a patient’s record and 
submits a report to the regulatory body. ADR reporting again was seen to apply 
to RCT rules. The patient was to give his informed consent to participation; the 
physician’s liability insurance must be shown to cover the intervention’s risks. A 
separate form was found for the parallel trial request.  
Extended access to unlicensed MPs was seen to be possible in Switzerland if an 
application for product licensure has been filed and for patients who participated 
in the clinical trial, had a benefit and who would like to continue the treatment 
after notice of compliance to the MP. The MP’s efficacy, safety and quality was to 
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be proven. The investigator or physician currently treating the patient may apply 
for special authorization. The IRB must give its consent. In case of extended 
access, there need not be an emergency or absence of therapeutic alternatives 
(Table 10). This procedure was also proven to have its separate request process. 
Applicants were charged CHF 200 per hour of processing at the time of the qua-
litative survey.  
premise 
NDU 
IRB 
opinion Drug status 
Emergency/ 
last option Alternatives 
SPECIAL 
DISPENSATION No 
Licensed abroad/ 
NDA/ solid 
evidence Must unavailable 
PARALLEL TRIAL Yes 
Licensed abroad/ 
RCT launched in 
Switzerland Must not available 
EXTENDED 
ACCESS Yes 
NDA, continuous 
treatment of 
former subjects Need not 
May be 
available 
Table 10 Three compassionate use mechanisms were identified in Switzerland 
AUSTRIA § 7 AMG-Au (Austrian Drug Act) was seen to require MPs to be ap-
proved by the regulatory body. § 20 ABO (Ordinance on the Operation of Phar-
macies) was found to regulate extemporaneous formulation. § 8 (a) N.2 AMG-Au 
was determined to exempt MPs from being licensed when supplied in response 
to the specifications of an authorized HCP for use by an individual patient 
suffering from a life threatening or serious disease who cannot be treated with 
available options according to the current state of knowledge. Demand for unli-
censed MPs was said to be covered by import from European MSs.N.17 However, 
an import was shown to require a notification for E.U. products or an authoriza-
tion for products from third party countries and is only permissible if alternatives 
are not available in Austria (§ 2 AWEG [Austrian Medicines’ Importation Act]).215 
An interview raised the ethical question of whether the delay of approximately 
two weeks for this permission is justifiable for life-saving products.N.19 
FRANCE MPs were found to need to receive a notice of compliance before mar-
keting (article L5121-8 CSP) or importation (article L.5121 CSP). 
Extemporaneous dispensing was seen licid (article L5121-1-3 CSP). The ATU 
(autorisation temporaire d’utilisation, temporary use authorization) was seen to 
be a permission granted by the French regulatory body AFSSAPS.N.34 It was 
shown to be issued only if no alternative French MP is suitable. A department 
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within AFSSAPS was reported to assess requests. Electronic submission was 
said to be planned for the future.N.37 The temporary use authorization was stated 
to be either patient specific (ATU nominative, ATUN) or group based (ATU de 
cohorte, ATUC). The ATUN also was observed to serve as an authorization to im-
port an MP. The temporary use authorization was considered to be an ex-
ceptional rule (L5121-12 CSP) and is applicable to the use of unlicensed MPs for 
the treatment, prevention or diagnosis of serious or rare disorders when no ade-
quate therapeutic option is available. ATUs were shown to correspond to Art. 83 
of Reg. 726/2004/EU and Art. 5 of Dir. 2001/83/EU if the MP is: 
• Efficacy and safety were seen to have to be evident from clinical trials per-
formed for licensing purposes. An NDA was required to have been filed or 
be filed within a given time frame (ATUC, art. R5126-103), or  
• If applicable, imported and was to be administered to a specific patient un-
der the responsibility of the physician in charge. A benefit to the patient 
was to be visible from the scientific state of knowledge about the MP’s ef-
ficacy and safety (ATUN, art. R5126-104 CSP). 
Legal use of an MP not approved in France was seen to only be permissible 
within the ATU framework. (a) Continued treatment at the end of a clinical trial, 
(b) off label use, (c) use of an MP that is licensed but not marketed and (d) ex-
temporaneous MPs prepared in the dispensary were found to not qualify for ATU 
application. Use of an MP within a temporary use authorization was observed to 
not be equivalent to clinical investigation. Though clinical data were found to de-
termine, whether a drug is made available on an ATU basis or must be subject to 
further investigation before temporary authorization. At an early point of drug de-
velopment, participation in clinical trials was said to always have to be fa-
vored.N.37  
ATUC was the key to allow unlicensed use of drugs at a late stage of clinical de-
velopment in a group or sub-group of patients. The ATU application was to be 
issued by the licensee either at the same time as the NDA or shortly before. In 
the later case, the application must be filed soon. The dossier was to encompass 
the application for ATUC including an explanatory statement (Art. L5121-12 CSP), 
the consent of the applicant to file the application pending a specified date, the 
conditions of dispensing and the expected number of patients eligible in France. 
Furthermore, the following were given to be added to the request for ATUC: A 
copy of the NDA, a copy of the foreign license if the drug is licensed abroad, the 
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SmPC, the last PSUR and the data for the upcoming PSUR, a draft protocol for 
therapeutic use and synopsis of information (Protocole d’utilisation thérapeutique 
et de recueil d´informations), a draft of the SmPC, label and PIL, information on 
current clinical trials for the same indications including data on investigators and 
centers, the OMP designation (if applicable), any information on compassionate 
use outside of France and copies of scientific evaluations by EMEA, AFSSAPS 
or other European regulatory bodies. The ‘Protocole d’utilisation thérapeutique et 
de recueil d´informations’ was to be presented in the IMPD format containing the 
principles of an ATU, the SmPC, conditions for the drug application, prescription 
and dispensing, patient information, patient monitoring provisions, data collection 
obligations for physicians and the license, measures of pharmacovigilance, re-
quirements for periodic reporting by the licensee and the periodic reports’ disse-
mination. When filing its decision, the AFSSAPS takes into consideration quality, 
safety and efficacy for the indication, the draft Protocole d’utilisation 
thérapeutique et de recueil d´informations, draft SmPC, patient information, pre-
scription as well as dispensing provisions and its significance compared to mar-
keted drugs. An ATUC was to be issued for a precise indication and remains valid 
for one year. Renewal is ideal two months before expiration. Re-submissions 
were necessary to include good reason, presentation of collected data, informa-
tion on risk/harm ratios, the quantity of dispensed MPs and the number of pa-
tients treated (Art. L5121-12 CSP).  
Patients were found to have to be informed about first the ATU, second the 
properties of the drug and finally monitoring in advance to treatment. Patients 
were to be provided patient information approved by AFSSAPS and are also in-
formed about data capture and transfer to the licensee and AFSSAPS (Law Nr. 
78-17 dated January 6th, 1978). The physician was obliged to inform the phar-
macist in charge about details of the ATU; the physician must also secure drug 
monitoring and data capturing, inform the licensee and the pharmacist in charge 
about irregularities as well as reasons and fulfill his tasks in terms of pharmacovi-
gilance.  
The pharmacist was to confirm the compliance of the treatment protocol and data 
collection. He or she was seen responsible to dispense the medication. A physi-
cian requiring an ATUC drug for a patient first was found to have to submit a re-
quest (Fiche de demande de protocole d’utilisation thérapeutique et de recueil 
d’informations) for the treatment protocol and data collection. He then was seen 
to have to send the entry-form via the pharmacist to the licensee, who validates 
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it. If all criteria are met, the licensee was to provide the pharmacy with the 
product. Importation of an ATUC drug was normal to require authorization by 
AFSSAPS. 
Circulars by the licensee were found to inform HCPs, regional pharmacovigilance 
centers and other drug safety institutions about ATUs. The licensee was shown 
to have to evaluate transmitted data; he also publishes periodic reports (rapports 
périodiques de synthèse). Reports were, at the time of this thesis, expected to 
include information on (a) the status of the product outside of France (i.e., NDA, 
NOC, and OMP designations), (b) current terms of the application (population, 
dose, criteria for administration, interactions with other MPs, etc.), (c) pharmaco-
vigilance and (d) recent results from clinical trials. The licensee was permitted on 
to forward circulars to HCPs only after periodic reports these are validated by 
AFSSAPS, regional pharmacovigilance centers and other drug safety institutions. 
An ATUN authorization was found to be able to be modified, cancelled or with-
drawn whenever circumstances, which have led to the authorization no longer 
apply. An ATUN application was seen to be launched by the prescribing physician 
and passed on to the pharmacist who forwards the request to AFSSAPS. ATUN 
MPs were found to only be dispensed by pharmacies in medical institutions. The 
physician was observed to hold the ATUN. His ATUN dossier was expected to 
convey information on the planned therapy, i.e., name of the MP, dose and dura-
tion of treatment, patient data (initials, gender and age) as well as the product’s 
indication and reasons for the application. The application form was noted to 
consist of one page. 
AFSSAPS and consulted experts were found to assess an ATUN proposal by 
evaluating the drug’s quality, safety and efficacy, its proposed indication as well 
as the absence of suitable, marketed alternative MPs. AFSSAPS also was seen 
to rely on a dossier which it requests from the licensee to-be. The dossier was 
observed to hold data on foreign SmPCs, information on quality, safety and effi-
cacy (bibliography, investigators’ brochure, and periodic safety reports) and a list 
of planned and completed clinical trials in France. The applicant for ATUN was 
also seen to be required to forward treatment data to the regulatory body.  
If an ATUN is granted, the permit was observed to have to provide information on 
the name of the MP, contact data of the physician, the patient’s initials, duration 
of the treatment and contact information of the hospital pharmacist. If applicable, 
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it was found to have to also inclose a copy of a foreign SmPC or a notice by 
AFSSAPS on the drug’s therapeutic use. 
An ATUN was seen to have to be rejected when (a) there is a therapeutic option 
available in France, (b) data does not provide evidence that the use of the MP 
would be beneficial to the patient or (c) an application for clinical trial was sub-
mitted. The evaluation process was found to take 24 to 48 hours if there has 
been previous assessment in other respects, processing time is determined by 
how long it takes to complete and review the dossier.  
An ATUN was given to be valid for a treatment period or a maximum of one year. 
If the treatment period was considered to exceed the given time frame, the appli-
cation may be prolonged and further reasoning that justifies continued treatment 
(data on safety and efficacy) may be required.  
The AFSSAPS was seen to both keep the physician up-to-date on an ATUN and 
provide him or her with information about warnings, safety precautions, ADRs, 
foreign SmPCs or a synopsis of the properties of the MP, etc. In some cases, the 
AFSSAPS was found to may be request compliance with a “therapeutic use and 
data collection protocol” similar to the ATUC. The physician was also shown to be 
required to (a) inform the patient about other physicians involved in treatment, (b) 
secure drug monitoring and pharmacovigilance, (c) inform the pharmacist in 
charge regularly and (d) provide AFSSAPS with any information required.  
The following rules were found to apply to dispensing: if a distributor is present in 
France, pharmacists will use an ATU order form from AFSSAPS to request a 
drug; the pharmacist then dispenses the drug. If the MP is not available in 
France, it must be imported by the pharmacist. The ATUN resembles an authori-
zation for import. The pharmacist may stock products with long delivery periods. 
Stockpiling for cases of emergency (frequent in hospital settings) may also be 
approved by AFSSAPS and is subject to a separate import authorization (Art. 
R5121-108 to R5121-114 CSP). Any information the licensee was found to want 
to circulate must be validated by AFSSAPS beforehand. The two ATUs were 
found to share the goal of providing early access to innovative treatments, though 
each targets at a different point of research and development (Table 11). 
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ATU 
 
 
 
 
CHARACTERISTIC Nominative  Cohort  
PATIENT named basis  group 
APPLICANT 
physician 
MAH  
RESPONSIBILITIES 
commitment to submit an MA, 
follow up of patients and data 
collection according to a protocol 
for therapeutic use and data 
collection, periodic data reporting 
to AFSSAPS 
SAFETY AND 
EFFICACY presumed highly presumed 
MANDATORY 
compassionate 
situations SmPC, PIL, labelling 
QUANTITIES 
many drugs, few 
patients few drugs, many patients 
Table 11 Summary and comparison of ATU characteristics 
ATU plays a major role in pediatrics: The AFSSAPS reported 251 pediatric hos-
pital formulations in 2006 and 135 nominative ATUs for children, i.e., 22% of all 
ATUN. Of 2081 clinical trials in 2002 in France, 222 (11%) were conducted in 
children, though children represent 22% of the French population.  
U.S. Section 301 (21 USC § 331) FD&C Act was seen to prohibit the sale, 
stocking or supply of unlicensed MPs for trade in the U.S. Section 801 FD&C Act 
(21 USC 381) was found to regulate the importation of goods; Section 804 (21 
USC 384) was observed to require an MA from an importer before a prescription 
drug is brought into the country. Individual import was to be tolerated on a small 
scale (Section 801(g) (1)). However, the FDA was discovered to be obliged to 
take measures when public health is endangered (Section 804(j) (1) (A)). Also, 
section 804(j) (1) (A) was given to exclude cases of individual use from handling 
by the FDA when no risk is evident. Section 804(j) (b) was recognized to enable 
the FDA to issue permissions for importation. Import from Canada was judged to 
be permissible according to Section 804(j) (2).  
The Drug Shortage Program (DSP) of the Center for Drug Evaluation and Re-
search (CDER) was seen to attempt to resolve problems relating to drug short-
ages in the U.S.216 Emergency IND (eIND), single patient INDN.9 and treatment 
IND (tIND) protocolN.9 were found in place within the FDA. Special exception 
protocols,217 treatment referral center protocols and group C protocols218 were 
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identified as National Cancer Institute (NCI) mechanisms for early access to 
NDU. Table 12 contrasts these mechanisms.  
ASPECT 
 
PROTOCOL Institute Request 
Point of 
time Regulation Applicant 
EMERGENCY 
IND 
FDA 
 
Subse-
quently 
RCT 
21 CFR 
312.36 
Physician 
SINGLE 
PATIENT IND 
In 
advance 
Physician/ 
MAH 
TREATMENT 
IND  
Early 
stages of 
develop-
ment 
21 CFR 
312.34 and 
312.35 
MAH/ 
physician 
SPECIAL 
EXCEPTION  
CTEPvi 
>Phase II 
and III ct ≙ eIND Physician 
TREATMENT 
REFERRAL 
CENTRE  
highly 
promising 
agents 
~ simple 
multicenter 
ct 
Patient/ 
physician 
GROUP C  
FDA/ 
NCI 
Phase III 
ct ؙ tIND 
CTEP/ 
(physician) 
Table 12 Mechanisms for NDU in the U.S. 
E.U. Art. 6 of Dir. 2001/83/EC was found to prohibit the sale, supply or stock-
keeping of MPs without an MA. Art. 3 of Dir. 2001/83/EC was seen to exempt 
extemporaneous products from registration requirements. Art. 5 of Dir. 
83/2001/EC was observed to exempt MPs supplied in response to a bona fide 
unsolicited order, formulated in accordance with the specifications of an autho-
rized HCP and for use by an individual patient under the HCP’s direct personal 
responsibility; this article has been associated with importation in the U.K., NDU 
in Austria, extemporaneous products by Blasius219 and named patient use by 
Akbarian220 and Schwarz221 in the E.U.  
A compassionate use concept was found to have been introduced at the E.U. 
level.N.31 Article 83 of Reg. 726/2004/EU, the Guideline on Compassionate Use of 
Medicinal Products, pursuant to article 83 of Regulation (EC) No 726/2004 and 
article 5 of Dir. 83/2001/EU were stated to regulate compassionate use in Eu-
rope. By way of exemption, MSs were found to be able to make an MP for human 
use available for compassionate use if the MP is eligible for authorization via the 
Centralized Procedure (CP, article 6 of Directive 2001/83/EC). When an MS was 
to envisage the need to make an MP available, the competent authority of that 
                                                            
vi Cancer Therapy Evaluation Program 
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MS is to notify the EMEA indicating whether they consider a CHMP opinion on 
the conditions for compassionate use to be of interest. Compassionate use of 
MPs belonging to the “optional scope” shall only be reported to the EMEA if the 
eligibility for the CP has been confirmed by CHMP.  
Companies were found to not be supposed to make contact EMEA directly to 
request a CHMP opinion, but may inform EMEA of compassionate use applica-
tions in an MS or of an ongoing application process for compassionate use at 
national level. CHMP opinions were seen to not be binding for the regulatory bo-
diesvii of an MS. Justifications for the need of a compassionate use program were 
observed to have to be enclosed to demonstrate meeting of the criteria of article 
83 (2). Any scientific data submitted was found to have to allow evaluation of the 
conditions for use of the MP in the target population. In terms of efficacy, the as-
sumptions for compassionate use were shown to have to be based on mature 
phase III RCTs. Acceptable assumptions may, however, already rely on 
promising data observed in exploratory trials. In terms of safety, submission of all 
available data was seen to be encouraged. 
GERMANY MPs were evidenced to have to receive MA before they are dispensed, 
stocked or supplied to patients in Germany (§ 21 AMG). Shipment of MPs re-
quiring registration was found to only be permissible under § 73 AMG if the MP is 
(a) licensed in Germany and (b) imported from the E.U. or ETA by (c) an MAH, a 
wholesaler, a veterinary or a pharmacy or shipped to a patient by a pharmacy 
from the U.K., the Netherlands or a pharmacy in another country possessing a 
shipment permit. Shipment of licensed MPs from third party states was seen to 
be permissible for persons holding a shipment permit according to § 72 AMG. 
§ 73 (c) was found to provide exemptions to the import of MPs not licensed in 
Germany. Medical products may be brought in in small amounts (no stock) for 
individual patients if first ordered by a pharmacy with an operating license and 
second licensed in their country of origin. Import from third party states was seen 
to require a valid prescription. Absence of identical E.U. products was found to be 
compulsoryN.43 (as shown in Table 13).  
                                                            
vii Germany has three regulatory agencies for 1) drugs and medical devices, 2) sera and vaccines 
and 3) consumer protection and food safety handling veterinary drugs 
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ASPECT 
ORIGIN  STATUS  PRESCRIPTION 
E.U./EEA  OTC  Non‐prescription 
E.U./EEA  Rx  Prescription 
THIRD PARTY COUNTRIES  OTC/Rx  prescription, absence of German alternative drugs 
Table 13 Prescription requirements for import to Germany 
According to § 18 ApoBetrO, the name of the MP, name and address of the 
manufacturer, quantity and formulation, name and address of the physician and 
patient, date of order and supply as well as the signature of the pharmacist in 
charge must be recorded. Multiple provisions including § 7 ApoBetrO, the EC-
GMP Guidance, Guidance for the manufacture and analysis of unsterile extem-
poraneous products by the Federal Chamber of Pharmacists, the New Extempo-
raneous Formulary (Neues Rezeptur Formularium, NRF), a guidance for sanita-
tion by the German Society for Dermatologic Pharmacy, the list of critical ingre-
dients (Bedenkliche Rezepturarzneimittel) of the Drug Commission of the Ger-
man Pharmaceutical Association (AMK), and the German and European Phar-
macopeia all were judged to regulate extemporaneous preparation of MPs in 
terms of quality management.  
Compassionate use was introduced in Germany by the 14th amendment of the 
AMG. Sect. 21 (b) N.6 AMG states that “(b) an MA is not required for MPs which 
[…] 2. are made available under the provisions laid down in article 83 of Regula-
tion (EC) N.726/2004 for (a) patients suffering from a disease leading to severe 
disability or (b) whose disease is life-threatening and who cannot be treated sa-
tisfactorily with an approved MP; procedural rules were stated to have to be de-
termined in a legal regulation (ordinance) in accordance with section 80. […] The 
German Federal Institute for Drugs and Medical Devices (BfArM) stated to cur-
rently not be authorized to make decisions on "compassionate use" programs on 
its website, for the reason that procedural rules according to sect. 80 were still 
being developed. Pharmaceutical companies, other persons or institutions were 
found to be able to refer to sect. 21 (b) N.6 AMG when conducting a "compassio-
nate use" program. Reference may also be made to article 5 of Directive 
2001/83/EC. BfArM was found to provide noncommittal recommendations: 
• “Existence of objective evidence that the patients suffer from a life-
threatening disease or a disease leading to severe disability. 
• Existence of objective evidence that there is no other satisfying treatment 
option with medicinal products approved in the European Community. 
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• Existence of objective evidence that a marketing authorisation application 
has been submitted for the medicinal product or that clinical trials with this 
medicinal product are still ongoing. 
• The "Guideline on Compassionate Use of Medicinal Products, Pursuant to 
Article 83 of Regulation (EC) No 726/2004 (Draft)" should be considered. 
• Appropriate documents such as an investigator’s brochure (IB) providing 
relevant non-clinical and clinical data proving safety and efficacy in the 
foreseen medical indication should be in place. 
• Inclusion and exclusion criteria as well as withdrawal criteria for the 
compassionate use program should be in place. 
• Provision for pharmacovigilance measures should be arranged.” 
“Recently, the German Ministry of Health proposed to exempt medicinal products 
available for compassionate use (article 83 EU 726/2004) from the general 
pharmacy-only requirement (§ 43 AMG), hence allowing direct supply from phar-
maceutical manufacturers or wholesalers to hospitals or physicians (draft for 
amendment to the German Drug Act (AMG) as of 22 December 2008). The 
ABDA-Federal Union of German Associations of Pharmacists officially objected 
to this proposal” (personal correspondence Lutz Tisch, ABDA, Berlin, 22 January 
2009). 
JAPAN Authorization for marketing of MPs (jap. shōnin) was found to be granted 
by the Ministry of Health, Labor and Welfare (MHLW). No MP that is licensed was 
seen to be allowed to be manufactured, imported, stocked or supplied if its ingre-
dients, properties or quality deviate from the regulatory provisions (art. 56 PAL). 
Article 22 PAL was shown to regulate extemporaneous formulations.  
MPs were to be imported if a plant of the company is located in Japan, but when 
manufacture takes place abroad, an importation permit is mandatory and a local 
distributor is appointed. In April 2007. the Japanese Department of Health pro-
posed a compassionate use system based on that of the EU and the U.S. for 
unlicensed MPs to treat serious illness in the absence of alternative options. Indi-
vidual import was found to be feasible. 
Table 14 contrasts the regulations affecting treatment of patients outside an MA 
or products requiring but missing a valid product license. In summary, importation 
of MPs was seen regulated in all nations; however, no harmonized rules were 
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identified for the E.U. as a whole. Extemporaneous preparation was seen to be 
subject to pharmaceutical law in eight countries of investigations. In all countries 
but Japan, which plans to implement a strategy, there were conventions in place 
that allow for compassionate supply in theory. Off label use was never regulated 
by law. 
Results 
60 
 
NDU
COUNTRY 
Registration 
requirement 
Unlicensed Use Compassionate use 
Import 
Extemporaneous 
products 
Named patient 
use Expanded access 
GERMANY § 21 AMG 
§ 73 (c) AMG, § 18 
ApoBetrO § 7 ApoBetrO unidentified § 21 (b) N.6 AMG 
AUSTRIA § 7 AMG-Au § 2 AWEG  § 20 ABO § 8 (a) N.2 AMG-Au unidentified 
SWITZERLAND Art. 9 HMG, VAM Art. 36 AMBV Art. 9 Abs. 2 HMG 
Art. 36, Abs. 3 bis 5 
der AMBV Art. 9 Abs. 4 HMG 
FRANCE Art. L5121-8 CSP Art. L.5121 CSP Art. L5121-1-3 CSP Art. R5126-104 CSP Art. R5126-103 
U.K.  
§§ 18 ff Medicines 
Act 
MCA Guidance 
Note N.14. Feb 
2000. 
Schedule 1 of 1994/SI 
3144 SI 2005 Nr. 2879 unidentified 
E.U. 
Art. 6 Dir. 
2001/83/EC unidentified Art. 3 Dir. 2001/83/EC 
Art. 5 of Dir. 
83/2001/EC 
Art. 83 of Reg. 726/2004/EC, 
Guideline on Compassionate 
Use of Medicinal Products, 
Pursuant to Article 83 of 
Regulation (EC) No 726/2004  
U.S. 
Section 301 (21 
USC § 331) FD&C 
Act 
Section 801 FD&C 
Act (21 USC 381), 
Section 804 (21 
USC 384) unidentified unidentified 
21 CFR 312.36, 21 CFR 
312.34 and 312.35 
CANADA C.01.014 FDR C.01.014.1. FDR unidentified Sections C.08.010 and C.08.011 FDR 
JAPAN Art. 12-14 PAL Art. 56 PAL 
Article 22 PAL, 
PFSB/CND Notification 
N.0331004, March 31, 
2005  unidentified planned 
Table 14 Synopsis of the regulations affecting nonlincensed drug use in selected industrial countries 
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3.3. Texts of law regulating nonlicensed drug use with 
regard to drug safety  
Safety of and low-risk access to NDU has primarily been studied in pediatrics. In 
2004, the EMEA reported harm to children in the course of off-label- and unli-
censed use to the EC. Fewer adverse reactions were reported for children than 
for adults. Of the 820 serious ADRs that had been reported to the EMEA, 130 
were fatal. Several studies (Schirm 2004, Ufer 2004, Horen 2002, Clarkson 2001, 
Turner 1999, Gill 1995) showed a higher incidence of ADRs in children. In pedia-
tric inpatient care, twice as many ADRs were identified in comparison to adult 
settings. The relative risk for ADRs in outpatient pediatric care was reported to be 
3.44 (95 percent confidence interval). The EMEA disapproved of SmPCs and 
PILs concerning pediatric information, especially with regard to a lack of recom-
mendations for dosage. Dosing mistakes commonly were said to lead to medica-
tion errors in children. An accordingly large quantity of extemporaneous prepara-
tion was stated to be the result of absent pediatric formulations.  
In terms of quality in patient care, harm to patients because of denied treatment 
versus ADR as a result of NDU was found to be unproven. Present studies were 
seen to also not give consistent evidence on whether ADRs occur more often 
during NDU or as frequently as with licensed MPs’ use: Turner et al. and Horen 
et al. found that ADRs occurred at a higher rate during off label drug use.222 223 
ADRs are more frequent in children (7%-20% in inpatient care, i.e., 38%-45% out 
of all ADRs occurring) because dosages are commonly matched to age and 
weight.224 Choonara et al. could not support this conclusion in their review.225 
Table 32 is a synopsis of further studies presenting incidences of ADRs over a 
period of NDU. 
ADR reporting and pharmacovigilance in general was found to be regulated in 
pharmaceutical law and is often identical for licensed or INDs and nonlicensed 
drug use. INDs and compassionate use were seen to usually be subject to clini-
cal trial provisions with regard to ADR reporting. Reporting practices for marketed 
products were observed to vary; mandatory systems are present in France, Italy 
and Sweden, and a voluntary reporting system e.g. in the U.K.226 Any present foci 
were shown to turn to APIs as opposed to a drug’s terms of use, e.g., thalidomide 
in AustriaN.17 or Japan, new APIs in the U.K. and vaccines in the U.S. (see Table 
15).  
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SCHEME 
 
COUNTRY Reporting 
U.K. 
Black Triangle Scheme  
Drug Safety Research Unit (DSRU) 
Yellow Card System 
Serious Adverse Blood Reactions and Events (SABRE) 
GERMANY 
Reporting of drug risks according to graduated plan procedure 
error reporting and learning system for office based physicians
FRANCE Regional centres for pharmacovigilance (CRPV) 
EU 
EUDRAvigilanceN.29 
Council for International Organizations of Medical Sciences (CIOMS) 
AUSTRIA 
ADR Reporting  
Arzneimittelsicherheit in der Psychiatrie (AMSP, Drug Safety in 
Psychiatry) 
GERMANY 
SWITZERLAND 
Critical Incidents Reporting System (CIRS) 
Swiss Paediatric Surveillance Unit (SPSU) 
Regional centres for pharmacovigilance  
Product defects and toxicologic centre 
CANADA Canadian Adverse Drug Reaction Monitoring Program (CADRMP) 
U.S. 
Adverse Event Reporting System (AERS) 
Kaiser Permanente National Patient Safety Program 
FDA MedWatch Program 
Vaccine Adverse Event Reporting System (VAERS) 
JAPAN Safety Management System for unapproved drugs (SMUD) 
Electronic ADR Reporting System 
Table 15 Selected mechanisms of ADR reporting in surveyed countries 
E.U. The European Risk Management Strategy (ERMS) was found to require 
applicants for MA to monitor off label use within the scope of the systematic im-
plementation of risk management plans. Potential off label pediatric use of MPs 
in MSs was found to be discussed in NDAs. Off label use was seen to have to be 
covered by the commitment to PSURs. Reports on suspected adverse reactions 
after off label use, the potential of off label use (including pediatric off label use) 
and exposures that differed from those predicted were seen to have to be inter-
preted. The harm/benefit ratio was required to be evaluated in addition to a stan-
dard safety assessment. The possibility of introducing patient reporting in future 
to improve the overall reporting rate has been discussed. The reporting rate was 
said to be estimated to be low in the MS e.g. Belgium and ADRs after off label 
use are thought to be reported more rarely than in licensed use.N.33 The reporting 
mechanisms were judged to not function for unlicensed MPs; separate 
mechanisms were present for compassionate use due to the regulation of clinical 
trials (see 3.2 Investigations into supply shortages of drugs and the necessity as 
well as procedure of nonlicensed drug use). EudraVigilance was identified as a 
data processing network and management system for reporting and evaluating 
suspected ADRs during the development of MPs in the European Economic Area 
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(EEA) and following their MA. The CIOMS ADR Working Group (composed of 
representatives of seven multinational pharmaceutical manufacturers and six 
regulatory authorities) developed and implemented a standardized method for 
reporting post-NOC ADRs. 
AUSTRIA was alike other MS suggested also to lack customized 
pharmacovigilance for NDU. A pilot project in Salzburg named ‘medicinal 
products seatbelt’ (“Arzneimittelsicherheitsgurt”) was stated to analyze drug 
interactions. Specific requirements for dispensing thalidomide formulations; con-
tribute to drug safety in Austria. In all other respects, general rules for ADR re-
porting were seen to be valid. The Vienna Medical Association contemplated es-
tablishing an anonymous reporting scheme in the future. Together with Swiss, 
Hungarian and German hospitals, Austrian hospitals were found to participate in 
a program determining serious ADRs in inpatient psychiatry wards (AMSP, Table 
15). Until 2006, 45 sites monitored 166,073 patients. Case reports were to be 
evaluated by local review boards. Apart from this scheme, no reviews on safety 
issues during NDU were identified. In contrast to labeled use, the frequencies of 
ADRs in off label use were unavailable. The proportion of reports on ADRs after 
off label use was judged to be very low. According to the interviewees, reasons 
for this finding were at the time of this research. An unreadiness to report ADRs 
on the part of physicians and patients. Readiness to report ADRs was said to be 
overall low and presumably decreases when using medical products in an off 
label way. All three strategies for drug safety monitoring in Austria were judged 
not to be custom-made to NDU. 
SWITZERLAND CIRS was identified as an anonymous and international forum on 
critical incidents in anesthesiology. SPSU, an established hospital reporting sys-
tem, was seen to monitor rare pediatric diseases. Regional centers for pharma-
covigilance as well as a product defects and toxicological center were found to 
collect ADR case reports. No separate obligations to report ADRs in NDU were 
acknowledged in Switzerland.N.12  
U.S. An Adverse Event Reporting System (AERS) was shown to be a 
computerized database supporting the FDA's post-marketing safety surveillance 
for approved MPs. It was reported to monitor new adverse events and medication 
errors. ADR reporting was seen to be voluntary for HCPs in the U.S.N.8 If a 
manufacturer receives an adverse event report, he or she was said to be re-
quired to send the report to the FDA as specified by regulations (MedWatch, 
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mandatory reporting).N.4 Interdisciplinary teams at Kaiser Permanente National 
Patient Safety Program have been developing strategies to mitigate the risks of 
preventable adverse events.N.9 The Vaccine Adverse Event Reporting System 
(VAERS) was identified as a program of the Centers for Disease Control and 
Prevention (CDC) and the Food and Drug Administration (FDA). VAERS was 
found to be a post-marketing safety surveillance program that collects information 
about adverse events after the administration of U.S. licensed vaccines. Experts 
put the overall reporting rate at one to ten percent.N.5 
U.K. In the U.K., black triangle drugs were seen to be intensively monitored, in 
addition to new MPs and vaccines, in order to confirm the risk/chance profile of 
the MP. The U.K.'s spontaneous ADR reporting scheme, the Yellow Card 
Scheme,N.26 was found to receive reports of ADRs from HCPs and patients. Clini-
cians were reported to tend to not report ADRs with off label use.N.27 A Drug 
Safety Research Unit (DSRU) was found to perform prescription event monitoring 
on selected newly marketed drugs in general practice. Hospital blood banks, 
transfusion teams and other blood establishments were found to be able to report 
serious ADR and ADE relating to blood to the MHRA via SABRE. For compas-
sionate use, a company was said to be able to draw up a contract with the pre-
scriber to provide certain information in particular regarding safety.N.27 In the qua-
litative survey the reporting rate was judged to be poorN.24 N.21 and more reporting 
was demanded.N.22 N.28 The quality of ADRs in children treated with antidepres-
sants was criticized to justify end of treatment. A slight increase of ADR in unli-
censed use over the past ten years was reported.N.21  
GERMANY Reports from healthcare professionals about MPs’ risks in accordance 
with the German graduated scheme procedure (Stufenplanverfahren) are re-
quired to be sent to the professional association, the MAH or the regulatory body 
in charge. There was evidence that off label use may not be reported at all, be-
cause the MP is not used according to the label because of the wording of law:227 
§ 4 (13) AMG was said to distinguish ADR only when an MP is used according to 
the terms of the label. Use according to the label was taken to include obvious 
incorrect use, frequent incorrect use and acknowledged medical use.228 For this 
reason and on one occasion, off label use that is not medically acknowledged 
was explained not to be subject to reporting requirements.   
CANADA Mandatory ADR reportsN.2 were to be submitted to the Canadian ADR 
Monitoring Program (CADRMP). The Canada Vigilance Online Database was 
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found to be called MedEffect. The reporting rate was estimated by polled experts 
to be 10%.N.2 
JAPAN The Japanese PDMA has provided HCPs and medical institutions with an 
electronic ADR reporting system since April 2005. These reports by MAH have 
been published in an online database since January 2006. In 2005, the SMUD 
program was introduced in order to monitor and assess the medical use of thali-
domidei. 
FRANCE The French drug surveillance (pharmacovigilance) system was found to 
be based on a network of 31 regional centers that enter ADR reports from health 
professionals into a common database. With respect to NDU, French physicians 
were seen to be obliged to keep records of patients treated under ATU permis-
sion and file reports with the AFSSAPS.  
As a closing remark: Intensified monitoring of ADRs with nonlicensed drug use 
was not the specific aim of any mechanism. Some reporting forms (CIOMS form 
I, yellow card, Meldebogen für unerwünschte Arzneimittelwirkungen [BfArM, 
Germany]) permitted a comparison of terms of use of the MP for which an ADR 
was reported. Regulatory bodies, however, have not published such assess-
ments in annual reports. 
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3.4. Regulations applying to health care professionals 
and law on supply and use of nonlicensed drugs  
The supply and use of nonlicensed drugs was found to be subject to laws: The-
rapeutic freedom, emergency, duty of care, obligation of contract and objection to 
risky agents most commonly affect the practice of medicine.  
In terms of NDU, MPs were able to, from a pharmaceutical law point of view, be 
provided to patients by pharmacists unless critical agents (§ 5 AMG in Germany, 
§ 13 (d) ABO in Austria) are recognized. If the pharmacist was to have no rea-
sonable concerns, he or she has the obligation to dispense the drug (§ 17 IV 
ApoBetrO in Germany, § 25 ABO in Austria). 
Physicians were seen to be free to prescribe MPs as he or she feels necessary 
(§ 1 Abs. 2 BÄO [National Law on Physicians] in Germany,N.37 N.39 N.41 N.42 N.44 Art 6 
StGG in AustriaN.15 N.19). Therapeutic freedom was found to be present for Bri-
tainN.23 N.26 N.28 (Section 9 (a) of the Medicines Act 1968) and unlicensed and off 
label products may be legally dispensed by pharmacists (Section 10 of the Medi-
cines Act 1968)N.21 or administered by supplementary prescribers (Section 11 of 
the Medicines Act 1968).N.24 It was observed to be in the realm of medicine to use 
an MP off label in Canada.N.2 A physician in the U.S. was also judged to be free 
to prescribe an MP outside of its labeling,N.8 N.7 N.6 N.5 N.4 N.3 but should be able to 
defend its use in front of a jury of peers.N.9 The right to prescribe medications in 
similar terms was also claimed to be present in IrelandN.32 and Belgium.N.33 
A physician was even found to be obliged to treat a patient in a nonlicensed in 
the case of an emergency (§ 34 StGB in Germany, § 1306a ABGB [Austrian Civil 
Code] in Austria). However, he or she was seen to have to assure the current 
standard of care (§ 276 BGB in Germany, § 55 ÄG [Austrian National Law on 
Physicians] in Austria).  
There was no evidence for prohibition of NDU for physicians and patients in 
health care law. A supply chain for MPs nevertheless involves MAH, wholesalers 
and pharmacists, whose actions may be restricted. Importation of MPs in such as 
it is relevant to unlicensed drug use was shown to be subject to restrictions (see 
3.3 Texts of law regulating nonlicensed drug use with regard to drug safety).  
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3.5. Operating experience with provisions for 
nonlicensed drug use 
 
Operating experiences with e.g. a temporary use program were taken as impor-
tant indicators for the feasibility and acceptance of a solution. Operating 
experience was also assumed to illustrate what impact of an approach on the 
NDU difficulty. Different levels of knowledge of temporary use procedures among 
professionals became apparent and public training was found to be desirable. 
U.K. According to expert N.22, a British regulation of compassionate use (de-
scribing patients, dosage and length of treatment) was in place. An investigation 
of the MHRA Guidance Note No.14 by the author of this work however, docu-
mented that the regulatory agency refers to the Guideline on compassionate use 
of medicinal products pursuant to Regulation (EC) 726/2004 for compassionate 
use. National legislation was not identified. The expert challenged the concept 
that illegitimate NDU can be regulated and believed that off label use cannot be 
regulated by law. In contrast findings in literature showed that the MHRA 
Guidance Note No.14 governs “the supply of unlicensed relevant medicinal 
products to individual patients” (see 3.3 Texts of law regulating nonlicensed drug 
use with regard to drug safety) and refers to off label use. The interviewee was 
aware of the Department of Health’s “Medicines Management Framework and 
Standards for Better Health” but seemingly unaware of subsequent policies for 
the use of unlicensed (and off label use) medicines in U.K. NHS trusts. He disap-
proved of a federal indemnity fund for harmful consequences of NDU as sug-
gested by the interviewer, because in his opinion “it makes a mockery of the li-
censing system”.  
The British Interviewee N.23 (pediatric affiliation) believed NDU is necessary in 
the short term, but objected to NDU in the long term. He appreciated the financial 
incentives for MAHs and was confident in “legislation introduced in Europe to 
finally improve the situation”, referring to pediatric regulation (PedReg), although 
he was reserved on its success in pediatrics and allotted “a couple of years” to 
judge the success of the regulation. By January 26th, 2013, the Commission is to 
present to the European Parliament and Council a general report on its expe-
rience.229 The first positive opinion on a pediatric formulation of powder and sol-
vent for the oral suspension of losartanei potassium according to article 29 of the 
Pediatric Regulation (1901/2006) was given on October 23rd 2007 (see 3.8 
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Criteria for simplified variation while assuring drug safety: Incentives and 
duties).230 The expert linked the therapeutic freedom of pediatricians and current 
best practices (see 3.4 Regulations applying to health care professionals and law 
on supply and use of nonlicensed drugs).  
Respondent N.24 of the U.K., also in pediatrics, recognized the PedReg as a 
provision in place to decrease NDU and underlined that until the PedReg’s ar-
rival, an MP’s label could easily have excluded children from pharmacotherapy. 
She criticized the MAH’s disinclination to perform clinical trials in children. Up 
until the PedReg came into force, she explained, best empiric practice deter-
mined standards of pediatric care. She still was concerned about the lack of in-
formation on older drugs currently used off label and suspects that “long-mar-
keted drugs is the only area where the regulation perhaps is not as good as it 
could be”. She was aware of provisions addressing older drugs (N.B. pediatric 
use MA [PUMA]) and believed this regulation aims to “collect information on day 
to day use of off label drugs”. The Task-force in Europe for Drug Development for 
the Young (TEDDY) is to set up a ‘European Pediatric Drug Database’ by ex-
ploring, validating and consolidating existing data sources containing information 
on MPs used in children (see 3.3 Texts of law regulating nonlicensed drug use 
with regard to drug safety).231 The academic stated that NDU prescription, 
administration and dispensing were legal, but under the professional 
responsibility of a physician, nurse or pharmacist: A professional only “uses unli-
censed or off label medicines when there is no alternative” (see 3.4 Regulations 
applying to health care professionals and law on supply and use of nonlicensed 
drugs).  
A representative of U.K. general practitioners assumed that there is little legisla-
tion on NDU; expert N.25 pictured shortfalls in regulation. Health care planner 
N.26 however, recognized named patient use of the Medicines Act as a provision 
for NDU “in individuals without identification”. He described the provisions as 
“modest” and “loose”. The expert acknowledged that (a) pediatricians may be too 
overloaded to notify each case of NDU, (b) regulation was developed in order to 
control MAHs (as opposed to physicians) and (c) the biggest NDU issue (child-
ren) is addressed by the new EU arrangements to promote better licensing. In 
spite of named patient use and in a liability suit, the physician would have to 
prove his cautious behavior (see 3.6 Liability for nonlicensed drug use); neverthe-
less, the interviewee did not express any desire to have extra primary legislation 
enacted. Despite named patient use, pharmaceutical manufacturers were seen 
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not to be permitted to promote NDU. Regulation 3 of the Advertising Regulations 
confirmed that MPs without valid MA may not be advertised for medicinal pur-
poses.232 Also, material relating to products that do not hold U.K. MAs was found 
to be permitted to be displayed at international events provided that first a signifi-
cant proportion of the attendees are from countries outside the U.K. where the 
product is licensed, and finally it is clearly and prominently indicated that the 
product is not licensed in the U.K. 
A British industry associateN.27 assumed NDU is used as often as 15% in general 
practice and expects a future decrease with European legislation. He also stated 
that compassionate use is regulated through MHRA guidance, while believing off 
label use unregulated. He was familiar with a ban of advertising MPs to the pub-
lic, as well as off label use to all addressees (see 3.7  Circumvention of drug 
approval: Law on advertising). He recognized the legality of pharmaceutical 
advertisement of licensed MPs and licensed uses to HCPs. A company was also 
found to be allowed to respond to a HCP’s request for information about a NDU 
(see 3.7 Circumvention of drug approval: Law on advertising).  
A hospital pharmacistN.21 identified MPs that are made under section 10 of the 
1968 Medicines Act, i.e., extemporaneous products, as “specials” and as an 
example of unlicensed use. He identified licensing and importation requirements 
as safety measures, but demanded safer practice. He did not think that gover-
ment arrangements around using unlicensed MPs are adequate. In his opinion, 
all needed drugs should be available in the required formulations and licensed for 
essential indications, because bioavailability studies and standardization are ab-
sent for extemporaneous preparations. ‘Specials’ manufacturers, who are often 
assigned extemporaneous preparation in the U.K., are as per his statements, not 
responsible for clinical suitability; pharmacists are often unaware of their respon-
sibility for a product’s suitability (N.B.: plausibility check). He pointed out that 
there is a pediatric committee at the MHRA similar to the EMEA’s PDCO. The 
Paediatric Medicines Expert Advisory Group of the Committee of the Safety of 
Medicines was found to advise on the safety, quality and efficacy of MPs for pe-
diatric use, and on the implementation of the Department of Health’s and 
MHRA’s pediatric strategy, the recently implemented EU pediatric work sharing 
project, and the European regulation on MPs for pediatric use (see 3.3 Texts of 
law regulating nonlicensed drug use with regard to drug safety).233 Therapeutic 
freedom, patient rights and dispensing were seen to remain unaffected by current 
legislation according to the interviewee’s statements (see 3.4  Regulations 
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applying to health care professionals and law on supply and use of nonlicensed 
drugs). 
Regulatory expert N.28 did not “think [compassionate use] has a very precise 
legal meaning in the English system” and described it as a loose term assigned 
for reimbursement aspects. He understood off label use not as a problem but as 
a consequence of the lack of suitable MPs. The effort to include pediatric indica-
tions onto product licenses throughout the EU is, in his opinion, an attempt to 
reduce off label prescribing. He underlined that a prescriber must accept NDU 
risks but is free to prescribe MPs off-label, and that hence off label use is feasible 
(see 3.4 Regulations applying to health care professionals and law on supply and 
use of nonlicensed drugs). In his view, current rules on unlicensed use required 
no changes, but uncertainties needed clarification. MHRA has not undertaken 
specific measures to influence unlicensed use nor to the “very small field” of 
compassionate use. Legislation was in his mind focused on the marketing of 
drugs and law derived from cases (N.B.: no case law was identified). Advertising 
of products without MA was seen to indeed be prohibited (see 3.7 Circumvention 
of drug approval: Law on advertising). Seven NDU provisions were unequally 
known in the U.K. (Table 16).  
LAW 
 
 
 
EXPERT 
DH 
Med. 
Manag. 
Frame. 
Guid. 
Note 
14 
Art. 
83 
Reg. 
EC 
726/ 
2004  
E.U. 
Ped 
Reg 
Sec. 10 
Med. Act 
(NPU, 
specials) 
Reg. 3 
Med. Act 
(Advert.)
DH, 
MHRA 
Ped. 
Strateg. 
22 Y N P N N N N 
23 N N N Y N N N 
24 N N N Y N N N 
25 N N N N Y Y N 
27 N P P P Y N N 
21 N N N Y N Y Y 
28 N N N Y Y N N 
Table 16 Provisions familiar to the British (y=known, n=unknown, p=probably referred to)  
CANADA Expert N.2 explained that in Canada, off label use is part of medical 
practice and that governors will in the future analyze NDU as a result of the Pro-
gressive Licensing Framework, and hence identify areas for improvement. Pro-
gressive licensing will mean increased flexibility in the regulatory system to ad-
dress particular medical needs or exceptional circumstances, such as rare dis-
eases or compassionate use. This is confirmed by data by Yeates et al.234 The 
polled expert saw minimal regulatory tools present to direct pharmacovigilance in 
general. Although the SAP was reported to adopt the International Conference of 
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Harmonization (ICH) principles for ADR reporting, with regard to events that 
should be reported and associated timeframes.235 Compassionate use requires 
previous authorization in Canada, as expert N.1 pointed out (see 3.2 
Investigations into supply shortages of drugs and the necessity as well as 
procedure of nonlicensed drug use).  
JAPAN In Japan, nothing more than on-label use is permitted, said interviewee 
N.12. It was found to have become possible to conduct clinical studies on unap-
proved drugs obtained by physicians and medical institutions or clinical studies 
on off label applications of approved drugs (MHLW Ordinance N.106 dated June 
12, 2003, the revised GCP). With the broadening of the internet, cases of adver-
tisement of unapproved drugs increased. One lecturer believed that a notification 
concerning the guidance and control of individual importers, including items re-
lated to drug advertising, has been issued (Notification N.0828014 of the PFSB 
dated August 28, 2002). Also, notifications for the guidance and control of per-
sonal import services as well as the appropriateness of advertising foreign drugs 
on the internet (Notification N.0828014 of PFSB dated August 28, 2002) were 
enacted.236 The purpose of the notification was however, judged to be more likely 
to combat counterfeit drugs than to manage NDU.  
SWITZERLAND Interviewee N.14 primarily distinguished between off-label, unli-
censed and licensed use for Switzerland. Off label use is, according to him, not 
subject to legal provisions. Compassionate use requires prior authorization, 
which he thought, is necessary. Unlicensed use is prohibited; individual import 
(§ 36 of the Arzneimittel-Bewilligungsverordnung, Ordinance for the Authorization 
of Pharmaceuticals) is an exception from Swiss licensing requirements. The 
regulatory affairs manager did not regard use of products that do not require li-
censing as unlicensed use (also see 3.1 Terminology). A Swiss industry ex-
pert,N.13 on the other hand, did assign individual import to the category of unli-
censed use and said regulation there is similar to Germany. Extemporaneous 
preparation and analogous products manufactured by hospital pharmacies, he 
explained, are not subject to licensing but to the pharmacopeia and special GMP 
rules (N.B.: Ph.Helv. 10 and Suppl. 4 to Ph.Helv. 9). The Swiss drug act provides 
a rule for its regulatory agency to reflect on decisions filed by the EMEA, but data 
exchange is poor as per the expert’s information. The association of Swiss MAHs 
“Interpharma” is proposing a memorandum of understanding to increase data 
exchange between regulatory agencies. Interpharma also participated in the de-
sign of an up-to-date database237 by health insurance suppliers and leading 
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oncologists for medically-acknowledged off label use in malignancy therapies; 
this database contains recommendations and detailed descriptions of indications. 
Affirmations were published; an extension of the database to other diseases is 
planned for the future (see 3.3 Texts of law regulating nonlicensed drug use with 
regard to drug safety). The industry associate demanded provisions for NDU, i.e., 
a requirement for peer review data on the safety, efficacy and quality of the 
product from RCTs or other research prior to off label use. There were plans to 
set up a clinical trial registry in Switzerland. Advertising to the public is prohibited 
with regard to prescription drugs, but circumvention of rules was observed.N.15 N.16 
The industry associates suggested a lower level of evidence for OMPs. A pub-
lished list of OMPs primarily serves commercial purposes, in the opinion of polled 
health care planners.  
AUSTRIA In Austria, an attorneyN.17 reported that consensus on NDU is easily 
found among Austrian peers, though agreements remain undocumented. By drug 
law, the interviewee declared, a physician may have to treat a patient off label or 
with an unlicensed MP if licensed treatments fail (see 3.4 Regulations applying to 
health care professionals and law on supply and use of nonlicensed drugs). If an 
MP is available abroad, affluent patients are at any rate mobile enough to receive 
the treatment in a foreign country (N.B. health tourism). Reformulation of licensed 
MPs (e.g., into pediatric preparations) were regarded as extemporaneous 
products, which are regulated under the Austrian Drug Act. Off label use was not 
addressed in this context. The representative of the Vienna Medical Association 
was satisfied with Austrian legislation as it pertains to NDU and is not aware of 
deficiencies in pharmaceutical law. Liability is subject to the Austrian Civil Code 
dated 1811. Continuing education is not restricted to in-label use in Austria. A 
representative of the Austrian pharmacist associationN.19 called attention to the 
missing indication on a prescription; liability is however, indefinite in the case of 
harm and a pharmacist’s knowledge about off label use. The pharmacist must not 
fill a prescription that gives him or her cause for concern; the pharmacy will con-
fer with the physician and keep a record if the physician insists on a medication. 
The expert was satisfied with provisions of the Arzneiwareneinfuhrgesetz (regu-
lations on the importation of MPs) and explained that (a) imports from the EU are 
uncomplicated, (b) drugs from Germany arrived quickly (within hours) and (c) 
compounds from outside the E.U. were subject to prior permission. Within the 
scope of vocational and professional law, ADRs were found to have to be re-
ported to AGES according to section 75 of the Austrian Medicines Act.  
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In Austria, a database for case reports on off label use of biologicals was said to 
be available to dermatologists and venereologists.238 N.18 The Austrian Society for 
Dermatology and Venereology was informed to legal problems in 2007 and 
therefore restricted access to the data. An emergency law in the Austrian civil 
code was cited as support for NDU by an industry associate.N.19 Unlicensed use 
is, in the interviewees opinion, not regulated in Austria. The expressions used in 
3.1 Terminology were not widespread, but circumscribed in Austrian legislation. 
Drugs were reported to only be legally dispensed when licensed or if import is 
permitted. Section 7 AMG-Au was said to exempt drugs from this provision that 
are approved centrally or when importation is authorized according to section 5 of 
the importation regulations. Unlicensed use was stated to only be permissible in 
terms of importation and only if no licensed option is available in Austria; off label 
use was considered to be under a physician’s personal responsibility. The Aus-
trian Association of Pharmaceutical Industries (Pharmig) saw room for improve-
ment in legislation on importation (i.e., its administrative costs and duration). Lia-
bility was observed to be subject to pharmaceutical, professional, civil and 
product liability law in Austria (see 3.4  Regulations applying to health care 
professionals and law on supply and use of nonlicensed drugs). Pharmaceutical 
advertisements were found to have to be compliant with the SmPC, excepting 
information in response to a physician’ request for information about NDU to the 
MAH (see 3.7 Circumvention of drug approval: Law on advertising).  
An executive of AGESN.23 considered off label use lawful and under the direct 
responsibility of the physician only to treat life-threatening diseases. Section 8 of 
the AMG-Au matched the described rule: 1) (a) Proprietary MPs do not require 
MA, if […] 2. A physician, dentist or veterinary authorized to practice medicine in 
Austria certifies that the proprietary MP is urgently needed to combat a fatal or 
serious disease and that licensed as well as available MPs can almost certainly 
not achieve the desired outcome. […] AMG-Au. 
FRANCE In France, MPs (a) without French MA, (b) to be used in a rare disease 
and (c) with no options of treatment in France were said to be available through 
the ATU program by law.N.34 Article L.5121-12 of the French Public Health Code, 
emerging from law N.92-1729 of 8th December 1992, amended by law 96-452 of 
May 28th, 1996, provided the rules for (a) use of, (b) therapeutic purposes of and 
(c) exceptional measures for MPs without an MA in France.239 Article 126a of 
Directive 2004/27/EC was said to be a promising opportunity to introduce a sim-
plified procedure to authorize marketing of MPs. The interviewee also reported 
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provisions dealing with pharmacovigilance: Decree N.95-278 of 13th March 1995 
relative to pharmacovigilance applies to MPs that are subject to ATU (article 
R.5144-3). Advertising must be in accordance with MA, said the expert. An MP 
with an ATU cannot be the subject of any advertising in accordance with article 
L.551-2 of the Public Health Code. French experts (industry, regulatory) were 
highly satisfied with the ATU procedure.N.34, N.35  
U.S. Compassionate use was an expression not to be found in U.S. regulation.N.9 
To obtain FDA approval for so-called “Single Patient-/Small Group Access”, the 
sponsor should submit an IDE (Investigational Device Exemption) supplement 
requesting approval for a protocol deviation under section 812.35(a) 21CFR.240 
An IND authorization was seen to also be an authorization for shipment 
(N.B.:312.40 (c) 21CFR).N.9 In the expert’s opinion, the compassionate use 
process is tightly regulated: Consultation of the FDA and IRBs is compulsory. In 
this context, patient registries are only managed if required by the FDA or else 
set up by a sponsor or shared within a Patient Efficacy Group. The polled physi-
cian recognized the U.S.’ efforts to stimulate research to increase pediatric infor-
mation, as a provision that affects NDU. He also quoted the proposal to allow 
pharmaceutical companies to market an off label use of a drug (N.B.: by January 
2009 finalized Guidance for Industry Good Reprint Practices for the Distribution 
of Medical Journal Articles and Medical or Scientific Reference Publications on 
Unapproved New Uses of Approved Drugs). The expert emphasized that, 
generally, marketing of off label use is illegal. In the finalized guidance, the FDA 
distinguishes promotional material from medical journal articles underlying speci-
fied criteria for acceptance and failure. The interviewee, however, criticized the 
guidance’s vulnerability to publication biases, conflict of interests and ghost 
writing. The guidance addresses these issues by excluding scientific or medical 
reference publications from distribution that are written, edited, excerpted or 
published specifically for, or at the request of, a drug manufacturer. The polled 
expert’s concern that “medical journals generally do not like negative studies” is 
not addressed in the guidance. He also brought up the complexity of cash flow; 
although the guidance demands disclosure of interests, sponsoring by a CME 
company may not reveal the subsequent funding from MAHs. The polled physi-
cian disapproved of direct consumer advertising, which, to his knowledge, is an 
interpretation of protected free speech and therefore a valued asset. On March 
15, 2009 the Obama administration was reported to review and possibly change 
the FDA guidance on off-label marketing, which was approved in the final days of 
the Bush administration.241 
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Obligations of U.S. physicians were seen to include obtainment of patient’s in-
formed consent for use of different interventions. Patient briefing was found to 
include medications, potential complications and the reasons for suggesting a 
drug. These requirements were observed to be legally framed as the ‘reasonable 
patient standard’. Compassionate use is done in the context of drug trials stated 
expert N.8 and is heavily regulated. The interviewee also associated provisions 
for pediatric studies with NDU, but believes these efforts to have subsided. He 
suggested caution with new drugs and pointed out that pediatric drugs have often 
been “grandfathered in”. Monitoring and regulation of pharmacovigilance is, ac-
cording to his experience and compared to outpatient settings, tighter in inpatient 
care. Expert N.6 connected NDU to importation, which he described to be plenti-
ful from Canada for reasons of cost. He suggested cooperation between regula-
tors, industry, academia and parents to improve the pediatric situation; the pe-
diatrician approved of FDAMA, FDAAA, BPCA and PREA. The interviewee 
(Dutch) and believes E.U. legislation to be more effective. Compassionate use, in 
his view, is primarily relevant in adults and is subject to reporting and record 
keeping requirements. The expert was uncomfortable with an obligation to inform 
parents about off label or unlicensed use in academic settings. He linked not only 
pediatrics but also rare disorders to NDU and was familiar with the Orphan Drug 
Regulation.  
An FDA associateN.5 explained that ‘unapproved drugs’ would be a term assigned 
to old drugs marketed before laws were in place, drugs which have been given 
time lines for applications but may currently still be marketed. She praised 150 
label changes for approved or disapproved use in pediatric patients. In 1/5 of the 
changes, dosages were corrected and unique mechanisms of action or safety 
profiles in children were identified. Though in practice, prescriptions habits need 
not change (see 3.8 Criteria for simplified variation while assuring drug safety: 
Incentives and duties). She proposed an increase of pediatric labels by 20% and 
that E.U. legislation helps to increase the full number of pediatric drugs. U.S. ex-
pert 4 pointed out that the FDA only has the statutory authority to regulate drugs, 
but not dietary supplements (see 3.1 Terminology). He thought guidelines for off 
label use to be absent in the US. He considered a system to collect information 
on the consequences of using drugs off label to be useful. The legal implementa-
tion of such a system, in his opinion, bears a risk of marketing NDU. This concern 
was not unusual; in the U.S., Medicare expanded its coverage of drugs for can-
cer treatments not approved by the Food and Drug Administration by increasing 
the number of reference guides that the Centers for Medicare and Medicaid Ser-
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vices (CMS) rely on for determining which off label uses of cancer drugs to 
cover.242 Coverage thereby is argued to open the market to NDU. 
U.S. expert N.3 (pharmaceutical society) regarded the prescriber’s ability to pre-
scribe off label as a grey area. She felt that there is a demand for more informa-
tion and regulatory guidance on NDU. Instead, scientific information and validity, 
in her opinion, are driven by standard of practice and care as well as the fluidity 
of research, which again are based on peer reviewed studies. She approved of 
the then-planned “FDA Guidance on Off label Use Publications” (see 3.7 
Circumvention of drug approval: Law on advertising).  
U.S. academic N.7 explained that therapeutic freedom is valid for any safe and 
effective purpose in line with a physician’s professional judgment. Biomedical 
research, he pointed out, is regulated in the Belmont Report, written in reaction to 
the Tuskegee Institute experiment. It withheld penicillin from a cohort of black 
men with syphilis. “It can be argued that the Belmont Report’s three guiding prin-
ciples of dignity, beneficence, and justice are ignored in allowing use of off-label, 
compassionate or unlicensed drugs. Patient dignity or autonomy is violated by 
physicians who knowingly use unproven drugs in uncontrolled experimentation 
on patients who are so desperate for a cure that they will reach for straws. The 
very suggestion that off-label use may make a difference is coercive suggestion. 
Beneficence requires that experimentation should contribute through the acquisi-
tion of knowledge to the future good of society. Uncontrolled experimentation 
cannot make such a claim. Justice in terms of the distribution of equal shares of 
benefits and costs is violated because off-label, compassionate or unlicensed 
drugs are largely available only to patients with financial means.” The interviewee 
regarded NDU as liberally-regulated and connected to commercial interest in-
stead of evidence-based medicine. He thought that U.S. law is unsystematic 
compared to German legislation. NDU in his opinion has the authority of law 
within the framework of the State Federal Vocational Rehabilitation Program and 
the Compassionate IND Program (see 3.3 Texts of law regulating nonlicensed 
drug use with regard to drug safety). He first addressed Whistle Blower Laws in 
context to NDU (see 3.7 Circumvention of drug approval: Law on advertising).  
E.U. Interviewee N.31 stated that compassionate use has legally defined, imple-
mented and frame-worked in 2005 by article 83 paragraph 1 of Regulation 
726/2004/EC. It addresses products that are eligible for the CP (see 3.3 Texts of 
law regulating nonlicensed drug use with regard to drug safety). The 
pharmaceutical manufacturer’s representative thought MPs, which have not re-
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ceived market authorization covered by law. She regarded patient treatment with 
foreign MPs as an ATUN covered by many countries and considers ATUN a suc-
cessful process. She approved of the prior access to promising treatments under 
official control. She said NDU is affected by pediatric, OMP and new medicines’ 
legislation as well as by the community code, in addition to the future provisions 
for clinical trials. She thought NDU a problem requiring case-by-case solutions. 
She reported discussions on making off label use official to be ongoing in the 
E.U. since 2008. National compassionate use procedures in her opinion are fast, 
short and cost-effective. The expert was unsure how successful the E.U. proce-
dure is working (see 3.3 Texts of law regulating nonlicensed drug use with regard 
to drug safety). Legislators by her information, intentionally chose “superficial” 
rules because of being aware that patients needed NDU. Finally, she empha-
sized the problem of little legislation being present for physicians (see 3.4 
Regulations applying to health care professionals and law on supply and use of 
nonlicensed drugs).  
Expert N.32 illustrated legislation in Ireland as an example for an MSs’ regulation 
on import of unlicensed MPs. Irish wholesalers were found to have to be autho-
rized to import MPs on a named patient basis. Ordering of quantities only suffi-
cient for one prescription was seen to be fixed. It is the wholesaler’s obligation to 
report imports to the Irish Medicines Board. In case of concerns, the Irish Medi-
cines Board can issue a recall to be followed-up by the wholesaler. This “paper 
trail” allows batch recalls. Preliminary notification was suggested in former times, 
but the Irish Pharmacists Union objected because of would-be delays in patient 
supply. Unlicensed MPs in Ireland also are not be advertised to public, 
consumers or HCPs. This provision extends to price lists. Absence of price lists 
was seen to complicate supply management in the U.K. Unlicensed MPs all are 
only available on prescription in Ireland.  
Interviewee N.30, a representative of European physicians, could not name laws 
that affect NDU. Continuing education cannot be regulated with regard to NDU in 
his opinion. Unlike expert N.29, who named Compassionate Use Regulation for 
circumstances (a) after recruitment for a RCT is closed and (b) an NDA is or will 
be filed. She approved of a restrictive handling to avoid none-submission of NDA. 
She did not understand pediatric, age-based off label use as a classic example 
for off label use (see 3.1 Terminology). E.U. Interviewee 29 said MAH spokes-
men sometimes look upon compassionate use as a new licensing strategy, which 
is incompatible with legislation. MAHs may conquer a market and then claim that 
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an MA is crucial, because patients are stabilized on the drug. The Compassio-
nate Use Regulation required application and data according to her information: 
When an MS envisages the need to make an MP available for compassionate 
use, as defined in paragraph (a) and (b) of article 83, the competent authority of 
that MS must notify the EMEA.243 She welcomed transparency and the future 
possibility to arrive at conclusions for patients and physicians. This work however 
could identify no opinions on compassionate use as by September 11th 2008.244 
EU Regulation 1901 is meant to improve the situation in pediatrics and 
neonatology by means of incentives and funds, according to the regulator; off 
label use is supposed to be contained. Though she described the regulatory 
framework to generally only support the approved use of MPs, it is recognized 
that patients can circumstantially not be left without treatment. She listed new 
options to license advanced therapeutics [new medical products based on genes 
(gene therapy), cells (cell therapy) and tissues (tissue engineering)] conditionally 
or under exceptional circumstances in order to forestall off label and unlicensed 
use. Regulators approved expedited assessment and conditional approval in or-
der to avoid off label use. She reported three compassionate uses, three condi-
tional MAs and three exceptional circumstances in 2007, mainly with regard to 
OMPs. This report could not be verified by an inquest at the EMEA (see 3.4 
Regulations applying to health care professionals and law on supply and use of 
nonlicensed drugs). Amendments to regulations on pharmacovigilance in 2009 
will, according to her information, provide further exceptions and open up the 
region to off label and unlicensed use. Liability is regulated in a different way in 
each MS, although all share compulsive duties for MAHs and sponsors, 
according to the poled regulatory associate. The interviewee pointed out that pe-
diatricians have complained about failing to accomplish casualty insurance for 
RCTs. A transparency guideline was enacted by the EC primarily to gain infor-
mation on drug pricing but also provided information about the difficulties of in-
surance for pediatric RCTs, as per the expert. The expert said that unlicensed 
use usually gets public attention only after an event occurs. She calls attention to 
patient reporting, which has been discussed in the past and is being discussed 
for future legislation.  
Pediatrician and expert N.33 verified the absence of a legal definition for off label 
use in the E.U. He was aware of legislation for compassionate use and distin-
guished group and named patient use, pointing to France. The Belgian pointed 
out compliance with the compassionate use guidance and the possibility of re-
quests for advice from the European authorities for group compassionate use. He 
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did not distinguish between drugs eligible for the CP and others. He was not fa-
miliar with any compassionate use dossier yet having been handled at the Euro-
pean level as of June 2008. He proposed that the potential off label or unlicensed 
use addressed in pharmacovigilance legislation did not mirror the practice of 
medicine.  
GERMANY A German attorney (interviewee N.43) differentiated between legal 
definitions of off label use in social as opposed to pharmaceutical law. He be-
lieved that a generic company is liable for generic off label use, given that generic 
use in the unlicensed indication is common. He believed U.S. products of an MP 
that is licensed both in Germany and the U.S. should be ‘licensed according to 
the model’ though technically the ‘pharmaceutical form’ misses German informa-
tive texts. However, import to Germany is only permissible from outside the E.U. 
if a demand is current. In drug law, he said, Avastin® in wet AMD is an example 
of an extemporaneous preparation and not unlicensed use. He mentioned that 
compassionate use is a technical term that was present in the E.U. long before 
compassionate use was introduced to Germany. The interviewee called for a 
statutory order for compassionate use. Public liability for any future administrative 
procedure is feasible only in theory, said the lawyer. He addressed the problem 
of the pharmacy-only requirement and remuneration of pharmacists for compas-
sionate dispensing. The German Ministry of Health proposed to exempt MPs 
available for compassionate use (article 83 EU 726/2004) from the pharmacy-
only requirements (§ 43 AMG). The ABDA-Federal Union of German Associa-
tions of Pharmacists officially objected to this proposal (see 3.2 Investigations 
into supply shortages of drugs and the necessity as well as procedure of 
nonlicensed drug use). Expert N.43 criticized the imprecise nature of current law 
for patients and demands transparency. He suggested an application procedure 
but for reimbursement of NDU. Comparable procedures are already present for 
expensive therapies with single health insurance companies.245 In Germany, 
patient education and informed consent are subject to prevailing case law, 
according to his information. He did not think a register of off label use is 
permissible under present law.  
Expert N.36 saw an unlegislated area regarding NDU. She thought individual 
treatment of a single patient is feasible in the scope of § 73 Sec. 3 AMG when 
first drugs are available (e.g. in the U.S.) and then in the case of emergency. To 
her knowledge, NDU in groups of patients is subject to compassionate use as 
amended in a draft by BfArM. She pointed out that off label use in RCTs can be 
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covered by health insurance companies nowadays (§ 35c SGB V) and that the 
project has made use of the rule.  
Polled expert N.38 understood compassionate use to be practiced as a way to 
bridge patient supply until the MA is granted after a RCT ends with a positive 
outcome. Unlicensed use is, in his opinion, an expression of social law and refers 
to imported MPs. He objected to including the use of extemporaneous formula-
tions into the definition of unlicensed use. He challenged the idea that compas-
sionate use drugs should be covered by health insurance companies or by the 
applicant for MA. The German Ministry of Health proposed that compassionate 
use drugs be provided free of charge, as enacted in the 15th amendment of the 
AMG (see 3.2Investigations into supply shortages of drugs and the necessity as 
well as procedure of nonlicensed drug use). The interviewee thought compassio-
nate use and import provisions to affect NDU, but saw no necessity for further 
pharmaceutical regulation. He expected the statutory order for compassionate 
use to first regulate care of former trial subjects and second duties for review 
boards. He supposed that a notification duty for physicians and a registry at the 
regulatory authority to be introduced.  
Interviewee N.37 said what off-label- and compassionate use had ‘a state of the-
rapeutic emergency’ in common. Compassionate use in her opinion is a “not le-
galized tradition of continuous supply of a drug after a RCT to patients until MA” 
(see 3.1 Terminology). The expert thought the G-BA and “expert groups for off 
label use at BfArM” did not have an impact on off label use. She believed unli-
censed use to be an issue for criminal prosecution. BfArM’s recommendations for 
compassionate use are, in her opinion, for information only and without govern-
mental liability. Since enactment of the GCP guideline, insurance for clinical trials 
has not been an issue anymore, said the DLH representative. When off label use 
occurs frequently, MAH are forced to act to the point of withdrawal of the MA, she 
explained.  
Expert N.39 emphasized that a final statutory order is absent for compassionate 
use in Germany and points out France, stating that a French procedure has been 
in place for many years. Only noncommittal guidance is present at BfArM he con-
firmed and rules on EU level apply to MP eligible for the CP. He thought that 
there always will be off label use because either a treatment option is not eco-
nomically feasible or expertise of the MAH is deficient for a new indication for an 
NDA. He saw room for improvement on behalf of the authorities in terms of time 
periods required to assess NDAs. He recognized PUMA i.e. ten years of 
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marketing exclusivity for children’s MPs in context with NDU. The industry asso-
ciate was confident that medical guidance for NDU is available and did not de-
mand changes. He approved of the off label expert groups, but regreted their 
small performance and achievements since starting.  
Expert N.42 cited (a) compassionate use in the AMG, (b) off label expert groups 
and (c) national reimbursement guideline (AMR) as impacting NDU in addition to 
orphan and pediatric drug provisions. He criticized legal uncertainty. He approved 
of the G-BA procedure, though he thought more NDU should be assessed by the 
expert group’s forces. Liability law was in his mind more complicated to regulate 
with regard to NDU; he believed that rules applying to compassionate use, expert 
groups and coverage of off label use in RCTs are crucial. Liability and reim-
bursement in his opinion are central aspects for the physician when treating pa-
tients off-label. Legislation is, in the contrary view of a polled expert N.44, cur-
rently sufficient.  
Interviewee N.40 classified NDU in respect to social and drug law again. He put 
down compassionate use as an issue for MAHs, while unlicensed use is a con-
cern for patients, physicians and health insurance companies. He supported 
listing of the federal social court’s off label criteria in a law to increase public 
transparency. This course of action was indeed taken in Austria (§ 8 AMG-Au). 
Both off label and unlicensed use are regulated less appropriately compared to 
compassionate use, says the German lawyer. The policy for unlicensed use, i.e., 
§ 73 Sec. 3 AMG in his opinion is restrictive. He approved of such a “basic ap-
proach” because of quality criteria and pharmacovigilance being guaranteed less 
as compared to off label use. He found liability to be well-regulated by the Ger-
man civil code (BGB), AMG and case law. Potential for conflict remained to be 
present between physicians and health insurance companies. The expert did not 
note any incentives for off label use. Though he suggested a clarification of the 
advertisement ban for off label use in legislation and a loosening of rules for post-
authorization safety studies (PASS).  
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Country 
 
CRITERIA  Austria 
U.K., Irelandviii, 
France 
Germany, 
Canada  Japan, U.S.  
PROVISION 
Duty to obtain a 
permit 
Disclosure duty 
subject to 
prohibition 
Prohibition 
subject to 
permission   prohibition 
PRO 
Preventive, 
recording of all 
imports 
Fast access, 
recording of all 
imports 
Flexible, no 
delay  Drug safety 
CON 
Administrative 
expenses, time 
lag 
Waiting periods 
delay fast access 
No capturing, 
recall, DDL  enforcement  
Table 17 Synopsis of expert’s valuation of import regulation  
Table 17 summarizes the assessment of import provisions; compassionate use 
programs were appreciated additionally but are discussed in 3.2 Investigations 
into supply shortages of drugs and the necessity as well as procedure of 
nonlicensed drug use. In summary, the narrated interview data illustrated 
deficiency of information and little transparency of applicable regulations.  
                                                            
viii Ireland was introduced by an EU‐representative 
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3.6. Liability for nonlicensed drug use 
Physicians prescribing in an off label manner may be found negligent and liable 
for harm by accusation of malpractice. Concerns have been raised regarding 
HCP’s liability in the event of adverse outcomes associated with unlicensed drug 
prescription. It was necessary to distinguish off label from unlicensed and from 
compassionate use as it concerns questions to liability. MAHs, HCPs, wholesa-
lers or sponsors of clinical trials were seen to possibly be held liable for harm 
caused by NDU. MAH, physicians and perhaps pharmacists may be found re-
sponsible for harm caused by an off label drug use. HCPs and MAHs were found 
to be at risk for criminal liability under acts of compassionate use. 
OFF LABEL USE By German civil law, MAHs were shown to be liable, independent 
of negligence for damage to health that is found to be not inconsequential and for 
harm that occurred while the MP was used as specified, including scientifically 
accepted as well as frequent or typical incorrect uses. Off label use was de-
scribed to occasionally be scientifically accepted, e.g., misoprostoli in obste-
trics.246 If the MAH would not address the risks of a drug use being discussed in 
the PIL or if he expedites the drug use through supportive publication, he may be 
found liable for consequential harm and charged with § 823 ff. BGB in case of 
fault based liability. He was found to be prosecutable according to § 5 AMG in 
conjunction with § 95 Para.1 as early as he markets a risky product and is found 
responsible for actual homicide by § 211 ff. StGB and §§ 223 ff. StGB for bodily 
injury.247 On the other hand, the acyclovir-case (30.5.1990 – 27 U 169/87) was 
frequently cited to give support for a circumstantial obligation to treat off label 
where an unlicensed treatment is considered to be state of the art.  
Liability cannot only be accepted by MAH, but also by HCPs: In Germany, a phy-
sician’s liability for medical malpractice was shown to originate from § 611 BGB 
(contractual relationship of physician and patient) and the law of torts §§ 823ff 
BGB. If a patient is killed or harmed by medication and the responsible phar-
macist could have prevented the event, the pharmacist was judged to be found 
guilty of tortuous liability in Germany.248 If a component is critical, the pharmacist 
was found to have to first refuse to dispense the MP and then inform the pre-
scribing physician. To know of and judge off label drug use, however, 
pharmacists were required to have to know the diagnosis, which is usually not 
recorded on the prescription and any such effort challenges German data privacy 
laws. Liability was estimated to be improbable if the pharmacist meets his duty to 
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demonstrate and explain an MP and maybe if the off label indication does not 
come to his attention and of course provided she or he did determine the pa-
tient’s need for counseling. Partial liability for ADE was found to be possible if a 
pharmacist, knowing about a critical off label use, failed to obtain the physician’s 
confirmation for the prescription. 
In Austria, the extent of liability for use of an MP was found to be limited through 
§ 15 AMG-Au and § 13 of the statutory instrument on SmPCs of proprietary MPs 
[Verordnung der Bundesministerin für AGS über die Fachinformation für 
Arzneispezialitäten]. Statutorily, absolute liability of an MAH for harm was seen to 
only be accepted if the MP was used according to its specifications. Off label use 
did not meet this criterion, but Austria often is observed to refer to German 
ruling.N.17 Therefore, scientifically accepted as well as frequent or typical incorrect 
use could be regarded as ‘use according to an MP’s specifications’ in Austrian 
courts. Austrian experts were unconcerned about liability for medical malpractice 
because it is regulated by ABGB 1811 and covered by professional liability 
insurance.N.15 But what happens when an off label ADR justifies lawful damages 
that are not born by a professional insurance company? Austria planned to com-
pensate the insolvent debtor’s penalties (N.B. Japan already has such a fund in 
place) in the future. In Austria, product liability was shown to decrease if the clai-
mant is jointly responsible (§ 11 Product Liability Act of Austria) and does not 
apply if the physician is found responsible. The physician was found to have a 
duty of care (§ 49 Abs 2 Nr. 2 physician’s law of Austria) due to his special skills 
(§ 1299 ABGB). By § 1311 ABGB, a person was also seen to be responsible for 
any harm caused after breach of the related protective law.  
Patient information was identified to play a superordinate role in Austria. The Su-
preme Court admitted a claim (Az. 6 Ob 54/04s) of a physician who had been 
treated with Novantron® (mitoxantronei) by a specialist to treat multiple sclerosis. 
Mitoxantronei had not been licensed for this indication at that time. The claimant 
sustained a myocardial syndrome. This ADR had been reported of in medical 
journals. The treating physician had not briefed her patient-colleague about the 
ADR and was found guilty. If a patient is not informed, consent has been judged 
to be missing or invalid and the treatment may be regarded as an unauthorized 
treatment (§§ 6, 88 und 110 StGB Austria). Informed consent was found to be 
dependent on a patient’s individual judgment and discernment. Obtaining infor-
mation and valid consent was necessary to require individual and comprehensive 
information as appropriate. The Austrian patient charters were found to constitute 
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the legal framework for the right to appropriate medical counseling. On the other 
hand, the patient charter also was estimated to increase the patient’s self-deter-
mination and personal responsibility in participating in a therapeutic decision. 
There were, however, exceptions to the physician’s duty to inform patients: the 
therapeutic privilege, mortal peril and quitclaim. In all other circumstances, the 
patient was found to have to be fully informed about the diagnosis, treatment, 
risks and aftercare. The extent of information to be provided increased with both 
decreasing benefit and growing risks. Art. 7 Para. 2 of the patient charter ad-
dressed accepted methods and the state of science. A patient was for instance, 
seen to have to be referred to a different health care provider if the primary prac-
tice cannot offer accepted methods and provide the standard of care with regard 
to treatment. Damages for non-performance were found to be possible. 
In the U.K., product liability was observed to be subject to the Consumer Protec-
tion Act of 1987. MAHs were judged to be liable for quality defects but are not 
responsible for harm as a result of unapproved use. British NHS trusts often were 
found to address liability issues in off label use guidance (see 3.3 Texts of law 
regulating nonlicensed drug use with regard to drug safety). Any liability asso-
ciated with the use of approved, unlicensed MPs (or MPs used off-label) was 
shown to be, for example, accepted by an employing authority provided that best 
practice has been followed. The ‘Policy for the Use of Unlicensed and Off Label 
Medicines’ was seen to not be legally binding, but may be consulted in court, 
comparable to forecasted consultation of the British National Formulary for Child-
ren (BNF-C). The NHS Litigation Authority and the Medicines Protection Society 
were not aware of any claims as a consequence of NDU to date in the United 
Kingdom. The Bolam suit of 1957 (indirectly linked to NDU) recognized that a 
physician offends his duty of care when not acting according to the state of 
science as accepted by a jury of peers. Therefore, when refusing to provide non-
licensed care, a physician was proven to offend his duty of care when NDU is the 
state-of-the-art of science. 
Patient information was also a major theme in U.K. legislation. According to sec-
tion 2 § 12 Para. 4 of the Consumer Protection Act, a physician is responsible 
and found guilty if he fails to provide information that affects the validity of a pa-
tient’s informed consent. The Northern Ireland Adverse Incident Centre was seen 
to take the perspective that use of a medicinal device outside of the recommen-
dations of the MAH may influence risks of care, safety and liability. For these rea-
sons, requirements for information were found to increase when treating a patient 
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in a nonlicensed compared to a licensed way. Also, under the British Code of 
Ethics for Pharmacists, pharmacists were observed to have a duty of care when 
checking reasonability of a prescription. A pharmacist is obliged to object to risky 
medication. The attestation of a physician or an MAH’s knowledge of off label use 
did not release the pharmacist from this responsibility. Over and above, British 
HCPs believed that the mutual trust of the patient in the physician should not be 
disturbed in the course of consultation. 
By article L3131-3 CSP, French MAHs were not shown to be liable for harm that 
occurred when a drug was used in an unlicensed indication or in unapproved 
terms of use.  
In Switzerland, liability for off label use of cytostatic preparations was found to be 
shared between physicians (for efficacy and safety-related harm) and 
pharmacists (for the extemporaneous formulation). But bear in mind: Extempora-
neous formulations were assigned to the term unlicensed use in the U.K. and the 
Netherlands, or might even not be regarded as unlicensed at all, because they 
are exempted from licensing requirements. Pharmacists were generally found 
responsible for quality defects of extemporaneous products.  
In summary, responsibility for harm in the wake of off label use was primarily 
shared between physicians and MAHs. Minor responsibility was shifted to phar-
macists depending on the country’s legal framework. An additional risk factor for 
unlicensed use was product quality, which was secured with off-label use. Latter 
products were unmanipulated and assumed to be licensed for other purposes. 
Quality was hence expected to be assured. Pharmaceutical companies, whole-
salers and HCPs were discovered to be governed by laws with respect to liability 
for unlicensed use.  
UNLICENSED USE Directive 85/374/EC was found to govern liability of defective 
products in the E.U. In Germany, an upper limit was seen to be fixed for civil pe-
nalties. § 88 AMG fixes a capital sum of € 600,000 or € 36,000 annually for a 
death, € 120 Mil. for a harmed person. And € 7.2 Mil. in case of death of or harm 
to multiple people. Absolute liability was found to not be applicable to MAHs of 
imported MPs imported on the basis of § 73 Abs. 3 AMG.249 Wholesalers and 
HCPs may be found liable for harm that results from quality defects of an MP 
imported from a third party country. A physician could be liable by § 611 BGB 
and §§ 823ff BGB for harm secondary to unlicensed use; the physician was seen 
to have far-reaching duties of information when using unlicensed MPs. If a pa-
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tient is harmed or killed because of a drug, and if this event could have been pre-
vented by the pharmacist’s accurate professionalism, claim for damages and 
compensation for immaterial damage (tortuous liability) towards the pharmacist 
was said to come into consideration.250 If a drug is harmful, the pharmacist was 
judged to have to object to filling the prescription and he or she must inform the 
prescriber.251 The pharmacist was seen to have an obligation to contract (§ 17 
Abs 4 ApoBetrO); he or she brings the MP into circulation. He or she must object 
to bringing products into circulation that are risky (§ 5 Abs 1 AMG). This provision 
was found to have a higher level than therapeutic freedom. German community 
pharmacies were found to also dispense approximately 25 Mil. extemporaneous 
products per year, i.e., 1100 formulations per pharmacy annually. 
Extemporaneous ointments, capsules, powders and infusion lotions were seen to 
be common in dermatology, oncology and otolaryngology. Pharmacies could es-
tablish a quality management system or participate in inter-laboratory tests con-
ducted by the central laboratory of German pharmacists (see Table 18) to 
minimize the risks and the probability of liability.  
Task 
 
 
CATEGORY 
Monograph Assessment  
Liability 
assumed  Inspection 
P
R
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P
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MAH BfArM, PEI, BVL MAH 
District 
Government 
E
X
TE
M
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R
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N
E
O
U
S
 
P
R
E
P
A
R
A
TI
O
N
S
 New 
German 
Formulary 
Central Laboratory 
of German 
Pharmacists 
HCPs 
Local health 
authority 
_HCP 
No systematic 
testing  
Table 18 Quality control of extemporaneous products in North Rhine-Westphalia 
In the U.K., the Bolton Primary Care Trust (PCT) Medicines Management Team 
placed the responsibility of obtaining informed consent from patients and care-
takers as well as informing GPs about the melatonin’s use onto the physician 
(see 3.3 Texts of law regulating nonlicensed drug use with regard to drug safety). 
Dispensing unlicensed products was shown to be prohibited according to the 
physicians’ professional law. A British expertN.24 reported that because of past 
manufacturing mistakes and errors, community pharmacies in the U.K. frequently 
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refer extemporaneous preparations to ‘specials’ manufacturers; though phar-
macists still remain liable for externally prepared specials. Extemporaneous 
preparation was reported to decline in British pharmacies. A second British ex-
pertN.21 criticized that outsourcing of extemporaneous preparations bears new 
sources of error (see 3.5 Operating experience with provisions for nonlicensed 
drug use). He underlined that the pharmacist must guarantee the product’s cor-
rect identity and its appropriateness for clinical use despite outsourcing. The PCT 
NHS Fife assigned documentation, briefing of physicians and obligations to pre-
serve records of NDU to its pharmacists. The Bolton PCT Medicines Manage-
ment Team referred employed pharmacists to follow through with the Royal 
Pharmaceutical Society of Great Britain’s guidance on quality assurance 
measures for unlicensed MPs. Liability of a pharmacist for imported MPs and for 
extemporaneous products was found to derive from section 1 § 2 Consumer 
Protection Act (liability of businessmen for faulty products).  
Placing MPs onto the market without an MA was found to generally be recipro-
cated with a fine. Pharmaceutical advertising of unlicensed MPs was prohibited in 
all researched countries (see 3.7  Circumvention of drug approval: Law on 
advertising). In France for example, MAHs were seen to be fined up to € 37,500 
for advertising unlicensed use. Beyond marketing and if entered into the supply 
chains, HCPs are ultimately in charge for public health; French pharmacists for 
instance were observed to be forbidden to dispense unlicensed MPs by profes-
sional law. 
Treatment providers were largely found to be responsible for harm resulting from 
unlicensed use and are thus liable for redress. Breach of abatement measures by 
wholesalers or MAHs were seen to probably cause both to be held responsible. 
Further rules were observed to be present for INDs used in clinical trials and 
compassionate use. MAHs, HCPs and sponsors were judged to be potentially 
liable for harm due to compassionate use.  
COMPASSIONATE USE In the E.U., MPs dispensed in accordance with art. 83 para. 
7 of Regulation (EC) N.726/2004 were found to be without prejudice to civil or 
penal responsibility of a sponsor.  
A French MAH, holder of a permission to import MPs or holder of an ATU (Art. 
L3131-3 CSP), was not seen to be liable for harm incurred during temporary au-
thorization for use. Before a treatment within scope of the French ATU was to 
begin, patients were required to give their informed consent and receive the pa-
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tient information validated by AFSSAPS. Furthermore, the hospital pharmacist 
was to be informed about the ATU treatment. Clinic pharmacists were obliged to 
fulfill duties with respect to the supply and monitoring of cohort ATUs. They were 
seen to have to contribute to the application process.  
§ 611 BGB and §§ 823ff BGB were found to govern a physician’s liability for 
compassionate use in Germany. He was seen to have to inform a patient about a 
considered compassionate drug use with accuracy similar to a participant’s edu-
cation about a clinical trial. In Germany, pharmacists were not said to be liable if 
the IND is supplied to the investigator directly as planned for the future.252 If the 
product was to be supplied via a hospital pharmacy, the pharmacist would have 
to assay the MP. He would have been responsible for quality and expiry, which 
would both have to be inspected regularly (§ 12 ApoBetrO).253  
The ‘Patient’s Charter for England dated 1997’ was identified to accord the right 
of (a) access to treatment, (b) information and (c) drugs within the scope of com-
passionate use to patients. Confidentiality was seen to be addressed (relevant in 
terms of compassionate use because of compulsory reports to regulatory bo-
dies). The guidance issued by the Sheffield Teaching Trust required physicians 
to provide sound scientific data, information and be experienced before using 
INDs in patients not participating in the corresponding trial, in order to avoid neg-
ligence. 
The following aspects were confirmed to affect liability issues in NDU in sum-
mary: patient’s informed consent, best practices, support from a jury of peers, 
MAHs’ pharmaceutical advertisement, the physicians’ duty of care, prohibition of 
risky active substances and the pharmacist’ obligation to contract (Table 19). 
Duties 
IN CHARGE Responsibilities 
PHYSICIAN 
To obtain informed consent 
Perform best practices 
Assure support from a jury of peers 
Comply with duty of care 
MAH 
Act on provisions for pharmaceutical advertisement 
Do not place risky active substances on the market/ 
quality assurance 
PHARMACIST Fulfill obligation to contract 
Table 19 Aspects with an impact on liability for NDU 
The higher the assumed risk of a treatment, the more information must be con-
veyed to a patient. The physician was found to have to provide best practices at 
all times and should only refer to unapproved methods when licensed options fail, 
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are inapplicable or exhausted. His or her approach should be estimated to re-
ceive support from a jury of peers and the measures taken should comply with 
duty of care requirements. Requirements to verify evidence for safety, efficacy 
and quality for an MP decreased with growing morbidity. The MAH must not in-
fringe on provisions for pharmaceutical advertisement; else it may be found re-
sponsible for harm related to NDU. The MAH must not market risky products 
which, if they enter the supply chain, must not be dispensed by a pharmacist 
judging his expertise. If there is no reason to object, the pharmacist was found to 
be obliged to fill a prescription but assure the products’ quality. 
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3.7. Circumvention of drug approval: Law on advertising 
Off label decision-making was found to be vulnerable to marketing practices.254 
To a great extent, literature gave evidence for NDU marketing practices, 
including pharmaceutical advertising and sales representatives detailing off label 
use. Thought-leader’s opinions, commentaries, case studies, abstracts, posters, 
compendia and using skilled sales representatives to solicit questions about off 
label use were described to be techniques by which companies covertly promote 
off label use.255 Graves and Baker reported that “sales-representatives are 
generally limited to discussing on-label topics, industry-based drug information 
practitioners are not”. Appropriately disclaimed off label information in response 
to an unsolicited inquiry was seen to be permissible.256 Samples have been de-
scribed to result in prescribing new drugs, often using NME for off label indica-
tions.257 A study by Steinman et al. showed that while Gabapentin was approved 
by the U.S. Food and Drug Administration only for the adjunctive treatment of 
partial seizures, in 38% of sales visits (44/115) the ‘‘main message’’ involved at 
least one off label use.258 Off label usage was confirmed to be rarely discouraged 
by manufacturers.259 Information (not) found in published trials may cause over-
prescription for off-labels; data by Rising et al. comparing NDAs for NMEs to the 
FDA showed that trials with favorable outcomes were more likely to be pub-
lished.260 Selective publication of clinical trials has led experts to suggest a 
compulsion to publish predefined outcomes of clinical trials. Some authors even 
went to such lengths as to suggest a public or independent trials body staffed by 
methodologists and on an international scale. This publicly funded international 
infrastructure would conduct proposed studies in conjunction with clinical experts 
from around the world.261 Radley et al. suggested more extensive post-marketing 
surveillance to identify non-evidence-based prescribing practices that lack FDA 
approval, and to research the potential influence of pharmaceutical marketing on 
off label use.262 MAH are barred by the FDA from promoting off-label use, but 
they are using medical science liaisons (MSLs), often physicians and 
pharmacists, to discuss off-label uses. The number of MSLs has increased stea-
dily, totaling 1,970 in 2008, up 48 percent from 1,335 in 2003.263 
Off label drug promotion was generally shown to be illegal in all researched 
countries. However, handling of NDU information ranged from retrospect ap-
proaches in the U.S. to prospective management in the U.K. The British regula-
tions were proven to allow the MHRA to require sight of advertising before it is 
issued. Self-regulation through Codes of Practice for MAHs, administered by 
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trade associations, was a mean of checks and balances in terms of competition 
law (see Table 20) was identified in Austria and Germany. In the U.S., 
whistleblowers were explained to report observed wrongdoings of employing 
MAH. Legal rights and safeguards for social security were reported to be in place 
for whistleblowers. This chapter looks at the laws governing drug information and 
pharmaceutical marketing in selected countries. 
Feature 
 
COUNTRY Tool Complainant(s) 
GERMANY 
Voluntary self-control for MAHs (Freiwillige 
Selbstkontrolle für die Arzneimittelindustrie 
e.V., FSA des VfA) MAH 
 
AUSTRIA Code of behavior (Verhaltenscodex) 
U.K. 
MHRA Independent Review Panel for 
Advertising (IRPA), Blue Guide  
Patients, HCP, 
MAH 
FRANCE 
Advertisements to HCP must be notified to 
AFSSAPs within 8 days n/a 
EU 
EFPIA Code of Practice on Relationships 
between MAHs and Patient Organizations  MAH 
SWITZERLAND 
seizure, safekeeping, destruction, 
prohibition of advertising materials by 
Swissmedic at the cost of the MAH  n/a 
U.S. 
FDA Risk communication advisory 
committee 
MAH 
CANADA 
Pharmaceutical Advertisement Advisory 
Board (PAAB) 
Table 20 Measures to control pharmaceutical advertising in selected countries 
Physicians regularly were seen to require and demand off label information on 
dosage, safety and effectiveness, e.g., for children. Advertising regulations and 
information duties were found to serve both purposes e.g., § 75 AMG and 
PharmRefPrV (sales representatives examination regulations) in Germany. In the 
U.S., court cases have gone to such lengths as to address the issue of whether 
FDA had interfered with drug manufacturers and physicians’ freedom of speech 
to communicate information about off label drug use.264 While some publications 
voluntarily started to disclose statements on discussions of off label use,265 the 
FDA issued tolerant guidance for the distribution of medical and scientific infor-
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mation on off label drug uses, the action of which is believed to lessen incentives 
to submit supplementary approvals.266 However, the guidance also was criticized 
to enable communication of incorrect off label use. A revised version of the Phy-
sician Payment Sunshine Act was seen to require drug manufacturers to disclose 
payments made to doctors that exceed $100 per year in the future. MAHs were 
found to be subject to penalties of up to $1 m for "knowingly failing" to disclose 
information.267 
Fear of litigation, regulation, or judicial fines were thought to improved abidance: 
In France for instance, companies that use advertisements which do not comply 
with the product license were shown to be able to be fined up to € 37,500. Penal-
ties to deter wrongdoing have however, been estimated to necessarily not yield 
the desired result. Several U.S. law suits have resolved allegations of improper 
off label marketing of drugs. Eli Lilly agreed to pay US$ 1.415 Billion in the U.S. 
on January 15th 2009 to resolve the allegations of off label promotion of Olanza-
pini (Zyprexa®) as treatment for dementia and other conditions, causing false 
claims to federal insurance programs, none of which provided coverage. Eli Lilly 
pled guilty and had paid $36 m to settle allegations in the past; the company had 
marketed its drug Evista® (raloxifenei) for off label uses. In 2004, the case 
against Pfizer-Warner-Lambert resulted in the company being fined $240 m and 
ordered to pay $152 m in damages for promoting the off label use of gabapentini 
(Neurontin®) in bipolar disorders and Lou Gehrigs-disease. Further cases of off 
label promotion in the U.S. were Sereno’s Somatropin promoted to treat AIDS-
related wasting, Schering’s Intron-A® and Amgen’s Enbrel®.268 Bristol Myer 
Squibb, among other pharmaceutical companies, published a corporate integrity 
agreement also governing information policy about off label use.269 Is it decent to 
then withhold information about effective treatments? 
Full approval in multiple diseases was verified to be costly. The absence of an 
MA was found to not have to mean inefficacy. On the other hand, a ‘narrow busi-
ness incentive’ choosing narrow indication strategically, but expecting wider 
range use was quoted in Ratner et al.’s paper as a cost saving regulatory 
strategy. He imposed the fundamental question on how approval can be made 
responsive to important drug use. For these and other reasons, lawmakers were 
expected to possibly reverse FDA guidelines on off label use.270 Also, FDA was 
found to be undertaking efforts to reform MA of drugs in oncology to not be li-
censed by body part but by tissue. Tumors found in the head and neck region 
were seen to supposedly be licensed for all squamous cell carcinomas.271 
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The German advertising regulation (Heilmittelwerbegesetz, HWG) was seen to 
prohibit NDU marketing. Pharmaceutical advertising was found to not be routinely 
assessed as to the conformity with the regulations in Germany. Data on the 
number of breaches was absent. Data from surveillance authorities at community 
and state level or by courts on breaches of advertising regulations was inac-
cessible. Self-regulation through Codes of Practice for MAHs (FSA) reported 50 
and 56 complaints in 2004 and 2005 of which two concern advertising regulation, 
but not NDU in specifically.  
Generic off label use plays a special role in context of advertisement: The asso-
ciations of MAHs, a study from Italy and the experts of the qualitative study also 
suggested that generics are as discussed in 3.1 Terminology, being advertised 
for nonlicensed indications by sales representatives. Table 6 illustrates legitimacy 
of generic substitution in selected countries.  
Substitution 
 
COUNTRY Generic  Therapeuticix 
Prescription 
of APIs 
GERMANY Present 
Emergency 
service, discount 
contract Present 
FRANCE Present Absent n/a 
U.K. Present Absent Present 
AUSTRIA Absent Absent n/a 
Table 21 Substitutability of medicinal products 
Drug industry detailing was stated to promote off-label uses. Expert 8 remarked 
about detailing that many U.S. medical schools now will not allow a drug com-
pany representative into the hospital. Health care trainees were seen to also tar-
geted in Germany (Novartis Studentenservice, Sanacorp Campus). In this con-
text, the Federal Association of Pharmacists in Public Service (Bundesverband 
der Apotheker im Öffentlichen Dienst) (BApÖD) in their policy document of 2005 
declared sales representatives and drug samples to be dispensable. To increase 
prescription of brand drugs, sales representatives were said to argue (a) against 
prescription of APIs and (b) that aut idem substitution offends therapeutic free-
dom. The association of national health care physicians of Bavaria (Kassenärztli-
chen Vereinigung Bayern) (KVB) also reported that generic manufacturers pro-
mote MPs for uses for which only brand products have received an MA, under-
lining absent legal responsibility.272 KVB quoted Dierks et al., who did not regard 
                                                            
ix Dispensing of a therapeutic alternative instead of identical PIL without the prescriber’s feedback  
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use of generics in brand indications as an off label use.  
Generic manufacturers were found to be liable also for the brand’s supplemen-
tary area of application (see 3.6 Liability for nonlicensed drug use). Generic off 
label use was also seen to occur in silico when indications are not taken into 
consideration in the search for cost-effective alternative products. In Germany, 
pharmacists were observed to be obligated to substitute discounted generics 
according to the patient’s health care insurance (see Table 21). Generic substitu-
tion was shown to be subject to § 129 Abs. 1 sentence 3 SGB V. A random aut-
idem search with selected pharmacy software (Pharmatechnik®, ADG® or 
WinApo®) was proven to take into account the API and indications in ABDATA® 
pharma data service and the ATC code to level 5.273 A search for Beloc ZOK® 
retrieved results for all metoprololei products and ATC codes, though only results 
that show equal or more indications will be displayed in green font. MPs with 
fewer or no matching indications were seen to be displayed in grey and red, re-
spectively, by the software. On the other hand, ifap® praxisCENTER for office-
based physicians also displayed metoprololei NOK Sandoz 95mg when a search 
for generics for Beloc Zok® 95 mg was performed, although the generic is solely 
licensed to treat hypertension and, e.g., not to prevent migraine.x In the strict 
sense, a physician would treat a patient off label using metoprololei NOK Sandoz 
95mg in the management of migraines. This detail was notable with respect to 
incentives for supplementary indications in off-patent products (e.g., orphan or 
pediatric drugs). On top of possible substitution to cheaper generics, pediatric 
and orphan incentives were judged to possibly become effectless through social 
law: Orphan or pediatric incentives may be repealed if MPs were found to be as-
signed the same fixed price group (Festbetragsgruppe) for reimbursement pur-
poses by German social law,274 not securing a return on investment for the MAH 
within the protection period. For these reasons, generic off label use was seen to 
not only be a result of marketing measures, but may also result from software, 
insurance contracts and drug information.  
Alternatively, cliniciane were said to rely on (industry-funded) expert recommen-
dation. Polled physicians also stated that, as residents learn to use medications 
for use in a particular patient population, they may never be aware of the product 
not being studied or labeled in the indication.N.5 Moreover only 10% of U.S. medi-
cal students were reported to be expected to have a mandated clinical pharma-
                                                            
x Tested on July 23rd 2007  
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cology course before seeing patients. For this reason, there was more evidence 
to support an unawareness of NDU among physicians (see 3.5 Operating 
experience with provisions for nonlicensed drug use).N.6   
The British regulatory agency was found to have a complaint procedure in place 
for violation of MPs advertisement rules. The outcomes of investigations into 
complaints about advertising of MPs were proven to be published. An Advertising 
complaint form was evidenced to be available.xi Members of public, HCPs and 
pharmaceutical companies were shown to be allowed to issue a complaint. The 
MHRA’s Review Panel for Advertising was seen to be state-run; administrative 
efforts for the complainant are small. The complaint was found to be subject to a 
transparent procedure. Committee members’ interests are reconciled. The com-
plainant’s data was observed to not be published unless he or she is industry-
affiliated.  
The afore named memorandums of understanding and codes of conduct re-
ported fewer complaints than federal bodies. From September 2005 to August 
2006 the IRPA received 172 complaints and initiated 136 investigations.275 The 
MHRA's Advertising Standards Unit also was found to routinely scrutinize medi-
cal journals, public magazines and the internet for the promotion of such com-
plaints. Selectively, advertising was said to be checked prior to issue. On top of a 
review of advertising, the U.K.'s Royal College of Physicians (RCP) is expected 
to release a report on February 4th 2009 recommending that pharmaceutical 
companies stop giving gifts to physicians. The report predicts that forbidding drug 
companies to give even small gifts to physicians would rebalance the relationship 
between medicine and industry.276 
Boundaries between advertising material and drug information often overlap. 
Both themes are assumed to affect patient information and consent. HCPs said 
they experience difficulties in obtaining information about NDU, which they re-
quired to educate and inform patients adequately. Expert 9 argued that physi-
cians nowadays have to convince parents to allow their children to go into re-
search treatment. Before, MPs had been used off label frequently without 
parents’ knowledge, thus leaving parents to believe that treatment options were 
sufficient. He would welcome parents to be better informed about what medica-
tion constitutes off label use. Unswayed materials for patient education on NDU 
(see 3.3 Texts of law regulating nonlicensed drug use with regard to drug safety) 
                                                            
xihttp://www.mhra.gov.uk/Howweregulate/Medicines/Advertisingofmedicines/Advertisinginvestigations/Adv
ertisingcomplaintform/index.htm 
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were however found to be limited. 
Information search was found to be challenging in terms of reliable supportive 
evidence for NDU. Publications addressed HCPs (e.g., Off label Drug Facts) or 
even patients (Patient’s Guide to Off label Use of FDA approved drugs). Some 
literature was specific to an area of expertise such as pediatrics (Pädiatrische 
Dosistabellen and Kinderdosierungen von Phytopharmaka), then only accessible 
to hospital employees (Unlicensed Medicines Database Birmingham) or next 
registered customers (Off-label.co.U.K.). Single regulatory authorities, i.e., Health 
Canada and AFSSAPS, were seen to maintain private databases. Information 
platforms for pediatric and rare disorders were identified (see Table 22).  
Some institutions have passed into the "right sizing" off label technology as 
shown in 3.3 Texts of law regulating nonlicensed drug use with regard to drug 
safety. The Massachusetts General Hospital’s IRB was reported to become in-
volved when the use of a product is outside of published norms (off label with 
insufficient published supportive data).277 Unfortunately, only patients transferred 
to such hospitals were found to benefit from regional procedures. In the U.K., 400 
physician’s offices were observed to contribute to the The General Practice Re-
search Database (GPRD) by filing anonymous case reports. A comprehensive, 
national database such as the British GPRD but for NDU assessment reports 
was present in no research country.  
A comparison of approaches to control pharmaceutical advertisement with regard 
to the impact onto prescribing patterns was found to be absent. Observations 
suggested that public training and continued education on regulatory issues, re-
solving the lack of enforcement of advertising regulation and an offer of indepen-
dent, reviewed information might alter the impact of promotion on NDU. 
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NDU
COUNTRY Pediatrics Off label Use Unlicensed Use Compassionate Use OMPs 
U.K. British National Formulary for Children 
Birmingham 
Unlicensed Drugs 
Database; IDIS 
Pharma,278 Fife 
UMP database IDIS Pharma 
Orpha.net,279 
National 
Organisation Rare 
Disorders Orphan 
Drug database280 
CANADA / / / 
Special Access Management System, formally known 
as Emergency Drug Release Programme database 
SWITZERLAND / Off label Use in Onkology281 / 
List of temporarily licensed 
medicines282 / 
AUSTRIA / Biddbase283 / / / 
FRANCE / / IDIS Pharma 
IDIS Pharma; non-public 
Autorisations temporaires 
d'utilisation database of 
Agence française de sécurité 
sanitaire des produits de 
santé / 
U.S. / 
Wolters Kluwer Facts & 
Comparisons: Off label Drug 
Facts (Loose-Leaf); The 
Guide to Off label Prescription 
Drugs: New Uses for FDA-
Approved Prescription Drugs / 
Treatment INDs Allowed to 
Proceed284 
List of Orphan 
Designations and 
Approvals285 
EU 
European Paediatric 
Medicines Database,286 
registry of pediatric studies 
within EudraCT, priority list / / 
„up-to-date list” of 
compassionate use products 
(planned) 
Orphan Drug List,287 
joint registry for 
orphan drugs 
GERMANY 
ZAK medicines for children 
database288 pediatric 
dosages of herbal medicines 
Tabulation of antipsychotic 
drugs licensed in Germany 
and their legitimate off label 
use;289 supplemental medical 
directive appendix 9290 IDIS Pharma  
Orphan-drugs by 
indication291 
Table 22 Sources of information with impact on NDU (/= no findings)
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3.8. Criteria for simplified variation while assuring drug safety: 
Incentives and duties 
Many key opinion leaders in regulatory affairs emphasized that for the patients’ 
benefit, research must result in an MA.292 Incentives for MA have been passed in 
the E.U. and North America primarily to overcome supply shortage and NDU in 
pediatrics. Some variations to MA were found to be offered incentives: Well-es-
tablished use, switch and significant, supplementary indications. Countries’ ef-
forts extended to patented and off-patent MPs with regard to the children’s and 
rare disorder’s fraction of NDU. Solutions, supportive measures and programs 
that have been introduced to encourage pediatric and OMP development were 
multiple. The work sharing project, committal non-clinical testing in juvenile ani-
mals and amendments to ICH E11 (guideline on clinical trials in children) were 
seen to be EU programs supportive of pediatric R&D. Further measures on an 
EU level included guidelines on pharmacokinetics in pediatric population and on 
trials in small populations, and an addendum on pediatric oncology. A reflection 
paper on pediatric formulations, concept papers on brain/lung and heart/liver im-
maturity, and a discussion paper on liver immaturity have highlighted pediatric 
problems in the EU. The European Organization for research and treatment of 
cancer (EORTC) was seen to engage itself with regard to NDU. An initiative to 
capture dosages and formulations in Swiss hospital pharmacies in co-operation 
with London’s School of Pharmacy was another example for cross-country re-
search activities in the E.U.  
In Germany, § 25 Sec. 7a AMG eased pediatric RCT for future MPs, while pedia-
tric dosage tables and the ZAK database for medicines for children were found to 
be sources of information for child medications already available today. In 
France, Réseau d’Investigations Pédiatriques des Produits Santé (RIPPS), a 
French society for pediatric oncology (SFOP), French acute Lymphoblastic leu-
kaemia group (FRALLE), Société Française de Pédiatrie (SFP) and Institut Na-
tional de la Santé et de la Recherche Médicale (INSERM) were identified to be 
organizations working on NDU. A Medicines for Children Research Network was 
seen to co-ordinate pediatric research activities in the U.K. U.K. physicians were 
reported to refer to the BNF-C for pediatric information. PILs by Royal College of 
Pediatrics and Child Health (RCPCH), continuing education in pediatric phar-
macy by NPPG (Neonatal Pediatric Pharmacists Group) and networking were 
found to help pharmacists overcome the obstacles of NDU in Great Britain. Up-
dating of SmPCs, improving transparency of pediatric information, and a call for 
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pediatric studies were found to be Swiss measures to surmount NDU. Simplified 
approval, improvement of circumstances for the development of formulations for 
children, and a list of essential medicines for children shall direct pediatric re-
search activities in Switzerland. The pediatric rule and exclusivity program, 
FDAMA, BPCA, PREA and FDAAA have been passed to increase pediatric NDA. 
The Children’s Oncology Group was judged to be an example for an U.S. associ-
ation that exchanges information with other institutions to secure best care for 
pediatric cancer patients. In Japan, the period for renewal of pediatric MA was 
extended from six to ten years. These mechanisms are choosy to pediatrics. Se-
lectivity of the regulatory tools may be responsible for a future success, but was 
also judged to disregard areas of NDU outside pediatrics or rare disorders.  
Further specific approaches to decrease NDU and drug supply shortages aimed 
at OMPs. As with NDU or age classes (pediatrics or geriatrics), rare disorders 
were also seen not to be characterized homogenously. They were distinguisha-
ble from “neglected diseases”, which occur frequently but in countries with little 
purchasing power (e.g., Dengue Fever in developing countries) and therefore do 
not trigger commercial research interests. Furthermore the expression “ultra or-
phan diseases” was found to describe disorders that occur in fewer than 10,000 
patients. All expressions jointly were observed to describe disorders with few 
therapeutic options available. Criteria for OMP designation and more regulatory 
incentives and duties are addressed among other incentives and duties affecting 
NDU. 
E.U.: Protecting and exempting children from participation in clinical trials has 
caused drugs not to be tested in children. Beginning in 1990, the WHO undertook 
efforts to eventually reduce child mortality by two thirds in children aged one to 
five years by 2015; these efforts include improvement of the medical treatment of 
children (e.g., EML for children).  
In the EU, incentives and duties were introduced to enhance commercial re-
search and the development of children’s medicines. All NDAs were found to be 
required to provide a pediatric investigation plan (PIP). By July 30th 2008, 218 
applications were subject to review for waivers or deferrals. Bonuses were also 
seen to be granted for negative outcomes, if transferred into the PIL and SmPC. 
The PIP compulsion was initiated to require companies to acquire pediatric ex-
pertise. Waiver or deferral of a manufacturer’s research duties was made possi-
ble with drugs that are not important for the pediatric population. An example for 
deferral was a product-related decision on clopidogreli that shall be available in 
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liquid form. It is planned to be studied in five RCTs (bioequivalence, pharmacoki-
netics, efficacy and safety, open label study and pharmacodynamics) for the 
treatment of thromboembolic events in children. The pharmaceutical company 
received a deferral with the aim of not delaying licensing for adults. Class waivers 
were to be feasible with conditions not relevant to pediatric patients, e.g., erectile 
dysfunction. Patented drugs may receive an extra six months of marketing exclu-
sivity for all indications for pediatric data. Four MAH were applying for a so-called 
pediatric use MA (PUMA) by June 30th, 2008.293 On October 23rd 2008 the 
CHMP recommended to license a pediatric formulation of losartanei– the first 
positive opinion subsequent to a PIP.294 An annual directory of all MAHs that re-
ceive bonuses is planned. Pediatric formulations of off-patent substances were 
governed to be able to acquire ten years of data protection, a PUMA. OMPs li-
censed for use in children in the EU may gain another two years of protection. 
Scientific consultation of the EMEA was found to be free of charge on pediatric 
matters.  
An E.U. Pediatric Committee (PDCO) (see Table 26) was formed to file decisions 
on the appropriateness and nature of clinical trials in children. The PDCO was 
initially assigned the task of suggesting a symbol for pediatric MPs. The commit-
tee, however, came to the conclusions that such a symbol was not recommenda-
ble because its drawbacks outweigh its benefits. On January 26th 2007, the 
Guideline on conduct of pharmacovigilance for medicines used by the pediatric 
population (EMEA/CHMP/PhVWP/235910/2005) came into effect, providing 
guidance on risk surveillance of medicines for children. An EU pediatric network 
was established to link pediatric research projects of the E.U. Pediatric trials can 
be funded by financial resources (MICE, Medicines Investigation for the Children 
of Europe) within the scope of the seventh framework project. A work-sharing 
project was organized to tie all MSs together committing them to collect pediatric 
data, which were transferred to the EMEA by January 26th 2009. In 2013 and 
2017 a field report and an analysis of the pediatric regulation are due.  
In the E.U., OMPs were decided to be given ten years of exclusivity, scientific 
advice, and reduction of fees, and may be funded research in the EU. OMPs 
must be designated first and can then be authorized for marketing as an OMP. 
Criteria for designation were developed to include either certain incidence rates 
or a predicted low return on investment and no satisfactory alternative or signifi-
cant benefit in comparison to licensed MPs. Until 2001, the EMEA’s Committee 
on OMPs (COMP) had announced 52 applications out of a received 131. While 
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22 applications were withdrawn, 73 applications received a positive and one a 
negative opinion. By 2001 52 OMPs were licensed.295 On one occasion, on Au-
gust 3rd 2001, two OMPs received approval for the same diagnosis 
(EU/1/01/188/001-003 and EU/1/01/189/001). Both OMPs were licensed to treat 
Fabry disease (Agalsidasei-Beta [Fabrazyme®] and -Alpha [Replagal®]) in the 
EU.  
Free-of-charge scientific advice through so-called Protocol Assistance was tai-
lored to be granted to MPs that have been assigned the OMP status in the EU. 
Conditional approval thus was made achievable. Research into rare disorders 
was ever since encouraged. A rare diseases task force was formed to advance 
the development of research strategies. The fifth framework for research, tech-
nological development and demonstration (FP5) funded 47 projects on rare 
diseases. The European Organisation for Orphan Disorders (EurOrDis) planned 
to introduce a service to answer questions on rare diseases.  
Art. 9 of the EU Orphan Medical Products Regulation demanded that MSs pro-
vide national incentives in the E.U. Between 1983 and 2006 all researched coun-
tries, except for Canada, additionally met measures to combat shortages of 
OMPs. Multiple criteria for the frequency of occurrence resulted from the 
individual legal definitions (see Table 23).  
Table 23 Provisions for orphan drug designation 
The effect of the above-named differences on regulatory practice was found to be 
unknown. No discussion on heterogeneous acknowledgement of an OMP status 
across countries has been observed in the literature. MPs to treat rare disorders 
were seen to hypothetically underlie regular provisions in some while being sub-
Details 
 
 
 
COUNTRY 
Coming 
into 
effect Legislation 
Rate [less 
than x 
patients/year]
Incidence 
[per 
10.000 
residents] 
Fre-
quency 
[out of x 
resi-
dents] 
GERMANY 
1999 
Orphan Drug 
Regulation 
 230.000 5 2.000  
AUSTRIA 
U.K. 
FRANCE 
E.U. 
SWITZERLAND 2000 
Art. 9 Sec. 4 
HMG 
U.S. 1983 
Orphan Drug 
Act 200.000  7.5  1.500  
JAPAN 1993 
Orphan Drug 
Law 50.000  4 2.400  
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ject to simplified requirements in other countries (see Table 24). Accordingly, 
MPs to treat disorders occurring fewer than 7.5 and more than 5 times in 10,000 
residents were found to be considered OMPs in the U.S. but need not be granted 
this status in Japan or the E.U. Drugs to treat conditions that are diagnosed fewer 
than 5, but more than 4 times in 10,000 residents, were seen to be OMPs in the 
E.U. and U.S. but not in Japan. Inconsistency in patient supply was already found 
to be known in the E.U. despite uniform legislation (see 3.2  Investigations into 
supply shortages of drugs and the necessity as well as procedure of nonlicensed 
drug use). It was unknown whether this outlook discourages pharmaceutical 
companies from performing research or cause the drug to be licensed and only 
be available in the U.S. or whether regulatory agencies mutually recognize sta-
tuses.  
Country
INCIDENCE E.U. U.S. Japan
7.5<X>5 PER 10.000 INHABITANTS No Yes No 
5<X>4 PER 10.000 INHABITANTS Yes No 
<4 PER 10.000 INHABITANTS Yes 
>7.5 PER 10.000 INHABITANTS No 
Table 24 Orphan drugs status in comparison 
In the E.U., non-selective incentives to encourage R&D were found to include 
expedited assessment, conditional approval, approval under exceptional cir-
cumstances (thereinafter discussed) and facilitations for investigator initiated 
trials (IITs). IITs were seen to mirror real practice and true patient supply, but 
NDUs must always not be subject to IITs. The sponsor of an IIT was observed to 
have to be a nonprofit organization, though pharmaceutical companies may con-
tribute to sponsorship. A sponsor was obliged to supervise the study’s design, 
procedure, documentation and reports. Germany introduced facilitations for 
pharmacovigilance in IITs (a saving of minimum £ 2,000 for EudraVigilance 
training) and health care insurances may cover off label use (§ 35c SGBV) in 
RCT; stakeholders additionally called for a waiver of fees and coverage of liability 
insurance by national reimbursement companies.  
Patents were judged to be the most efficacious incentive for drug development, 
affecting product extension strongly. Research into a treatment was only as-
sessed to be promising if patents are granted. A patent was found to last up to 20 
years (European Patent treaty of 1973, § 16 PatG of Germany) starting on the 
day on which the patent is registered (see figure 8). Several constellations 
causing a drug to be on the market exclusively were seen to be possible: 
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1. The patent protection period outlasts data protection period or market 
exclusivity  
a. Generic marketing may only start after the patent expires  
2. The data protection period or market exclusivity outlast patent protection  
a. Reference to the originator’s data may only be made after the data 
protection period has ended; marketing is legal after the marketing 
exclusivity expires  
b. After patent terms end, a company may conduct its own develop-
mental and clinical research into the efficacy and safety without 
making reference to the original research in an NDA  
Figure 8 Timelines for mechanisms of market exclusivity in the E.U. 
GERMANY Problems in pediatric drug supply were found to include (a) over- as 
well as under-dosage specific to each API, and (b) child maturity as seen with the 
Grey syndrome of newborns in response to the application of Chloramphenicol. 
Toxicity of adult drugs in children was not possible to be extrapolated from body 
weight, height or body surface. Growth can then either cause over-proportional 
metabolism or hyper-elimination of adult MPs in babies and infants.296 Age-appro-
priate MPs for children were found to be essential. Although dosage schemes 
have been developed at the university hospitals of Gottingen and Hamburg in 
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2005 e.g., for sotaloli,297 no licensed pediatric formulation was yet available by 
September 2008. As seen also in 3.7 Circumvention of drug approval: Law on 
advertising, it was judged to be possible that social regulation adds to the lack of 
interest in R&D: The joint national committee (G-BA) assigned a pediatric antibi-
otic drinking straw to the same fixed price group for reimbursement by public 
health insurance companies like other antibiotic formulations. Although an antibi-
otic drinking straw could have hypothetically been eligible to pediatric incentives if 
these had already been in place, fixed prices discourage the development of pe-
diatric formulations of off-patent APIs. A PUMA was therefore estimated to not be 
sufficient to encourage development of new children’s MPs with off-patent APIs 
in Germany. By German social law, generic substitution was also seen to be 
permissible even if the dispensed product has fewer indications than the pre-
scribed item (see 3.7 Circumvention of drug approval: Law on advertising). Phar-
macists are obliged to substitute an MP if the aut-idem box is not ticked on the 
prescription form.298 This compulsion may also affect incentives of pharmaceuti-
cal law such as PUMA because in spite of data exclusivity for off-patent pediatric 
or orphan products, there may not be a return on investment due to generic dis-
pensing (see 3.7 Circumvention of drug approval: Law on advertising). Substitu-
tion was found to require the pharmaceutical formulation of the drug to be iden-
tical to the prescribed item. Pharmaceutical companies were therefore prompted 
to develop pioneering formulations and dosages that are not divisible from MPs 
for adults in order to circumvent substitution and extemporaneous preparation. 
The compulsion to set up a commission to improve drug safety for children and 
adolescents at the BfArM was put through in the 12th amendment to the AMG 
(§ 25 Sec. 7a AMG). The commission for drugs for children and adolescents 
(Kommission für Arzneimittel für Kinder und Jugendliche, KAKJ) was formed to 
advise the regulatory body on questions relating to pediatric approvals. Scientific 
efforts to improve child health care were seen to be present in the department for 
clinical pharmacy at the Heinrich Heine University of Dusseldorf in Germany. ‘In 
silico’ simulation creating physiology based pharmacokinetic (PBPK) models was 
found to be studied as a tool to prevent medication errors. The PK-SIM® soft-
ware was reported to imitate a whole body model and can calculate personalized 
dosages.  
Experts identified increasing insurance premiums as a difficulty with regard to 
pediatric studies, leading to cancellation of RCTs in children: § 3 Sec. 3 AMG-
KostV was identified to address the option to reduce fees by up to three quarters 
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in response to an application showing that (a) the applicant cannot expect an 
economic benefit related to regulatory and development costs and, (b) if 
marketing of the drug for a specific indication has an impact on public health or 
(c) if the diagnosis is rare or the target population small. Further incentives were 
seen to be present in Germany in terms of scientific advice on pediatric drugs. 
Orphan therapeutic needs were observed to be partially meet by means of ex-
temporaneous preparation (see 3.2 Investigations into supply shortages of drugs 
and the necessity as well as procedure of nonlicensed drug use) in Germany: 
Monographs were proven to be present in the NRF e.g. 15.17 Cysteamini-hy-
drochloride eye drops 0.15 % or 0.5 % for the treatment of cystinosis (incidence 
1:60,000 to 1:100,000) or 22.3 % 3,4-Diaminopyridini capsules 5 or 10 mg to treat 
Lambert-Eaton-Myasthenia syndrome (LEMS, 1:100,000).299 The German federal 
government has discussed expedited approval for drugs with a great therapeutic 
impact, fewer administrative requirements for applications for relevant MPs and a 
research program for rare disorders.300  
Other than the mechanisms mentioned above, a number of regulatory tools were 
confirmed not focus on specific conditions. The options of variation, extension 
and NDAs in Germany are summarized in Figure 9. § 24b AMG was found to 
govern the licensure of generic pharmaceutics and data protection periods in 
Germany with regard to applications referring to data of the originator (§ 22 Sec. 
2 Sent. 1 N.2 and 3, Sec. 3c and § 23 Sec. 1). According to § 24 Sec. 1 Sent. 2 
N.2 – 4, a generic applicant was seen to be able to refer to the originator’s data if 
the drug has been licensed for a minimum of eight years (also see other E.U. 
MS). A generic product that was licensed in accordance with this provision may 
only be marketed ten years after the originator had been granted approval. This 
rule was evidenced to be known as: eight years of data protection plus two years 
of exclusive marketing (8 + 2). The period was found to be possibly extended by 
a single year if the MAH applies for an MA for one or more supplementary indica-
tions (see Figure 9). These indications were found to have to provide significant 
clinical benefit in comparison to established pharmacotherapies, as appraised 
through scientific assessment by the regulatory agency. This additional non-cu-
mulative exclusiveness of one year was verified to amount to a total period of 8 + 
2 + 1 years of market exclusiveness.  
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Figure 9 Types of variations and properties in addition to details and examples301 
In Germany, MAHs have suggested further approaches for the faster availability 
of innovative MPs by means of improved co-operation between regulatory agen-
cies in a policy paper. The task force ‘Regulatory Affairs and Health Policy’ of 
biotechnological industry organization (BIO) Germany called for reduction of ap-
plication fees, e.g., for an MA or for a permit to conduct clinical trials. Remission 
of fees and charges were seen to be in place for advice on development as it 
relates to pediatric quality, safety and efficacy.  
Both non-commercial IITs were found to be subject to fees in accordance with 
§ 33 Sec. 1 AMG. Legal facilitations were identified to be present in terms of 
coverage for standard treatment (§ 35c SGB V) and labeling for open-label trials 
(§ 5 N.8 GCP-V). IITs were to be exempt from EudraVigilance; ADR reporting is 
carried out by BfArM. Additionally, Clinical Study Support Cores (CSSCs) have 
been set up at university hospitals. CSSCs ate assigned the task of unburdening 
physicians from administrative duties and were formed to provide frame contracts 
for insurances, standard wording for patient information and contract templates 
for agreements between the principal investigator, the university’s office of ad-
ministration, investigators and the sponsor. CSSCs were also established to pro-
vide advice on RCTs, preliminary assays and to interact with research networks 
in Germany.  
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One final regulatory strategy was proven to be unique to Germany: standardized 
MA according to article 36 AMG. An applicant was shown to refer to a previously 
existing monograph without presenting documentation to the BfArM. Monographs 
were seen to include analytical test requirements and templates for PILs. Com-
pliance with the monograph was found to be controlled by the local inspection 
authority. Standardized MA was identified to be the pre-emptive development of 
a drug model by the regulatory agency, historically introduced to combat post-
licensing. In the past, 279 monographs have been published. The procedure was 
given as follows: An MP may be suggested to the expert advisory board, which 
forwards the proposal to the German Ministry of Health, which then drafts an or-
dinance. External experts and the BfArM first conduct research and development 
and then draft the monograph which is then presented to specialist audience. 
Secondly, the expert advisory board reassesses the draft and shows it to a spe-
cialist audience after public comment. Lastly, the finalized ordinance is presented 
to the Federal Assembly for enactment. Well-established APIs were found to cur-
rently be eligible for standardized MA.302  
Lastly, BfArM was seen to publish harmonized specimen texts for informative 
labels (i.e., SmPCs and PILs) taking into account the originator’s labels and rele-
vant, state of the art and recent scientific information (see 3.1 Terminology).  
AUSTRIA As of October 2007, Austria had not granted reduced fees to pediatric or 
OMP development. Variations were found to cause high monitoring and adminis-
trative expenses in Austria, whereas restrictions can be added to a label easily 
and inexpensively. This detail was judged to be important for off label use, be-
cause contraindications may be effortlessly imposed and hypothetically lessen 
treatment options. As an E.U. MS, Austrian marketing exclusivity was also ob-
served to be extended to eleven years (§ 10 Sec. 3 und 6 N.2 AMG-Au). An MAH 
was obliged to provide data for significant indications as assessed by a scientific 
assessment of the federal office for safety in health care (Bundesamt für Sicher-
heit im Gesundheitswesen) within eight years after licensure in order to achieve 
this extended protection period (§ 24 AMG-Au). The European joint term for this 
recurrent mechanism was seen to be Art. 14 Sec. 11 of regulation (EC) 
N.726/2004.  
SWITZERLAND Information on the use of MPs in children was being collected in 
Swiss hospitals in cooperation with the London School of Pharmacy. To date, 
Swissmedic published three diploma theses on pediatric drug safety identifying 
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insufficiencies in SmPCs with regard to drug use in children. An essential child-
ren’s medicines list was issued by the agency. The protection period for an MP 
may be lengthened by five years if a new drug development involves pediatric 
formulations or dosages.  
Art. 17 Sec. 2 VAM was found to authorize an additional protection period of 
three years for original MPs that are licensed for new indications, dosages, and 
formulations or are to be given via a new route of application to humans in Swit-
zerland. Article 13 HMG was seen to simplify variation to MA as to the current 
state of knowledge for applicants in Switzerland by considering results that have 
been subject to granted MA in other countries with similar regulatory criteria. 
FRANCE The French Comité d’orientation pédiatrique (COP) was founded in 2000 
and advises AFSSAPS on questions of MPs for children, extemporaneous for-
mulations, hospital preparations, a list of essential medicines for children and the 
implementation of the E.U. pediatric regulations. Different schemes were identi-
fied to support pediatric research.  
In France, 20% of all “médicaments orphelins” were seen to be accessed early 
via the temporary use authorization. A total of 23 out of 34 OMPs that received 
approval via the central procedure had already been dispensed to patients in 
France. Exceptional approval was confirmed to be permissible in accordance 
with L5121-9 CSP. The applicant was found to be able to make reference to well-
established use and extemporaneous products. Waivers for fees, inexpensive 
scientific advice, reduced taxes and price fixing within 15 days were shown to be 
feasible with OMPs. Several initiatives were grouped and now jointly build a 
single platform for information on rare diseases. In 2004, a national plan for rare 
disorders supplying financial support was enacted.  
In France, extemporaneous preparations by hospital pharmacies were estimated 
to close supply gaps. Hospital pharmacists were obliged to notify the regulatory 
agency about new extemporaneous formulations and report on the quality and 
number of extemporaneous products to the agency every two years. All data was 
found to be entered into a public database. Forty preparations are then identified 
and classified with regard to licensed alternatives or ATUs. Essential formulations 
are to be standardized.  
U.K. The U.K.’s Department of Health and MHRA was found to pursue a pediatric 
strategy that encourages MAHs to (a) seek supplementary licensing of pediatric 
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line extensions, (b) improve the research environment for RCTs in children (U.K. 
Medicines for Children Research Network) and (c) improve access to pediatric 
drug information (BNF-C, British National Formulary for Children) for HCPs. 
Priority lists of essential extemporaneous products and desired proprietary MPs 
were identified on the MHRA web page. The Commission on Human Medicines 
(CHM) Expert Advisory Group on Pediatric Medicines (PMEAG), established in 
2006, replaced the Committee on Safety of Medicines (CSM) Pediatric Medicines 
Working Group (PMWG). PMEAG advises the CHM on MPs for pediatric use and 
on the implementation of (a) the pediatric strategy, (b) the E.U. pediatric work 
sharing project, and (c) the European regulation of medicines for pediatric use 
(Regulation (EC) No 1901/2006). Small U.K. entities, such as groups of hospital 
pharmacists and physicians, were seen to practice networking to collect pediatric 
information or else rely on good medical practices. Medicines for Children 
(RCPCH Publications Ltd) and the British National Formulary were seen to form 
the basis for BNF-C. Its predecessor ‘Medicines for Children’ has been formerly 
translated into at least one foreign language (Italian).  
COSTS
NECESSITY Fee 
FULL DOCUMENTATION € 232,000,- 
TYPE I & II VARIATIONS € 5,800,- and € 69,600,- respectively
SCIENTIFIC ADVICE Up to € 69,600,- 
Table 25 Regulatory fees in the U.K.303 
Table 25 illustrates the costs of different types of variations for the U.K. Scientific 
advice on pediatric questions was found to be at no cost in the U.K. No applica-
tion fees for new pediatric formulations or indications were identified. Also, varia-
tions to adult dosages for pediatric purposes were seen to be implemented at no 
costs. If the annual return on investment was rated to be low, e.g., in pediatric 
patients or rare disorders, a further reduction of fees was seen to be permissible.  
Despite low cost MA, future MPs for children need not be inexpensive. Expirience 
with OMPs showed price explosions. Cost explosions for licensed OMPs such as 
nitrogen monoxide, which had previously been used (as biological active sub-
stances) in the U.K. were condemned by physicians.  
The Council Regulation EEC N.1768/92 and Patent Protection Act were shown to 
contain British protection rights. Supplementary protection certificates, market 
exclusivity and additional exclusiveness (8 + 2 + 1) were found to be achievable. 
Interestingly, the U.K. has a statute that was found to oblige manufacturers to 
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guarantee a drug’s supply via wholesalers, importers or specials’ manufacturers if 
marketing of an MP is stopped. 
ASPECT 
 
 
COUNTRY Committee 
 
Pediatric 
protection 
(variation) 
E.U. Pediatric Committee (PDCO) ½ year 
U.K. Expert Advisory Group on Pediatric Medicines (PMEAG) 
FRANCE Comité d’orientation pédiatrique (COP) 
USA Pediatric Review Committee (PReC) 
CANADA Office of Pediatric Initiatives  
GERMANY 
Kommission für Arzneimittel für Kinder und Jugendliche 
(KAKJ) 
SWITZERLAND absent 5 years 
Table 26 Selected countries' pediatric commissions and supplementary protection 
U.S. In addition to pediatric research units, several legal instruments have ad-
vanced pediatric drug development in the U.S.: BPCA (Best Pharmaceuticals for 
Children Act), FDAMA (Food and Drug  Administration Modernization Act of 
1997), FDAAA (FDA Amendments Act) and PREA (Pediatric Research Equity 
Act). As early as 2001, Pediatric Exclusivity was introduced to the U.S. A Pedia-
tric Review Committee (PReC) was founded in 2007 (see Table 26). As of August 
18th 2008, the program had already led to the approval of 16 pediatric formula-
tions. Furthermore, 149 label changes recommended or opposed a drug’s use in 
children. Applications for 853 CTs were submitted to the FDA, leading to 301 
pediatric drug applications; of these, 155 drugs managed an extension of the 
market exclusivity period. Physician and expert N.5 declared that the number of 
MPs licensed for use in children since the 1980s has risen from 20% to 30%. 
However, she criticized the poor regulatory knowledge of physicians. This was 
found to be a possible explanation for the increase in prescription rates despite 
negative outcome to the pediatric information: In the U.S., a clinical trial304 
targeting the extension of patent-produced data showed that carvedilole305 306 was 
not suitable for patients younger than 18 years. Nonetheless, there was a 9% 
increase in off label use among 12.4 prescriptions within 12 months.307 But as 
seen in 3.7 Circumvention of drug approval: Law on advertising, announcement 
of discouraging research findings by drug detailers is unlikely. Such label 
changes were judged to not be sufficiently made known. HCPs do not re-
examine SmPCs regularly.  
In the U.S., RCTs with regard to licensing of OMPs were seen to receive a 50% 
tax reduction. US$ 200,000 and US$ 350,000 respectively, can be granted to 
phase I and II OMP RCTs for a total period of three years in the U.S. No licen-
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sure fees are charged. The period of marketing exclusivity was found to be seven 
years for OMPs, five years for new APIs, three years for others, six months for 
pediatrics and 180 days for patent challenge.  
Conditional approval (Section 506(b) (21 USC 356 FD&C Act), expedited as-
sessment (21 CFR 601 Subpart E) and exceptional circumstances for these re-
quirements (Section 506 (21 USC 356 FD&C Act) were identified in the U.S. The 
U.S. was also found to give a five-year period of data protection to the pioneer 
applicant for an NCE and a three-year data exclusivity period for new indications. 
CANADA There were no duties identified with regard to pediatric trials, but MAHs 
are advised to follow the ICH-Guideline E11 on the subject of pediatric investiga-
tions. Data protection was found to be extended by six months in return for pe-
diatric trials within five years after NOC. Pediatric protection was not found to, 
protect from me-too products e.g. valsartanei from competing with AT II 
antagonists loosing patent protection.  
The RCTs grants program of the Canadian Institute of Health Research was 
seen to provide aid to clinical trials on drugs with expired patents. An Institute for 
Human Development, Child and Youth Health was found to fund research on 
child pharmacotherapy. Application fees were observed to be reduced for drugs 
that are expected to achieve a low return on investment. Tax incentives were 
shown to be present for conducting RCTs. The Biomarker Initiative of the Ontario 
Cancer Research Network was known to provide funding for biomarker analysis 
in drug development in order to better understand efficacy in specific patients and 
hence demonstrate efficacy in subpopulations.  
Canadian patent law was judged to be similar to the regulations in other industrial 
countries; forced licensing has been restricted. It previously allowed the use of a 
patent without a patentee’s permission if a compensation of 4% of the sales 
revenue was paid. Nowadays, generic manufacturers may only prepare an appli-
cation preceding the patent’s expiry. Health Canada issues the NOC as recently 
as the patent has ended.  
Use patents for off-patent APIs were seen to not protect patentees infinitely. An 
appeal by Lundbeck against the application of an MP containing citalopram for 
the unpatented indication of depression was dismissed by a Canadian court: The 
law court did not agree that the approval should be prohibited due to an ex-
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cepted, law-violating off label use. Expected off label use was found to not sup-
port claims on use patents.  
Market exclusivity was seen to be granted for eight years in Canada. An appli-
cant may refer to the originator’s data after a period of six years. Variations were 
verified to cost less than half of what an NDA costs. Priority assessment of NDAs 
and variations of MPs was proven to be first possible for the treatment, preven-
tion or diagnosis of serious or fatal diseases or diseases affecting quality of life 
and then applyed to disorders where there is no MP marketed yet, or finally to 
new drug significantly improving tolerance in comparison to old MPs. Survival 
rates and the probability of health impairment without effective treatment were 
seen to be referred to in order to determine seriousness of disorders. HIV/AIDS, 
Alzheimer’s disease, amyotrophic lateral sclerosis, angina pectoris, myocardial 
insufficiency and malignant neoplasms were judged to be serious diseases. The 
MAH was found to have to apply for expedited assessment before submitting the 
NDA. Conditional approval of MPs and prescription monitoring to ensure data-
driven development of relevant MPs was being discussed in Canada. 
JAPAN Japan reported time problems in supply with innovative drugs. By 2009, 
processing of 80% of NDA shall take less than one year in Japan. Since April 
2005, scientific advice is offered to MAHs. Conditional approval for early 
marketing was evidenced to be permissible, provided that further RCTs are 
guaranteed. Simplified licensing was confirmed to be present for variations to 
indications sought by medical associations. Parts of or entire RCTs may not be 
necessary if a dossier is filed that has been submitted to a comparable licensing 
authority or publications in an international, medical journal are enclosed.  
In Japan, the data exclusivity period was found to vary from four years (new indi-
cations, formulations, dosages, or compositions) to six years (new chemical entity 
or composition, or formulation for a new route of administration) to ten years 
(OMPs or new drugs requiring pharmaco-epidemiological data).308 
Ultimately, 14 pharmaceutical bills affect NDU in eight countries and the E.U. 
(Table 27). 
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MA 
 
COUNTRY 
Conditional 
approval 
Expedited 
assessment 
Exceptional 
circumstances
Temporary 
approval 
GERMANY 
§ 28 Sec. 3 
AMG 
Art. 14 VO 
(EG) 
N.726/2004 
Art. 14 Sec. 8 
VO (EG) 
N.726/2004 
Unidentified 
AUSTRIA 
Art. 14 Sec. 7 
VO (EG) 
N.726/2004 
n/a 
U.K. 
E.U. 
FRANCE 
Article L5121-9 
CSP Unidentified 
SWITZERLAND Art. 14 HMG Art. 5 VAM Unidentified 
Art 9 Sec. 4 
HMG 
CANADA Unidentified 
Priority 
Review of 
Drug 
Submissions 
– Policy Unidentified Unidentified 
U.S. 
Section 
506(b) (21 
USC 356 
FD&C Act 
21 CFR 601 
Subpart E 
Section 506 
(21 USC 356 
FD&C Act Unidentified 
JAPAN Present Present Unidentified Unidentified 
Table 27 Marketing authorization clauses with an impact on NDU 
Discussion 
115 
 
4. Discussion 
OUTLINE The emphasis of the present comparison of the impact of nonlicensed 
drug use (NDU) lies on aspects of (a) terminology for NDU, (b) supply, necessity 
and inevitability of NDU, (c) pharmaceutical promotion of NDU, (d) legal obliga-
tions and (e) policies related to NDU. Best solutions are postulated after 
prioritizing patient safety and medical attendance over realization of profit and 
after weighing the advantages and disadvantages of approaches. Appraisal by 
other authors, who choose to assign different weighting, may lead to different 
conclusions. 
LIMITATIONS In this study, triangulation is used to assess the impact of NDU on 
health care legislation. This investigation comes to the following main conclu-
sions: The impact of NDU on health care law is varying. A standard definition for 
NDUs is advisable in all countries as well as short term management and long 
term solutions. This study is representative for the current situation in eight coun-
tries and the E.U. The study period limits validity of the results. Underrepresenta-
tion is addressed sufficiently by triangulation.  
Off-label use is interpreted to first refer to a breach of no more than an medicinal 
product’s (MP’s) indication or second to medically ordered drug use that is not 
listed in the label and finally to any use, which is eligible to variation, extension or 
an NDA. Seven types of off-label use are categorized. Unlicensed use is incom-
prehensible and associated to drug importation in Japan, extemporaneous 
products in the Netherlands and use of biological active substances (BAS) as 
MPs in the U.K. E.U. legislation provides definitions for compassionate use, dis-
tinguishing between use in (a) cohorts, in the following ‘expanded access’, and 
(b) named patient use in individuals.  
The regulatory points of time and product identities form a common pattern of 
understanding of NDU: Off-label use is best related to proprietary MPs, used 
post- marketing authorization (MA) and pre-variation. Compassionate use hap-
pens peri-randomized control trial (RCT) as well as pre-notice of compliance 
(NOC) and is linked to investigational new drugs (active treatment) in groups and 
individuals. The product identity of unlicensed MPs often is ‘imported’, ‘BAS’ or 
‘extemporaneous products’, which are being put to use pre-RCT relating to the 
country of drug use. The term ‘off-label use’ is often defined as a breach of preset 
indication. In literature however, use by another route of administration or by 
physicians without additional qualifications is also termed ‘off–label’. Therefore 
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‘use outside the terms of indication’ does not emerge to be an appropriate de-
scription. ‘Use outside the terms of a PIL’ is a model that excludes dosage-based 
and population-based off-label use from the definition, because a PIL may very 
well allow a physician to alter e.g. a dose or may not describe the target popula-
tion in detail. Off-label use defined as ‘the use of a proprietary MP in a way, re-
quiring a variation to the MA, extension of the MA or a new MA, describes all 
seven off-label-classes and takes the aforementioned regulatory point of time into 
account. 
Interestingly, importations, BAS (both eligible to MA) and extemporaneous 
products (exempted from MA), are assigned to the concept of ‘unlicensed use’. 
There is a discrepancy between the U.K., Ireland and the Netherlands and Ger-
man-speaking countries as to whether to solely judge ‘unlicensed use’ by 
presence or absence of a product license or take into account registration re-
quirements. There is no explanation for the discrepancy; pharmaceutical law in 
all countries exempts extemporaneous products from licensing requirements. If a 
country plans to consider extemporaneous products when assessing NDU, defi-
nition must be comprehensive. In consequence, an all-encompassing definition 
must consider that an unlicensed product fulfils medicine criteria, though it does 
not need an MA or if requiring an MA, then has neither an MA nor CTA in the 
country at the time.  
There is no need to define ‘compassionate use’. Definitions are available in the 
E.U., the U.S. and Canada. Japan is planning to adopt a compassionate use 
system. The mediocre level of recognition of the meaning among experts in the 
survey suggests further quantitative research to measure the true level of aware-
ness among peers. If surveys confirm false or no knowledge of the term, public 
training and continues medical education will be necessary.  
Investigations into the supply of MPs give evidence of a circumstantial need for 
nonlicensed drug uses. On top of a situational necessity for NDU, physicians are 
commonly awarded therapeutic freedom e.g. in Austria or Germany and are 
therefore entitled to NDU. Legislation of many countries also imposes a duty of 
care on physicians, irrespective of medicines’ marketing statuses and hence an 
obligation to perform best practice irrespective of MA. However, evidence can 
also be found illustrating practice of unsupported, non-indicated off-label use and 
non-standard, irrational NDU.  
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Therapeutic need and patient protection are particularly relevant to the discus-
sion of NDU. There is mutual agreement that safe and efficacious MPs shall be 
accessible to patients in need of treatment (first quarter of Figure 10). A 
disproportionate harm-benefit ratio may be accepted for salvage therapy of se-
vere diseases with no treatment options (fourth quarter). Patients must not be 
treated with inefficacious MPs (second and third quarter).  
 
Figure 10 Coordinate plan of favored and unwanted NDU 
Early access to unmarketed MPs is possible in a controlled way in some indus-
trial countries. Different systems to manage unlicensed and compassionate use 
are present in Ireland, the U.K., France, Canada and the U.S. Wherever nonli-
censed use is subject to regulatory requirements, safety mechanisms are ex-
panded as well. Batch recalls, “Dear HCP”-letters or notices to doctors are 
possible for MPs imported to Ireland or compassionate use products in France. 
Market surveillance of nonlicensed drug use in other countries relies on ADR 
reporting and good practice. Whenever temporary use authorizations are 
adopted successfully, access to treatment also is on equal terms for all patients 
and not dependant on the individual commitment of patients or physicians as 
seen in Austria.  
E.U. and German temporary use authorizations are offered in principle, but not 
implemented successfully and therefore unsought. Effective solutions for the 
short term management of nonlicensed drug use can be obtained from U.K., 
France, Canada and the U.S. This qualitative analysis finds a high acceptance of 
systems in the U.K. and France.  
Four centralized methods of resolution are to be conceptualized for the short 
term management of nonlicensed drug use: (a) prohibition i.e. off-label use in 
Japan, (b) permission e.g. for compassionate use in France, (c) notification (for 
example imported MPs in the U.K.) and (d) administration of data (for instance 
extemporaneous products in France).  
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Japan’s prohibition policy for off-label use is unsusceptible to marketing, explicit 
and bears low costs. Unfortunately, breaches are observed, patient’s needs re-
main unidentified and therapeutic requirements may not be met. ‘Obligations to 
obtain permits’ allow a check by a second instance and can contribute to drug 
safety. However, time-lags and conflicts of interest must be avoided to assure 
prompt patient supply and independent filing of decisions. ‘Obligations to obtain 
permits’ affect physician’s therapeutic freedom, but they may be suitable for ex-
panded access programs by MAH. ‘Notification’ guarantees an immediate supply 
while an intervention is possible if necessary. This approach may be suitable for 
named patient use and drug importation. Data capturing is advantageous to 
identify essential medicines and publish lists. Given this, a hypothesis is 
postulated that data capturing from electronic health records, modeled on the 
GPRD, DSRU and IMS Health or French hospital pharmacies reporting extempo-
raneous products to Afssaps can be used to review off-label use. In general, 
management of nonlicensed drug use is welcomed in short the term, but experts 
call for full MAs in the long term. Therefore long term solutions are discussed 
later.  
Liability for ADE in consequence of nonlicensed drug use is shared between 
MAH and HCPs. MAH are found liable for harm if they violate advertisement law 
as seen in the U.S. Physicians are found guilty for ADRs as a result of nonli-
censed drug use as shown in Austria if they fail to acquire valid informed consent 
from the patient. In Germany, physicians are also found responsible for the 
course of the disease when denying a state of the art off-label treatment. Al-
though no court trials have been held against pharmacists, experts judge them to 
be held responsible for harm resulting from quality defects of dispensed, unli-
censed or compassionate use products. In this context, British experts assume 
that a pharmacist’s best care and attention must always be dedicated to advising 
the patient properly, to conferring with the physician or even not filling a risky 
prescription.  
Different solutions for claims costs are available: Experts in the U.K. argue that 
professional indemnity insurances cover nonlicensed drug use if a treatment is 
standard of care. In Austria, an expert proposed to introduce a fund to cover pa-
tient claims in case of a declaration of inability to pay. Funds to cover patient 
claims are criticized, because the low risk for patients and physicians is feared to 
lead to an incautious exposure to NDU. In Japan, injuries as a result of off-label 
use are not covered by public health insurances thereby increasing claims costs. 
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This approach is also questionable for ethical reasons. It was seen that afore-
mentioned temporary use procedures and derivatively negative assessment re-
ports can give legal certainty and define the liability. Wherever reasonable, per-
manent “legalization” of NDU or negative assessment reports would provide legal 
certainty. 
There is isolated data by different authors concerning inappropriate detailing 
about off-label use and compassionate use as a pre-launch marketing strategy 
e.g. in Italy and for instance in Germany respectively. Trials held in U.S. courts 
give evidence for illegal advertising of off-label use. Pharmaceutical law in the 
U.K. explicitly demands that health care professionals (HCPs) are pointed to 
missing MA at conferences in the U.K. and in medical journals; lists of foreign 
MPs available via wholesalers are prohibited. On the other hand, information 
needs are expressed by HCPs. Information demand is also apparent when 
looking at the plentiful, non-commercial and commercial databases and publica-
tions, which are offered across the world as sources for information about off-
label use, unlicensed MPs, pediatric drugs or OMPs.  
One can identify three core approaches to control drug commercials: German 
and Austrian codes of conduct, U.S. whistle blower laws and British preliminary 
assessment. Additional research is necessary to better determine (a) the true 
dimension of NDU marketing ubiquitously and (b) which attempts are most effec-
tive to control inappropriate marketing of nonlicensed drug use.  
Variations or extensions of MA and new drug application (NDA) for non-
patentable agents often are not cost-effective. In the E.U., the long-term change 
of off-label use to in-label use is only rewarded on for occasions with non-cumu-
lative market exclusivity for a relevant new indication or NDA for non-patentable 
agents only in pediatric and rare conditions.  
Potentially, amendment of templates by the competent authority offer a way to 
authorize an off-label use in the long term provided that sound scientific proof is 
available for its efficacy and safety. Compassionate use MPs meeting safety and 
efficacy requirements must be followed by full NDA. MA for unlicensed MPs how-
ever, is only sought by MAHs for new chemical or biological entities, pediatric 
and OMPs. Research into other off-patent MPs is unprofitable. Furthermore, price 
increases for formerly unlicensed children’s MPs or OMPs are subject to criti-
cism. Only one country is able to issue an MA, in spite of missing incentives, 
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which also allows price competition: Germany’s uniquexii procedure the ‘standard 
MA’ is the development of a drug monograph by BfArM. All applicants for the 
standard MA must refer to the standard MA monograph. Currently, general sales 
list medicines are preferred for a standardized MA; suggestions for monographs 
may be made to an expert advisory board. Latter rules must be amended to allow 
a data-driven development of essential medicines. Negative assessment reports 
could suspend inadequate drug uses. Figure 11 depicts a possible model of NDU 
processing. 
 
Figure 11 Three-step approach to the authentication of NDU 
CONCLUSION AND OUTLOOK Nonlicensed drug use has lead to miscellaneous 
concept formulations. The NDU classes identified give support for first, an off-
license understanding of off-label use, next a perception of unlicensed-use to 
also include preparations not eligible to MA and finally a distinction between 
expanded access in groups of patients and named patient use in individuals as 
compassionate uses. Temporary approval settles responsibilities in the short 
term and in the long term, MA incur liabilities. With regard to inappropriate 
advertising and at this stage, it can only be marked that further research into 
actual marketing practice and control procedures is advisable.  
In the short term, an ATUc procedure is suitable for expanded access compas-
sionate use, as experience in France displays that early access to innovative 
drugs proves itself. A procedure similar to ATUN for named patient use and im-
portation will improve equal access for all patients and assure 
                                                            
xii  A second nation, Switzerland, is considering introducing the standard MA in near future. 
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pharmacovigilance. The procedure must not call for permission, but for notifica-
tion as to not violate physicians’ therapeutic freedom. Data capturing is a short 
term solution to collect information about essential extemporaneous products as 
seen in France and off-label use from electronic health records. In the long term, 
compassionate use results in full MA or non-admission. If an NDA is unprofitable 
for an essential unlicensed MP, the German standard MA may provide a key so-
lution to authentication. Scientific sound off-label use could be recognized offi-
cially by amendment of templates. Negative assessment reports could dispose of 
inadequate treatments.  
NDU 
 
TERM 
Compassionate use Unlicensed-Use 
Off-label 
Use 
Expanded 
access 
Named-
Patient 
Use 
Imported 
medicines 
Extemporaneous 
products 
SHORT  
Permit 
procedure 
Notification (subject to 
prohibition) Data capturing 
LONG  
Full MA Standardized MA 
Data 
driven 
templates 
Or negative pledge 
Table 28 Model management assumption  
A new data set on solutions is to be presented, which could be used to develop a 
system to manage NDU (Table 28) in the future. The relevance of this system is 
eloquently shown by the observation that NDU is inevitable in specific medical 
situations.  
In summary, the data demonstrate that the impact of NDU on health care law is 
most pronounced. NDU is a major factor in the development of temporary use 
authorizations. Temporary use authorizations assure that special medical needs 
are met by providing early access to medications while securing 
pharmacovigilance. A suggestion for the long term management of supply 
shortage in medical areas, providing for incentives and duties, emanates from 
NDU: Temporary use provisions and data capturing may be used to identify es-
sential medicines and channel research and drug development into the authenti-
cation of efficacious and safe NDU. The next stage of work will involve a pilot 
study into the feasibility and acceptance of the short term solutions. 
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Appendix 
FEATURE 
NUMBER Country Institution 
1.  
Canada 
Coverage 
2.  Regulatory  
3.  
U.S. 
Society 
4.  Academia 
5.  Regulatory  
6.  Academia 
7.  Academia 
8.  Academia 
9.  Academia 
10.  
Japan 
Academia 11.  
12.  Academia 
13.  
Switzerland 
MAH 
14.  Regulatory  
15.  
Coverage 16.  
17.  
Austria 
Society 
18.  Coverage 
19.  Society 
20.  Academia 
21.  
MAH 22.  
23.  Regulatory  
24.  
GB 
Academia 
25.  Society 
26.  Academia 
27.  Academia 
28.  Society 
29.  HTA 
30.  MAH 
31.  Regulatory  
32.  
E.U. 
Regulatory  
33.  Society
34.  MAH 
35.  Society 
36.  Regulatory  
37.  
France 
Regulatory  
38.  MAH 
39.  
Germany 
Society 
40.  Coverage 
41.  Coverage 
42.  MAH 
43.  Academia 
44.  Academia 
45.  MAH 
46.  Academia 
47.  Academia 
Table 29 Participants by country and institution 
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Number Date 
(dd.mm.yy)
Time 
(hh:mm) CET 
Length 
[min] 
Interviewer 
[initials] 
Mode  
1.  06.12.2008 08:00 am 44 VP Telephone 
2.  02.01.2008 03:00 pm 35 VP Telephone 
3.  12.12.2008 08:00 am  58 VP Telephone 
4.  10.04.2008 02:00 pm 60 VP Telephone 
5.  28.04.2008 03:00 pm 47 VP Telephone 
6.  30.04.2008 04:00 pm 39 VP Telephone 
7.  25.04.2008 03:00 pm 89 VP Telephone 
8.  02.05.2008 06:00 pm 60 VP Telephone 
9.  05.05.2008 02:00 pm  65 VP Telephone 
10.  29.01.2008 03:00 pm 53 VP Group 
11.  11.04.2008 09:00 am 37 VP Telephone 
12.  12.12.2007 09:00 am 150 CB One-to-one 
13.  13.02.2008 02:00 pm 42 CB Telephone 
14.  13.12.2007 02:00 pm 120 CB One-to-one 
15.  26.03.2007 02:00 pm 60 CB&VP Group 
16.  26.03.2007 11:00 am 30 VP Group 
17.  28.03.2007 09:00 am  60 CB&VP Group 
18.  08.11.2006 09:15 am 9 VP Telephone 
19.  26.03.2007 09:00 am 180 CB Group 
20.  13.09.2006 07:00 pm 10 VP Telephone 
21.  29.11.2007 03:00 pm 60 VP Telephone 
22.  21.11.2007 03:00 pm 60 VP Telephone 
23.  05.12.2007 11:00 am 20 VP Telephone 
24.  14.12.2007 09:00 am 47 VP Telephone 
25.  12.12.2007 04:00 pm 21 VP Telephone 
26.  08.01.2008 04:00 pm 29 VP Telephone 
27.  22.11.2007 02:00 pm 30 VP Telephone 
28.  22.10.2007 01:00 pm 30 VP One-to-one 
29.  18.02.2008 11:00 am 60 VP One-to-one 
30.  19.03.2008 02:00 pm 14 VP Telephone 
31.  16.05.2008 09:30 am 50 VP Telephone 
32.  14.04.2008 03:00 pm 45 VP Telephone 
33.  16.06.2008 04:00 pm 54 VP One-to-one 
34.  11.03.2008 10:00 am 54 VP Telephone 
35.  16.04.2008 03:00 pm 25 VP Telephone 
36.  11.04.2008 03:00 pm 90 PN&VP Group 
37.  16.04.2008 04:00 pm 95 PN&VP Group, 
Telephone 
38.  16.04.2008 10:00 am 40 VP One-to-one 
39.  16.04.2008 04:00 pm 31 VP Telephone 
40.  13.05.2008 03:30 pm 67 VP One-to-one 
41.  06.05.2008 11:00 am 48 VP Telephone 
42.  24.04.2008 04:30 pm 120 PN&VP Group 
43.  15.05.2008 05:00 pm 120 PN&VP Group 
44.  28.04.2008 05:30 pm 45 PN One-to-one 
Table 30 Details of expert interviews 
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Table 31 Definitions to NDU by source and country abbreviated according to the predefined categories (cancelled= excluded, pl= pre-licensing, pct= post-clinical-
trial/ pre-NDA, pe= post-enrollment, imp= imported MP, inp= investigational new product, u= undefined, ol= off-license, oolu=out of label use, nri= not registered 
indications, npu= named patient use, ea= expanded access, a= absent) 
NDU
COUNTRY   
Off label use Compassionate use Unlicensed use 
Legislation Literature query Legislation Literature query Legislation Literature query 
GERMANY 
u 
 
Ol, 309 nri, 
310 oolu311 
Ol, 
N.43,N.38,N.
39 nriN.42 
Ea/pl,312 
npu313 
Npu/ 
inp314 
Ea,N.43 pl,N.43 
pct,N.36  
u 
 
ep315 impN.36 
AUSTRIA nri316 nriN.19,  pe317 Npu/Imp/ plN.19  u aN.19 
FRANCE 
Ol, 318 
oolu, 319  
Ol,N.34 
ooluN.35 U 
Pl,N.34 ea/ 
npuN.34,N.35 u AN.34,N.35
U.K. 
Ol,320 321 322 
323 324 oolu, 
325 326 nri 
327 328 
Ol, 
N.22,N.23,N.
21,N.28 
nriN.25,N.2
7 pl329 
Pe/pl/pct/eas,N.22 
a, N.23,N.25  
Ep/pl/imp330, 
pe/inp331 
nri,N.25 ep,N.22 
imp,N.24 plN.28 
E.U.  ol332 Oolu/ ol333 
Nri,N.29,N
.31,N.32 
ooluN.33 Ea334 
Ea/npu,N.33 
pe/inp,N.31 pe/pl/ 
pctN.29  Ep/imp335 ep336 
oolu,N.31 a,N.32 
pl,N.30 imp,N.29,N.33  
SWITZERLAND 
u 
ol337338339 OlN.12 
u 
pl340 NpuN.12
u 
Off label 
use341 ImpN.12 
U.S. oolu342 
Oolu,N.9,
N.3,N.7 
nriN.5  
Inp, 
npu343 
pl,N.9 pct,N.8 
inp,N.5 off-
labelN.3 u 
A,N.9 imp,N.8 off-
label 
use,N.6,N.5,N.4,N.3,N.7  
CANADA ol344 NriN.1 u Pct/pe/npuN.1 u AN.1
JAPAN ol345 NriN.11 U AN.11 u Op/pct/pl/impN.11 
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CITATION Result 
GILL AM ET AL.: ADVERSE DRUG REACTIONS IN A PAEDIATRIC 
INTENSIVE CARE UNIT. ACTA PAEDIATRICA; 84 (D); 438-41 
One-third of the ADRs were due to drugs used outside their product license. 
JONVILLE-BÉRA AP ET AL.: ARE INCORRECTLY USED DRUGS 
MORE FREQUENTLY INVOLVED IN ADVERSE DRUG REACTIONS? A 
PROSPECTIVE STUDY. 2005, EUROPEAN JOURNAL OF CLINICAL 
PHARMACOLOGY 61(3):231-6 
Of 642 drugs, 169 (26%) were incorrectly used in 81 patients (44.5%), ADRs 
involved at least one “incorrectly” used drug. These included 10% (64 of 642) drug 
interactions, 7.3% (47 of 642) off-license indications, 5% (32 of 642) inadequate 
dosage, 3% (20 of 642) incorrect duration of treatment and 1% (6 of 642) 
contraindications. “Correctly” used drugs appeared to be less often the cause of 
ADRs than “incorrectly” used drugs (59.4% versus 75%, P=0.0001). 
LADEWSKI LA ET AL.: DISSEMINATION OF INFORMATION ON 
POTENTIALLY FATAL ADVERSE DRUG REACTIONS FOR CANCER 
DRUGS FROM 2000 TO 2002: FIRST RESULTS FROM THE 
RESEARCH ON ADVERSE DRUG EVENTS AND REPORTS PROJECT. 
2003, JOURNAL OF CLINICAL ONCOLOGY 21(20):3859-66 
Twenty-five serious ADRs associated with 22 oncology drugs were identified after 
approval. ADRs were described in articles in medical journals (17 ADRs), PIL 
revisions (18 ADRs), and Dear Doctor letters (12 ADRs). Five of the seven ADRs 
lacking PI changes occurred with off label use.  
MCQUEEN KD, MILTON JD: MULTICENTER POSTMARKETING 
SURVEILLANCE OF ONDANSETRON THERAPY IN PEDIATRIC-
PATIENTS. 1994, THE ANNALS OF PHARMACOTHERAPY 
28(1):85-92 
Surveys from 197 of the 210 patients enrolled were complete for evaluation. 
Ondansetron was used to treat chemotherapy-induced emesis in 88% of the 
patients and 12% received it for various other indications. Ondansetron dosing was 
off label in 15% and 73% prior to and after an emetogenic exposure, respectively. 
Possible ondansetron-associated adverse reactions were similar to those of 
previous reports for all patients, although some recorded reactions are not 
currently included in package labeling. 
NEUBERT A ET AL.: THE IMPACT OF UNLICENSED AND OFF LABEL 
DRUG USE ON ADVERSE DRUG REACTIONS IN PAEDIATRIC 
PATIENTS. 2004, DRUG SAFETY 27(13):1059-67 
A total of 178 patients were included in the study and 740 drug prescriptions were 
given to 156 patients (median three prescriptions per patient). In 198 cases (27.7% 
of all prescriptions) drugs were used in either an unlicensed (n = 3) or off label (n = 
195) manner. A total of 46 ADRs were observed in 31 patients (17.4%). Patients 
receiving at least one unlicensed or off label drug prescription during 
hospitalization (n = 92) experienced an ADR significantly more frequently (n = 26 
patients) than patients receiving only licensed drugs (n = 64.5 patients). ADRs 
were associated with 29 (5.6%) of the 517 licensed drug prescriptions and with 12 
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(6.1%) of the 198 unlicensed or off label drug prescriptions. The majority of ADRs 
caused by unlicensed and off label drug use were recognized by the attending 
physician. However, statistical analysis revealed no significant difference in the 
number of licensed and unlicensed/off label drug prescriptions causing ADRs. 
RODRIGUEZ W ET AL.: ADVERSE DRUG EVENTS IN CHILDREN: 
THE U.S. FOOD AND DRUG ADMINISTRATION PERSPECTIVE. 
2001, CURRENT THERAPEUTIC RESEARCH - CLINICAL AND 
EXPERIMENTAL 62(10):711-23 
Of the first 16 products that were subsequently studied in children, 6 (37.5%) had 
significant changes in labeling that had an impact on safety or efficacy. Situations 
in which proposed dosing could have led to overdosing or under dosing and in 
which adverse events, previously not described, could be expected were identified. 
SCHIRM E ET AL.: REPORTED ADVERSE DRUG REACTIONS AND 
THEIR DETERMINANTS IN DUTCH CHILDREN OUTSIDE THE 
HOSPITAL. 2004, PHARMACOEPIDEMIOLOGY & DRUG SAFETY 
13(3): 159-65 
The main findings were that ADRs were disproportionately more often reported on 
systemic drugs (OR 3.0; [95%CI: 1.9-4.8]), new drugs (2.4; [1.6-2.7]), anti-infective 
drugs (1.7; [1.1-2.7]) and nervous system drugs (2.1; [1.3-3.5]), whereas 
unlicensed drugs (0.1; [0.0-0.4]), frequently used drugs (0.3; [0.2-0.5]) and 
dermatological drugs (0.1; [0.0-0.4]) were less likely to be associated with a 
reported ADR. Overall, the proportion of off label prescriptions did not differ 
between drugs with a suspected ADR and drugs used by children in a general 
population. 
TURNER S ET AL.: ADVERSE DRUG REACTIONS TO UNLICENSED 
AND OFF LABEL DRUGS ON PAEDIATRIC WARDS: A PROSPECTIVE 
STUDY. ACTA PAEDIATR. 1999 SEP;88(9):965-8.  
ADR: 3.9% in 2881 licensed drugs, 6% out of 1574 unlicensed or off label drugs 
UFER M. ET AL.: ADVERSE DRUG REACTIONS AND OFF LABEL 
PRESCRIBING FOR PAEDIATRIC OUTPATIENTS: A ONE-YEAR 
SURVEY OF SPONTANEOUS REPORTS IN SWEDEN. 2004, 
PHARMACOEPIDEMIOLOGY & DRUG SAFETY 13(3): 147-52 
The average proportion of off label drug prescribing amounted to 42.4%. It was 
more frequently associated with serious than non-serious ADRs and mostly due to 
a non-approved age or dose. The most common clinical manifestations were 
psychiatric disorders and mucocutaneous inflammatory reactions. 
VALICENTI-MCDERMOTT, MR, DEMB H: CLINICAL EFFECTS AND 
ADVERSE REACTIONS OF OFF LABEL USE OF ARIPIPRAZOLE IN 
CHILDREN AND ADOLESCENTS WITH DEVELOPMENTAL 
DISABILITIES. 2006, JOURNAL OF CHILD AND ADOLESCENT 
PSYCHOPHARMACOLOGY 16(5):549-60 
Side effects were reported in 16 (50%), with the most frequent being sleepiness (n 
= 6). 
Table 32 Summary of studies on the frequency of ADRs during NDU 
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Project description 
 
„Comparative survey of off-label, unlicensed and compassionate use in selected 
industrial countries“  
 
I. Research question 
 
About 25% to 90% inpatient and 13% to 70% outpatient prescriptions are not 
within the terms of the medicines’ marketing authorization (off label use) or 
include medicines prescribed without a marketing authorization (unlicensed use). 
The meaning and consequences of off-label, unlicensed and compassionate use 
of medicines in outpatient and inpatient care has not yet been subject to research 
in Germany. A comprehensive, cross-national appraisal including Germany and 
relevant industrial countries is not available up until now. Information on off label 
use is poorly or inaccessible for both physicians and pharmacists.  
Recommendations on off label use are produced heterogeneously and do not 
meet the standards of evidence-based medicine. An expert group was founded in 
Germany in 2002 whose responsibility is to decide in which situations medicines 
can be applied, despite the fact that they are not approved for an indication or the 
treatment of a severe disease.  
Reasonable off label use is supposed to be reimbursed and should be supported 
on the basis of earlier theories. The group experienced that assessment is very 
complicated and only few results were achieved. However, since there is an 
unequivocal therapeutic need in certain medical disciplines (or even a statutory 
commitment) for the described application in individual cases, despite the risks to 
patients of prescription freedom on behalf of physicians, data for evidence-based 
decisions is crucial. 
The aim of this and subsequent projects is to improve drug therapy by 
introducing a rational, scientifically founded application of medicines outside the 
terms of (or even without) a marketing authorization. A special objective of the 
project is to compare regulations or practices in foreign countries in depth with 
the situation in Germany. There are three stages to the project: 
A. Pre-stage: 
This stage includes the literature research, analysis and documentation of the 
international and scientific existing state analysis as preliminary and legwork for 
the German groups. As a part of the complete pre-stage part of the project, all 
documentation of the international and scientific status of off-label, unlicensed 
and compassionate use will be made available for public (project years one and 
two). 
B. Recommended action: 
Check sheets and other tools are developed for support of concerned physicians 
and pharmacists regarding their decisions and documentation (project year 
three). 
C. Support to the decision maker: 
The continuing support of the work of future decision makers (e.g., off label 
committee) and prescriber/applicant/patient/pharmacists by supplying data 
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according to A. and B. (from 2008 onward) is a key issue. A decision on this part 
will be made in 2007. 
 
II. Initial stage 
 
Definition 
The quality of drug therapy in Germany is assured under the German drug act 
(circulation safety) and the same is assured for national health care by the social 
security code (benefit and cost effectiveness). Nevertheless, both inpatient and 
outpatient consumer health care in Germany is affected by applications that have 
not been approved by one of these entities. This problematic use of medicines is 
characterized by the terms ‘off label use’, ‘unlicensed use’ and ‘compassionate 
use’. 
Off label use is the use of medicines outside the terms of the application for a 
marketing authorization and is neither verified nor approved by the authorities. 
This definition can include the drug’s use for another indication, but also with a 
different dose, interval of application, route of administration and even type of use 
(such as single or combined therapy) or for specific patient’s features (e.g., age, 
co-morbidity).  
Unlicensed use is the use of medicines without a marketing authorization. 
Compassionate use is widely understood to be the accepted use of a medicine 
either outside its license or before it is licensed by authorities for compassionate 
reasons.  
All terms are used heterogeneously according to the national legal status or the 
academic use, as well as to individual levels of awareness and assessment. 
Since these medicines or their specific use have not undergone testing regarding 
efficacy, quality and risks, both cost -effectiveness and safety of such drug 
therapy are not guaranteed. Thus the German social security code largely 
abandons own rules on how to secure quality, notwithstanding other services; it 
is bound compulsorily to the German drug act and obliged to the drug act’s 
criteria concerning the quality, efficacy and safety of a drug. If a medicine for 
which proof of quality, efficacy and safety has not been provided is used, its cost-
effectiveness and benefit cannot be assumed. However, absence of benefit of 
such a medicine can also not be assumed merely because the formal 
authorization process has not been performed with the available scientific data. 
Therefore, uncertainty regarding reimbursement arises, which again undoubtedly 
influences the quality of consumer health care. Statements regarding this issue 
were only made in distinct sectors and are usually not based on empirical 
studies. The problem of co-operation between regulatory agencies and 
reimbursement through the social security system in order to best use financial 
resources as well as supply the country with medicines is also present in foreign 
countries. 
The circumvention of the German drug act due to off-label, unlicensed and 
compassionate use is all the more difficult if the origin of the act is considered. 
This act is inseparably linked to the thalidomide scandal; it was enacted to 
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protect patients from serious harm by unavoidable risks of medicines.xiii xiv The 
drug act demands exceptionally high requirements from the pharmaceutical 
industry for proof of efficacy and safety through clinical trials. The specification 
‘use in compliance with the label’ by both SPC and PIL as a core element of 
consumer protection is negated when regulatory status and therapeutic efficacy 
grow apart. 
 
Recent papers are calling to attention the presence of significant circumvention of 
these legal mechanisms of protection. The dimension of off-label and unlicensed 
use varies depending on patients and the supply area.xv Bücheler et al. 
discovered in their study that 13.2% out of a total of 1,74 Mio. prescriptions in the 
first quarter of the year written by all pediatric physicians, general practitioners 
and internal specialists at the expense of an insurance company in 1999 (i.e., 
210,528 out of 1,59 Mio.) were off-label; in certain disciplines this percentage 
was even up to 64%.xvi Schirm et al. found a rate of 22.7% with extreme deviation 
in pediatric outpatient care in the Netherlands. Another survey by Conroy et al. 
suggests that off label use is even more common in specialized pediatric care. 
Their results show that on average among all institutions (46% of which were 
German institutions) in 41% of all cases patients did not receive prescriptions in 
accordance with the marketing authorization.xvii 
Further European and foreign studies verify this observation. Schirm et al. 
detected both off label use and unlicensed use in 22.7% and O’Donell at al. in 
58% of all child prescriptions.xviii xix The situation is even more dramatic in 
pediatric oncology. Conroy et al. found out that all children had at least one drug 
prescribed out of terms of the particular marketing authorization.xx This fraction is 
equal to 90% in neonatal care.xxi The German Ministry for Health estimates rates 
                                                            
xiii Amtliche Begründung zum Gesetz zur Neuordnung des Arzneimittelrechts. A. Allgemeiner Teil, 
August 24, 1976. 
xiv "Ausschußbericht zum Gesetz zur Neuordnung des Arzneimittelrechts: II. Allgemeiner Teil; 1. Die 
Mängel des geltenden Rechts." 24. 8. 1976. 
xv Schirm, E. "Risk Factors for Unlicensed and Off-Label Drug Use in Children Outside the 
Hospital." Pediatrics 111, no. 2 (2003): 291–95.  
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of 70-80% for off label use in oncology care in Germany.xxii Off label use and 
unlicensed use are explained to be due to the fact that use in compliance with the 
label of used medicines as regulated in a marketing authorization often does not 
comply with substantial care or state-of-the-art of medical science.xxiii xxiv xxv This 
statement corresponds to publications abroad.xxvi Governmental and academic 
facilities both publish lists and comments on reasonable and reviewed off label 
use.xxvii xxviii  
 
Reasons for the unevaluated use of medicines are numerous. 
 
The planning, transaction, evaluation and assessment of studies necessary in 
order to receive an approval require a lot of time. On the other hand, physicians 
and patients have a desire to employ medicines that have achieved first positive 
results in clinical trials as soon as possible in order to make use of the best 
possible practice. However, comprehensive proof of efficacy and safety is often 
not available for use of medicines beyond marketing authorization.  
 
Furthermore, the first approval of a medicine is often a model marketing 
authorization for which studies were performed in a small group of patients not 
including all possible applicants. From a point of view of patient supply, all 
desired therapeutic capabilities of an active agent may not be covered by a 
marketing authorization.  
 
Moreover, not all scientific information may exist in order to employ 
pharmacotherapy on a rational basis. The causes for the existence of only a few 
clinical trials are of an economic, ethical, scientific and practical nature.xxix There 
is, for instance, a missing incentive for studies in groups of patients with an 
expected narrow market. Even if some incentives are currently being provided, 
the limited nature of the capacities for the management of clinical trials and 
                                                            
xxii Deutscher Bundestag. Antwort der Bundesregierung auf die Kleine Anfrage der Abgeordneten. 
14/9274 (Drucksache). Bundesregierung, June 24, 2002. 
xxiii Weißbach, L., and E. A. Boedefeld. "Off-Label-Verordnungen in der Onkologie." 
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 46, no. 6 (2003): 462–66. 
xxiv Fritze, J., and M. Schmauß. "Off-Label-Use in der Psychopharmakotherapie." Nervenarzt  73, 
no. 8 (2002): 796–99. 
xxv See footnote xxi 
xxvi Department of Health and Human Services. "Patient Access to New Therapeutic Agents for 
Pediatric Cancer: Report to Congress." 12.2003. 
xxvii Federal Register 68, no. 13: 2789. 
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biometric problems will still make studying all possible patients impossible.xxx xxxi 
xxxii 
 
One possibility to encourage the pharmaceutical industry to perform more clinical 
trials is to offer incentives. This method is applied in the U.S. by means of the 
pediatric exclusivity provision. Pharmaceutical companies that begin specific 
research in children may be granted a six-month extended patent protection for 
the complete medicine. Due to combined regulations requiring manufacturers to 
assess the safety and effectiveness of new drugs and biological products in 
pediatric patients, which allows the FDA to request additional trials for the 
treatment of children for specific marketing authorizations, clinical trials in 
children have increased. Analogous incentives have already submitted to the 
parliament and council and are also now subject to approval by the EC.xxxiii 
Extended terms of copyright for product development, financial support for 
relevant research and simplified terms of approval are also regarded as positive 
incentives. In this way, the pharmaceutical companies are supposed to plan 
specific research for indications or groups of patients during the development of 
an active agent for which costs are currently not affordable during the data 
protection period. An approach such as the European regulation for medicines 
against rare disorders was successful and led to many accepted applications. 
Whether drug therapy can be improved and to what extent will have to be 
assessed after introduction of these regulations. Foreign experience in countries 
that have already provided incentives should also be assembled and assessed 
regarding their impact for Germany. A further method will be to review to what 
extent common off-label, unlicensed and compassionate uses are in accordance 
with the current state of scientific knowledge and are based on trial data.  
In Germany, the Department for Health started a group of experts in 2002 with 
the function of assessing which cases of medicines for treatment of severe 
disease may be applied, with these medicines not being approved under the drug 
act for that disease. Based on these results, off label or unlicensed use should be 
reimbursed, permitted and encouraged, and a marketing authorization supported. 
For supplying quality medicines, the following question is also relevant: ‘To what 
extent does off-label, compassionate, and unlicensed use endanger patients 
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Paediatric medicinal products," press statement, February 28, 2002; available from 
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Pharmaceutical for Children Act, PubLNo. 107-109, 115 Stat 1408 (2002); Internet, accessed 
February 17, 2009. 
xxxii European Medicines Agency. "Status Report on the Implementation of the European Parliament 
and Council Regulation on Orphan Medicinal Products: EMEA/7381/01." 08.04.2002. 
xxxiii Commission of the European Communities. "Proposal for a Regulation of the European 
Parliament and of the Council on medicinal products for paediatric use and amending Regulation 
(EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004: Final Proposal." (COM 
(2004) 599); available from http://eur-
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because they are denied effective therapies, and to what extent does danger 
patients because unexpected adverse reactions occur?’ Studies are evaluating 
the quality of pharmacotherapy on an off-label, unlicensed or compassionate use 
basis, especially investigating to what extent therapeutic decisions are based on 
scientific findings and whether therapeutic results justifying use are rare.  
Off-label, unlicensed and compassionate uses do not generally affect the quality 
of a pharmacotherapy supply. In individual cases there may well be medical 
reasons justifying a departure from use in accordance with the marketing 
authorization. A physician might even be obliged to prescribe off label or 
unlicensed (as in the acyclovir case) and may be liable for failing to render 
assistance.xxxiv 
A Canadian study on the use of immunoglobulins found rates of 53% off label 
use in adults and 38% in children, but analysis showed that a rate of 89% use 
was justified.xxxv  
The question of whether adverse drug reactions occur more often has not been 
answered. Turner et al. and Horen et al. recorded an increase in adverse 
reactions. Choonara et al. could not confirm this effect in their review.xxxvi xxxvii 
xxxviii  
 
The quality of pharmacotherapy is not limited to its efficacy and safety, but also 
includes financial security in the case of aftermath of harm from medicines, such 
as that which the German drug act grants under § 84. However, this security is 
limited to when the drug is used conventionally. In such cases liability may pass 
to the physician. This situation may burden the patient with his claims under 
private law against the physician.xxxix  
The patient must be informed that he is meant to be treated outside the approved 
indication, that this use is not conventional use and that the pharmaceutical 
company is not liable for possible harm (but instead the physician is). He must be 
informed on what basis of which scientific experience the physician chooses the 
treatment and of the risks existing for him. 
The extent to which these requirements are fulfilled abroad is unknown.  
III. Organizational implementation of the project 
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The Ministry for Heath and Social Security (Bundesministerium für Gesundheit 
und Soziale Sicherheit, BMGS) granted Prof. Dr. Harald Schweim, Department 
for Drug Regulatory Affairs, University of Bonn funds for three years. The 
furnishing of an opinion and the laying out of a library on off-label, unlicensed and 
compassionate use, especially the comparative study of off-label, 
compassionate, and unlicensed use in selected industrial countries (member 
states of the E.U. and the International Conference on Harmonization of 
principles, ICH) are required by the contract. The assessment especially 
considers the different groups in society such as children and people suffering 
from rare diseases.  
The following tasks will have to be performed: 
 
In the first and second years of the project: 
− Review the literature concerning methodological papers and 
studies on off-label, unlicensed and compassionate use 
− Request used methods in studies of scientific institutions  
− Analyze the offer of information  
− Search for information concerning organizational and institutional 
methods of resolution in the field of off-label, unlicensed and 
compassionate use.  
− Requests to scientific institutions concerning their methods of 
resolution 
− Analyze, compare and document regulations or constitutions 
under drug and social law in the named countries with reference to 
the reimbursement of unapproved medicines in addition to the 
research and analysis of studies on the consequences for medical 
service 
− Research the demand and/or consumption of unapproved 
medicines in the named countries and a comparative presentation 
of the facts 
− Research the consequences of off-label, unlicensed and 
compassionate on drug safety  
− Analyze the information/data acquired 
− Issue an opinion and a document of all information 
In the third year: 
− Issue a recommendation for action as part of the opinion on off-
label, compassionate, and unlicensed use in Germany and taking 
into account means available  
(From 2008 under reserve of examination in 2007): 
− Support decision-making unit in the development of finances of 
off-label, compassionate, and unlicensed use and taking into 
account means available 
 
Contact: 
Vanessa Plate 
Rhein. Friedr.-Wilh.-Univ. Bonn 
Pharm. Institut 
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Drug Regulatory Affairs 
c/o IZMB 
Raum 106b 
Kirschallee 1 
 
53115 Bonn 
 
Tel: +49 (0)228 736726 
Fax: +49 (0)228 739414 
 
dra@uni-bonn.de  
www.dra.uni-bonn.de 
  
CONFIDENTIALITY NOTICE 
The content of this description is confidential to the ordinary receiver to which it 
was given and may also be privileged. If you are not the addressee you may not 
copy, forward, disclose or otherwise use it or any part of it in any form 
whatsoever. If you have received this document in error please inform the author 
of this document. 
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Expert interview TOPIC GUIDE within the report 
“Comparative study of off-label, unlicensed and compassionate drug use in 
selected industrial countries” 
Questions refer to medicinal products for humans. The opinion of the respondent or 
his/her deputy is centered in the interview. 
Questions: 
1. Determination of terms 
a. What is understood by off label use in [country]? 
b. What is meant by compassionate use in [country]? 
c. Please, define the meaning of unlicensed use in [country] for me. 
2. Reasons for off-label, compassionate- and unlicensed use 
a. Which considerable reasons may be responsible for off-label, compassionate- 
and unlicensed use in [country]? 
b. What provisions affect off-label, compassionate- and unlicensed use in 
[country]?  
3. Functional implementation 
a. What influences the feasibility of off-label, compassionate- and unlicensed 
use in [country]? 
b. What improvements regarding a more efficient use of off-label, 
compassionate- and unlicensed use do you know? 
4. Relevance 
a. To what degree is using drugs off-label, compassionate or unlicensed a 
relevant problem in  
− medical science,  
− ethics,  
− liability law,  
− social justice and/or  
− insurance industry  
E.g., in quantity or drug safety in [country]? 
b. Which problems of off-label, compassionate or unlicensed use do you face in 
your field of work in [country]? 
5. Necessity 
To what extent is off-label, compassionate- and unlicensed use necessary in order to 
secure health care provision in [country]? 
6. Adequacy 
Are off-label, compassionate- and unlicensed use medically, ethically, concerning 
liability and social law adequate in their current practiced form in [country]? Please 
give reasons for your opinion. 
7. Regulation 
Are there any laws which affect off-label, compassionate- and unlicensed use in 
[country] or should there be? Please outline in detail. 
 
8. Liability policies  
Are product liability and liability for medical malpractice in [country] satisfactorily 
regulated for  
− Patients, family members or parents, 
− Authorities, 
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− Health care providers, 
− insurance suppliers, 
− Pharmaceutical industry or 
− Others? 
Please give reasons for your opinion. 
9. Scientific analysis 
a. In which way is scientific analysis of knowledge gained when using medicines 
off-label, compassionate- and unlicensed in [country] guaranteed?  
b. Would you support a national database which was supplied with off-label, 
compassionate- and unlicensed use case reports from health care providers? Explain 
why. 
10. Pharmacovigilance 
To which extent are concerns of Pharmacovigilance being met sufficiently in 
[country]?  
11. Scientific information/training 
To what extent is off-label, compassionate- and unlicensed use affected by laws and 
rules controlling scientific information/training in [country]? 
 
Comments: 
The following questions refer to public and private health insurance. 
12. Ruling 
Is using drugs off-label, compassionate- and unlicensed well-regulated in [country] 
social and insurance law? Please give reasons for your opinion. 
13. Transparency of law 
Is law in [country] apparent for: 
− Patients, family members, parents, 
− Authorities, 
− Health care providers, 
− Insurance companies, 
− Pharmaceutical industry or 
− Others? Please give reasons for your opinion. 
14. Reality of health care provision 
Do social law and insurance law respectively influence the quality of health care 
provision in [country]? Please give reasons for your opinion. 
15. References 
Which Preambles, documents on the discussions on laws, commentary on laws, 
commentary on the medicines act /social law, official reasons, directory of decisions 
or further contact persons in [country] can you recommend us? 
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Drug 
Regulatory 
Affairs 
 
Rheinische Friedrich-Wilhelms-Universität Bonn  
 
 
An 
[Adresse einfügen] 
Vanessa Plate 
Pharmazeutisches Institut 
Drug Regulatory Affairs 
c/o IZMB, Raum 106b 
Kirschallee 1 
53115 Bonn 
 
Tel: 0228/73-67 26 
Fax: 0228/73-94 14 
Cell: 0170/1548-373 
 
dra@uni-bonn.de 
www.dra.uni-bonn.de 
 
Dear Madam or Sir, 
The research group “Drug Regulatory Affairs” of the Department of Pharmacy at 
the Rhein. Friedr.-Wilh.-University of Bonn is currently preparing a report for the 
German Ministry of Health addressing pharmaceutical and social law in 
European and industrial countries regulating off-label, compassionate, and 
unlicensed use of medications. Please find the project description attached. 
Selected informational publications and literature on the subject of off-label, 
compassionate, and unlicensed use of medicinal products identifies you as an 
expert in this discipline. 
We would like to interview you on the topics off-label, compassionate, and 
unlicensed use emphasizing pharmaceutical and social law. Please find the 
interview topic guide attached to this message. 
We are looking forward to meeting you between 1st of December and 15th of 
December if you agree to share your points of view and experience.  
Yours sincerely, 
 
Vanessa Plate 
 
Attachments:  
1. Project description 
2. Questionnaire 
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Expertenrating 
 
Gutachter:   ________________________________ 
 
Berufsbezeichnung:  ________________________________ 
 
Tätigkeitsfeld:   ________________________________ 
Einstufung der Inhaltsvalidität des teilstandardisierten 
Interviewleitfadens für eine Expertenbefragung im Rahmen des 
Gutachten „Vergleichende Untersuchung des Off-Label, 
unlicensed und Compassionateuse in ausgewählten 
Industriestaaten“: 
o Hoch 
o Befriedigend 
o Niedrig (Bitte um Angabe hinsichtlich der Verbesserung des 
Interviews) 
 
Plausibilitätsüberlegungen: 
 
 
 
 
 
 
 
 
Ort, Datum        Unterschrift 
         
_________________________    __________________
    
Bibliography 
141 
 
Bibliography 
*All Sentences were retrieved from Juris – Rechtsinformationen. 
                                                            
1 Higgins, LC. et al "Off-label Rx. Insurers starting to balk." Med World News, 29 (20), October 24, 
1988, 22-4; 26; 31-2. 
2 Van der Ven, K. "Die Pille wird 50. Entwicklung der oralen Kontrazeption und heutige Indikation." 
AEKNO. Uni Club Bonn, February 04, 2009. 
3 Flannery, EJ. et al "Should it be easier or harder to use unapproved drugs and devices?". 
Hastings Center Report, The 16, no. 1 (1986): 17–23. 
4 Franklin, W. and Lowell, FC. "Sounding board. Unapproved drugs in the practice of medicine." 
The NEJM 292, no. 20 (1975): 1075–77. 
5 Bücheler, R. et al "Off label prescribing to children in primary care in Germany: retrospective 
cohort study." BMJ 324, no. 7349 (2002): 1311. 
6 Schütz, H. et al "Verwendung von Misoprostol in der Geburtshilfe–Eine bundesweite Erhebung." 
Geburtshilfe und Frauenheilkunde 67, no. 5 (2007): 541. 
7 Conroy, S. et al. "Survey of unlicensed and off label drug use in paediatric wards in European 
countries." BMJ 320, no. 7227 (2000): 79–82. 
8 Plate, V. et al. "Vergleichende Untersuchung des Off-Label-Use, Unlicensed-Use und 
Compassionate-Use in ausgewaehlten Industriestaaten: Endbericht zum Forschungsprojekt." 
(Analyse). Bonn, December 31, 2008. 
9 Krüßen, H. et al. "Arzneimittelimporte gemaeß § 73 Abs. 3- Was, wie viel und mit welchen 
Konsequenzen?". DAZ 145, no. 29 (2005): 54. 
10 Deutscher Bundestag. Antwort der Bundesregierung auf die Kleine Anfrage der Abgeordneten. 
(Drucksache),14/9274. Bundesregierung, June 24, 2002. 
11 Anonymus. "Arzneimittelzulassung und Therapiefreiheit: Anmerkungen des wissenschaftlichen 
Arbeitskreises der DGAI zum nichtbestimmungsgemaeßen Gebrauch zugelassener Medikamente 
in der Anaesthesie." Deutsche Gesellschaft zum Studium des Schmerzes e.V., 03.2001; available 
from http://www.kinderschmerz.org/?action=download&id=5; Internet, accessed February 12, 2009. 
12 Assion, HJ. et al "Off-label prescribing in a german psychiatric hospital." Pharmacopsychiatry, 40, 
no. 1 (2007): 30–36. 
13 Lauktien, G. "BtM-Rezeptausgabe, -auswertung und Substitutionsregister: Auswertung von BtM-
Rezepten (Beispiel-Methylphenidat)." BfArM. Bonn: BfArM, May 28, 2003; available from 
http://www.bfarm.de/nn_1232318/SharedDocs/Publikationen/DE/BfArM/publ/praesent/dialog__2001
-2005/dialog-030528/lauktien,templateId=raw,property=publicationFile.pdf/lauktien.pdf; Internet; 
accessed February 13, 2009. 
14 Blasius, H. et al "Die arzneimittel- und sozialrechtliche Stellung des Off-Label-Use, Unlicensed-
Use und Compassionate-Use in Frankreich." Bonn, 07.2008. 
15 European Medicines Agency. "Guideline on Compassionate Use of Medicinal Products, pursuant 
to Article 83 of Regulation (EC) No. 726/2004." (2007): 1–8. EUR-Lex Official Journal; available 
from www.emea.europa.eu/pdfs/human/euleg/2717006enfin.pdf; Internet, accessed February 12, 
2009. 
Bibliography 
142 
 
                                                                                                                                                                  
16 da Rocha Dias, S. Public register of CHMP opinions on products for compassionate use in the 
EU. E-Mail to V. Plate. London. September 11, 2008. 
17 Blasius, H. et al "Off-Label-, Unlicensed- und Compassionate-Use in der europaeischen 
Regelungen und den Festlegungen der ICH unter besonderer Berücksichtigung der arzneimittel- 
und sozialrechtlichen Regelungen." Remagen, 03.2008. (Projektbericht) 
18 "European Medicines Agency consulting on a draft guideline on pharmacovigilance for medicines 
used in children," press statement, August 12, 2005; available from 
http://www.emea.europa.eu/pdfs/human/press/pr/26213505en.pdf; Internet, accessed February 12, 
2009. 
19 Jōhōblog, "Unapproved anticancers in Japan: latest progress," press statement, July 29, 2005; 
available from http://jouhoublog.jouhoukoukai.com/?m=200507; Internet, accessed 10.2008. 
20 Wilton, LV. et al. "The use of newly marketed drugs in children and adolescents prescribed in 
general practice." Pharmacoepidemiology and Drug Safety 8, no. S1 (1999): S37-S45. 
21 Wilton, LV and Shakir, SA. "A Post-Marketing Surveillance Study of Formoterol (Foradil(R)): Its 
Use in General Practice in England." Drug Safety 25, no. 3 (2002): 213–23. 
22 Robinson, A. Notifications for named patient prescriptions to MHRA in the U.K. for 2002 till now. 
E-Mail to V. Plate. London. January 25, 2008. 
23 Conroy, S. et al "Unlicensed and off label drug use in acute lymphoblastic leukaemia and other 
malignancies in children." Annals of Oncology 14, no. 1 (2003): 42.  
24 See endnote 7 
25 See endnote 14 
26 See endnote 8 
27 Thouvenel, C. et al. "Autorisation de mise sur le marché et information pédiatrique pour les 
médicaments de chimiothérapie des cancers: état des lieux et propositions." Archives de pédiatrie, 
no. 7 (2002): 685–93. 
28 Autret-Leca, E. et al. "Particularité de l’évaluation des médicaments en pédiatrie et son 
application à la prescription en pédiatrie." Paediatrica, no. 7 (2002): 685–93. 
29 Autret-Leca, E. and Jonville-Béra, AP. "Besoin d'essais cliniques chez l'Enfant et aspects 
éthiques." SFP-Congrès. Cassis, 10.2003; available from 
http://www.sftox.com/congres/sft2003/posters/Elisabeth_Autret.pdf; Internet; accessed February 13, 
2009. 
30 Sommelet, D. et al "L’enfant et l’adolescent: un enjeu de société, une priorité du système de 
santé." Archives de pédiatrie 14, no. 8 (2007): 1011. 
31 Erickson, SH. et al "The use of drugs for unlabeled indications." JAMA 243, no. 15 (1980): 1543. 
32 Thompson, DF. and Heflin, NR. "Frequency and appropriateness of drug prescribing for 
unlabeled uses in pediatric patients." Am J Health Syst Pharm, no. 44 (1987): 792–94. 
33 Rayburn, WF. and Turnbull, GL. "Off-label drug prescribing on a state university obstetric 
service." Journal of reproductive medicine, no. 40 (1995): 186–88. 
34 Radley, D. C. et al. "Off-label Prescribing Among Office-Based Physicians." Archives of internal 
medicine 166, no. 9 (2006): 1021. 
35 Behles, C. et al. "Die arzneimittel- und sozialrechtliche Stellung des Off-Label-, Unlicensed-Use 
und Compassionate-Use in den USA." Bonn, 07.2006. 
36 U.S. General Accounting Office Washington, D. C. Off-label drugs: reimbursement policies 
constrain physicians in their choice of cancer therapies. GAO/PEMD-91-14 (report), 1991. 
Bibliography 
143 
 
                                                                                                                                                                  
37 Cote, C. J. et al. "Is the ‘therapeutic orphan’ about to be adopted?". Pediatrics 98, no. 1 (1996): 
118. 
38 Committee on Drugs. "Unapproved Uses of Approved Drugs: The Physician, the Package Insert, 
and the Food and Drug Administration: Subject Review." In vol. 98. American Academy of 
Pediatrics, 1996. Pediatrics: 143–45. 
39 Convington & Burling. Proposed Rules Regarding Requirements for Expanded Access to 
Investigational Drugs and Charging for Investigational Drugs 17.03.2009, March 17, 2009; available 
from 
http://209.85.129.132/search?q=cache:rquSAj054FYJ:www.linexlegal.com/content.php%3Fcontent
_id%3D40607+%22Emergency+INDs+per+year%22&cd=2&hl=en&ct=clnk&gl=uk; Internet. 
40 See endnote 8 
41 Health Canada. Special Access Programme Issue Identification Paper Health Canada, 2007, 
May 06, 2009; available from http://www.hc-sc.gc.ca/dhp-mps/acces/sap_pas_ident-eng.php; 
Internet. 
42 Weiss, E. et al. "Off-Label Use of Antipsychotic Drugs." Journal of clinical psychopharmacology 
20, no. 6 (2000): 695. 
43 Kurz, R. et al. Ethik in der paediatrischen Forschung: Grundsatzpapier der Ethik-Arbeitsgruppe 
der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde 2001; available from 
http://www.meduni-graz.at/ethikkommission/Forum/Download/Files/Paediatr.pdf; Internet; accessed 
February 13, 2009. 
44 Müllner, M. et al. "AGES Österreichische Agentur für Gesundheit and Ernaehrungsischerheit 
GmbH: Health. Nutrition, Safety. Our concern." AGES: AGES, May 15, 2007; available from 
http://www.ages.at/uploads/media/MA1_4llner_WS_Industrie_150507.pdf; Internet; accessed May 
06, 2009. 
45 Ibid. 
46 "Geschaeftsbericht 2002." Bern: Schweizerisches Heilmittelinstitut, 2002; available from 
http://www.swissmedic.ch/org/00064/00066/00323/index.html?lan; Internet, accessed May 06, 
2009. 
47 Scheurer, G. et al. "Arzneimittelsicherheit in der Paediatrie." Diplomarbeit, Universitaet Basel, 
Basel, 2003. 
48 Blöchliger, M. et al. "Arzneimittelsicherheit in der Paediatrie." Diplomarbeit, Universitaet Basel, 
Bern, 2005. 
49 Schirm, E. et al. "Unlicensed and off label drug use by children in the community: cross sectional 
study." BMJ 324, no. 7349 (2002): 1312. 
50 Schirm, E. et al. "Risk Factors for Unlicensed and Off-Label Drug Use in Children Outside the 
Hospital." Pediatrics 111, no. 2 (2003): 291.  
51 O'Donnell, CPF. et al. "Unlicensed and Off-Label Drug Use in an Australian Neonatal Intensive 
Care Unit." Pediatrics 110, no. 5 (2002). 
52 See endnote 8 
53 Mays, N., and Pope, C. "Assessing quality in qualitative research." BMJ 320, no. 7226 (2000): 
50. 
54 Walji, R. et al. "Herbal product related adverse events- Pharmacies vs. health food stores." In vol. 
30. ISoP, October 21, 2007. Drug Safety: 948. 
Bibliography 
144 
 
                                                                                                                                                                  
55 Teng, L. et al. "Views and behaviours towards effectiveness and safety of chinese herbal 
meidicne (CHM) – Qualitative interviews with CHM shop employees in London." In vol. 30. ISoP, 
October 21, 2007. Drug Safety: 937. 
56 Knight, C., and Wilkinson, J. "Independent Safety Evaluation for all Newly licensed Medicines – 
an in-depth study of expert opinion within industry and society." In vol. 30. ISoP, October 21, 2007. 
Drug Safety: 935. 
57 Oosterhuis, I. et al. "Lareb intensive monitoring – an interim analysis." In vol. 30. ISoP, October 
21, 2007. Drug Safety: 960. 
58 Bennett, A. et al. "The Agenda: The development of qualitative methods." Qualitative methods 1, 
no. 1 (2003): 14. 
59 Chi, MTH. "Quantifying Qualitative Analysis of Verbal Data: A Practical Guide." The journal of the 
learning sciences 6, no. 3 (1997): 271. 
60 Hernandez, M. and Davis, C. "Review Team Leader Training Manual." University of South 
Florida, 02.2004; available from http://rtckids.fmhi.usf.edu/rtcpubs/SOCPR/ReviewTeamLeader.pdf; 
Internet, accessed February 13, 2009. 
61 de Ruyter, K. and Scholl, N. "Positioning qualitative market research: reflections from theory and 
practice." Qualitative market research 1, no. 1 (1998): 7. 
62 Lorenzen, M. et al. "The land of confusion? High school students and their use of the World Wide 
Web for research." Research strategies 18, no. 2 (2001): 151. 
63 Mlcakova, A. and Whitley, EA. "Configuring peer-to-peer software: an empirical study of how 
users react to the regulatory features of software." European Journal of Information Systems 13, 
no. 2 (2004): 95. 
64 Hay, I. et al. Qualitative research methods in human geography. 2. ed. South Melbourne, Vic.: 
Oxford Univ. Press, 2005. 
65 Robert Wood Johnson Foundation. Semi-structured Interviews Robert Wood Johnson 
Foundation; available from http://www.qualres.org/HomeSemi-3629.html; Internet; accessed 
February 13, 2009. 
66 University of the West of England. Research Observatory University of the West of England; 
available from 
http://ro.uwe.ac.uk/RenderPages/RenderLearningObject.aspx?Context=7&Area=1&Room=3&Cons
tellation=25&LearningObject=113; Internet; accessed February 13, 2009. 
67 Sturges, JE. and Hanrahan, KJ. "Comparing telephone and face-to-face qualitative interviewing- 
a research note." Qualitative Research 4, no. I (2004): 107–18. 
68 Bauer, MW. and Gaskell, G. "Qualitative Researching with Text, Image and Sound." SAGE 
(2000): 38–57. 
69 Guest, G. et al. "How Many Interviews Are Enough?: An Experiment with Data Saturation and 
Variability." Field methods 18, no. 1 (2006): 59. 
70 Ibid.   
71 Chew-Graham, CA. et al. "Qualitative research and the problem of judgement: lessons from 
interviewing fellow professionals." Family Practice 19, no. 3 (2002): 285. 
72 Silverman, M. et al. "Strategies for Increasing the Rigor of Qualitative Methods in Evaluation of 
Health Care Programs." Evaluation review 14, no. 1 (1990): 57. 
73 Hopf, G. et al. "Bevacizumab-Ranibizumab." In Hess. AErztebl., vol. 2 (2008), 227. 
74 See endnote 72 
Bibliography 
145 
 
                                                                                                                                                                  
75 Miller, PR. et al. "Inpatient diagnostic assessments: 1. Accuracy of structured vs. unstructured 
interviews." Psychiatry Research 105, no. 3 (2001): 255. 
76 See endnote 65 
77 Webb, C. et al. "Feminist research: definitions, methodology, methods and evaluation." Journal of 
advanced nursing 18, no. 3 (1993): 416. 
78 Hsieh, HF. et al. "Three Approaches to Qualitative Content Analysis." Qualitative health research 
15, no. 9 (2005): 1277. 
79 Whittemore, R. et al. "Validity in Qualitative Research." Qualitative health research 11, no. 4 
(2001): 522. 
80 Stiles, WB. et al. "Quality control in qualitative research." Clinical Psychology Review 13, no. 6 
(1993): 593. 
81 Onwuegbuzie, AJ. and Daniel, GD. Typology of Analytical and Interpretational Errors in 
Quantitative and Qualitative Educational Research 2003, February 16, 2009; available from 
http://cie.asu.edu/volume6/number2/; Internet.  
82 Madill, A. et al. "Objectivity and reliability in qualitative analysis: Realist, contextualist and radical 
constructionist epistemologies." British Journal of Psychology 91, no. 1 (2000): 1. 
83 Neubert, A. et al. "The impact of unlicensed and off-label drug use on adverse drug reactions in 
paediatric patients." Drug Safety 27, no. 13 (2004): 1059–67. 
84 Ruiz-Casado, A. et al. "Ecteinascidin in heavily pretreated advanced sarcoma patients as a 
compassionate basis." In vol. 21, 2002: (abstr 1631); available from 
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?abstractID
=1631&confID=16&index=y&vmview=abst_detail_view; Internet, accessed February 12, 2009. 
85 See endnote 5 
86 Perucca, E. et al. "Should widespread compassionate use before registration be allowed? A 
contrary view." In vol. 1995: 217; available from http://www3.interscience.wiley.com/cgi-
bin/fulltext/119235258/PDFSTART; Internet, accessed February 12, 2009. 
87 Schweim, HG. "Projektantrag „Vergleichende Untersuchung des Off-label-, Unlicensed- und 
Compassionate-use in ausgewaehlten Industriestaaten“." Bonn: Rheinische Friedrich-Wilhelms-
Universitaet, 12.12.04. 
88 Choonara, I. and Conroy, S. "Unlicensed and Off-Label Drug Use in Children: Implications for 
Safety." Drug Safety 25, no. 1 (2002): 1–5. 
89 Schroeder-Printzen, J. and Tadayon, A. "Die Zulaessigkeit des Off-label use nach der 
Entscheidung des BSG vom 19.3.2002." Sgb, no. 12 (2002): 664. 
90 "Food and Drug Act: FD&C Act." In 21 U.S.C. 321, Section 201. Amended Through December 
31, 2004 
91 Storz, G. VFA-Positionspapier: Zulassungsüberschreitender Einsatz von Medikamenten bei 
schweren Erkrankungen VfA, 2009, April 02, 2009; available from 
http://www.vfa.de/download/SHOW/de/presse/positionen/offlabeluse.html/offlabeluse.pdf; Internet; 
accessed May 06, 2009. 
92 Dierks, C. et al. "Gesetzliche Rahmenbedingungen und die Leistungsgrenzen der GKV für die 
Arzneimitteltherapie." In Glaeske, G. and  Dierks, C. "Off-Label-Use Weichenstellung nach dem 
BSG Urteil 2002"", 56. 
Bibliography 
146 
 
                                                                                                                                                                  
93 Franken, A. "Zwischen Haftung und Mitverantwortung: Wo liegt die Bestimmung eines 
Arzneimittels?". Arzneimittel&Recht, no. 4 (2006): 156–58. 
94 Anynomus. Themen- Arzneimittelinformation: Bewertung aus der Praxis für die Praxis ABDA, 
02.08.2007, August 02, 2007; available from http://www.abda.de/810.html; Internet 
95 Kraemer, M. BPI-Positionspapier Orphan Drugs: Compassionate use, wirtschaftliche Anreize, 
Erstattungsfaehigkeit Berlin, Heidelberg: BPI, 2005, October 21, 2004; available from 
http://www.bpi.de/UserFiles/File/bpi/publikationen/BPI-OrphanDrugs.pdf; Internet; accessed May 
06, 2009. 
96 Nies, P. Gemeinsamer Bundesausschuss - Fragen und Antworten zum "Off-Label-Use" G-BA, 
01.04.2009, April 01, 2009; available from http://www.g-ba.de/institution/sys/faq/78/; Internet; 
accessed May 06, 2009. 
97 BfArM. BfArM Off-Label (Expertengruppen): Die Expertengruppen Off-Label - Anwendung von 
Arzneimitteln außerhalb des zugelassenen Indikationsbereichs BfArM, 2006, May 01, 2009; 
available from 
http://www.bfarm.de/nn_424278/DE/Arzneimittel/3__nachDerZulassung/offLabel/offlabel-
node.html__nnn=true; Internet; accessed May 06, 2009. 
98 Stöcker, S. and Ruhaltinger, D. Optimale Anwendung intravenöser Immunglobuline: 
Internationale Konferenz am Paul-Ehrlich-Institut in Langen PEI, 2001; available from 
http://www.pei.de/cln_048/nn_154580/sid_D993ED83BA58C4CCD8D3F53025627DDA/DE/infos/pr
esse/pm/2001/16.html?__nnn=true; Internet; accessed August 02, 2007. 
99 See endnote 88 
100 Higher social court Berlin L 15 B 34/02 KR ER. September 11, 2002.* 
101 Appleby, J. et al. 'Off-label' drugs denied to patients in Medicare D USA Today, 2007, August 
02, 2007; available from http://www.usatoday.com/money/industries/health/2007-08-01-medicare-
drugs_N.htm; Internet; accessed May 06, 2009. 
102 Sanmaier, C. et al. Langzyklus: Verhütung ohne Pause PZ, 2005; available from 
http://www.pharmazeutische-zeitung.de/fileadmin/pza/2005-13/pharm2.htm; Internet; accessed 
August 02, 2007. 
103 Hoffmeister, C. et al. Off-Label-Use Landessozialgericht München; available from 
http://www.sanofi-aventis.de/live/de/de/layout.jsp?cnt=C70E505C-53EA-4B55-8772-
93C680D46276; Internet; accessed May 06, 2009. 
104 Seyberth, JH. "Mehr Arzneimittelsicherheit für Kinder." Dtsch Arztebl 96 (1999): 547–50. 
105 See endnote 7 
106 Fritze, J. and Schmauß, M. "Off-Label-Use in der Psychopharmakotherapie." Psychoneuro 28, 
no. 8 (2002): 431–39. 
107 Bavarian Higher social court L 12 KA 107/03. March 02, 2005.* 
108 Higher social court Berlin L 15 B 43/02 KR ER. September 11, 2002.* 
109 Higher social court Berlin L 9 KR 70/00. April 02, 2003.* 
110 Higher social court Hamburg L 1 KR 115/04. March 30, 2006.* 
111 Higher social court North Rhine-Westphalia L 5 KR 144/03. September 20, 2005.* 
112 Higher social court North Rhine-Westphalia L 5 KR 171/04. September 20, 2005.* 
113 Higher social court Saxony-Anhalt Az.: L 4 KR 114/04. April 25, 2006.* 
114 Federal social court B 1 KR 27/05 R. September 26, 2006.* 
115 Federal social court B 1 KR 15/06 R. September 26, 2006.* 
Bibliography 
147 
 
                                                                                                                                                                  
116 Federal social court B 1 KR 14/06 R. September 26, 2006.* 
117 Higher social court Saxony-Anhalt L 4 KR 36/99. December 10, 2002.* 
118 Higher social court Hamburg L 1 KR 46/03. July 14, 2004.* 
119 Higher social court Hamburg S 23 KR 871/02. April 14, 2003.* 
120 "Familienplanungs-Rundbrief." Pro familia, 11.2006; available from www.profamilia.de; Internet. 
121 BVHK. Aus der Rechtsprechung 2005 BVHK; available from 
http://www.bvhk.de/dokument_8.33.583.html; Internet; accessed May 21, 2008. 
122 Bücheler, R. et al. "„Off-label “Verschreibung von Arzneimitteln in der ambulanten Versorgung 
von Kindern und Jugendlichen." Deutsche medizinische Wochenschrift 127, no. 48 (2002): 2551. 
123 Knöppel, C. et al. "Anwendung von Medikamenten außerhalb der Zulassung oder ohne 
Zulassung bei Kindern." Monatsschrift Kinderheilkunde 148, no. 10 (2000): 904–08. 
124 "Beschluss des Gemeinsamen Bundesausschusses zur Erteilung von Auftraegen zur Erstellung 
von Bewertungen an die Expertengruppen Off-Label nach § 1 Abs. 3 des Erlasses über die 
Einrichtung von Expertengruppen Off-Label nach § 35b Abs. 3 SGB V." In February 21, 2006; 
available from www.g-ba.de; Internet. 
125 Rabe, T., and Brucker, C. Gemeinsame Stellungnahme der Deutschen Gesellschaft für 
Gynaekologische Endokrinologie undFortpflanzungsmedizin e.V. (DGGEFe.V.) in Zusammenarbeit 
mit demBerufsverband der Frauenaerzte e.V.:Empfaengnisverhütung -Familienplanung in 
Deutschland 2004; available from http://www.kup.at/kup/pdf/4698.pdf; Internet; accessed 
December 13, 2009. 
126 Horen, B. et al. "Adverse drug reactions and off-label drug use in paediatric outpatients." British 
journal of clinical pharmacology 54, no. 6 (2002): 665. 
127 Zylka-Menhorn, V. "Bayer/Lipobay: Ringen um die Arzneimittelsicherheit." Dtsch Arztebl 98, no. 
33 (2001): 51–52. 
128 See endnote 13 
129 Kompetenzzentrum Verordnungs-Management. Generika: Kostenbewusstsein ohne 
Qualitaetsverlust Kassenaerztlichen Vereinigung Bayerns, 2005; available from 
www.kvb.de/servlet/PB/show/1005741/Arzneimittel-im-Fokus-Generika-1.05.pdf; Internet; accessed 
February 14, 2009. 
130 Anonymus. Zaepfchen Hexal; available from 
http://www.hexal.de/subdomains/praeparate/arzneimittel-richtig-anwenden/zaepfchen/hinweise-
tipps-zaepfchen.php; Internet; accessed December 13, 2009. 
131 Anonymus. "Fachinformation Proleukin®." Novartis Pharma, 03.2003; available from 
www.fachinfo.de; Internet, accessed December 13, 2008. 
132 Ibid. 
133 Bock, F. et al. "Antiangiogene Therapie am vorderen Augenabschnitt." Ophthalmologe 104, no. 
4 (2007): 336–44. 
134 Shivas, T. et al. Compassionate use of experimental drugs 1999, January 21, 1999; available 
from http://bioethics.net/articles.php?viewCat=7&articleId=116; Internet; accessed May 06, 2009. 
135 Tolle, A., and Meyer-Sabellek, W. "Off-Label-Use." Bundesgesundheitsblatt, 
Gesundheitsforschung, Gesundheitsschutz, no. 6 (2003): 504–07, accessed May 06, 2009. 
Bibliography 
148 
 
                                                                                                                                                                  
136 Copeland, JG. et al. "Cardiac Replacement with a Total Artificial Heart as a Bridge to 
Transplantation." The NEJM 351, no. 9 (2004): 859–67, accessed May 06, 2009; available from 
http://journal.shouxi.net/qikan/article.php?id=209921; Internet. 
137 Neubert, A. et al. "Defining off-label and unlicensed use of medicines for children: Results of a 
Delphi survey." Pharmacological research 58, no. 5-6 (2008): 316–22, accessed May 06, 2009; 
available from http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WP9-4TG9HV6-
1&_user=1848530&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000055082&_version=
1&_urlVersion=0&_userid=1848530&md5=d10ca3cdbf9402f52ef6814d9a2eecaf; Internet. 
138 Jones, M. "Policy for Patient Group Directions (PGDs)." In . Harrogate and District NHS 
Foundation Trust, 04.2006: 1–23; available from http://www.hdft.nhs.uk/site-info/?asset=2082; 
Internet, accessed May 06, 2009. 
139 ABDA. Umstrittene Rezepturen und Nischenarzneimittel Eschborn, 2008, September 30, 2008; 
available from http://www.pharmazeutische-zeitung.de/fileadmin/nrf/PDF/1-Umstrittene-
Rezepturen.pdf; Internet; accessed May 06, 2009. 
140 See endnote 332 
141 See endnote 88 
142 Turner, S. et al. "Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a 
prospective study." Acta Paediatrica 88, no. 9 (1999): 965–68. 
143 Conroy, S. et al. "Extemporaneous (magistral) preparation of oral medicines for children in 
European hospitals." Acta Paediatrica 92 (2003): 408–10. 
144 See endnote 332 
145 Nies, P. Auswirkungen des Off-Label -, Unlicensed- & Compassionate-use auf das System der 
Arzneimittelzulassung sowie auf die Qualitaet der Arzneimitteltherapie und –versorgung Bonn: 
Rheinische Friedrich-Wilhelms-Universitaet, 2006; available from 
http://home.arcor.de/schweim.privat/Nies.pdf; Internet; accessed February 13, 2009. 
146 Harvey, E. D. et al. "Early/Expanded Access Provisions for Unapproved/Investigational Medical 
Devices.": Food and Law Institute, April 08, 2005; available from 
http://www.fda.gov/cdrh/present/fdli-apr05-harvey/index_files/textonly/slide1.html; Internet; 
accessed May 05, 2009. 
147 Jassal, SS. et al. Basic symptom control in paeditric palliative care- The rainbows children’s 
hospice guidelines; available from http://www.act.org.uk/dmdocuments/Microsoft_Word_-
_2008_Symptom_Control_Manual.pdf; Internet; accessed February 13, 2009. 
148 Conroy, S. et al. "Unlicensed and off-label drug use: issues and recommendations." Paediatric 
drugs 4, no. 6 (2002): 353–59. 
149 Turner, S. et al. "Unlicensed and Off-label Drug Use in Australia." Paediatric and perinatal drug 
therapy 4, no. 1 (2000): 24. 
150 Kay, L. et al. "Pharmaproduce innovative products- patients can’t access them." Autumn 
Symposium 2007 of the Guild of Healthcare pharmacists; available from 
www.ghp.org.uk/ContentFiles/ghppdig0711a.ppt; Internet; accessed February 13, 2009. 
151 Scottish Quality Assurance Specialist Interest Group. "Guidelines on unlicensed medicines 
(‘specials’)." (2001); available from 
www.astcp.scot.nhs.uk/QASIG/QASIG%20Specials/Specials.doc; Internet, accessed February 13, 
2009. 
Bibliography 
149 
 
                                                                                                                                                                  
152 Cancer Network Pharmacists Forum & British Oncology Pharmacy Association. Joint Position 
Statement on Access to Unlicensed Drugs Outside of Clinical Trials Cancer Network Pharmacists 
Forum & British Oncology Pharmacy Association, 2006; available from www.bopawebsite.org/tiki-
download_file.php?fileId=10; Internet; accessed December 13, 2009. 
153 Hill, R. and Box, J. Unlicensed medicines policy CNWL NHS Foundation Trust, 2008. 
154 Federal Constitutional Court BvR 1071/95. March 05, 1997.* 
155 Federal social court B 1 KR 19/96. July 23, 1998.* 
156 Blumer, JL. et al. "Off-Label Uses of Drugs in Children." Pediatrics 104, no. 3 (1999): 598–602. 
157 Hanna, K. et al. "Intravenous immune globulin use in Canada." The Canadian journal of clinical 
pharmacology 10, no. 1 (2003): 11–16. 
158 Parisse-Brassens, J. et al. Survey: 4th Eurordis Survey on Orphan Drugs Availability in Europe 
(2007) EurOrDis, 2007; available from http://www.eurordis.org/article.php3?id_article=1644; 
Internet; accessed February 14, 2009. 
159 Jensen, V. et al. An Overview of the FDA’s Drug Shortage Program P&T, 03.2005; available 
from http://www.ptcommunity.com/ptjournal/fulltext/30/3/PTJ3003174.pdf; Internet; accessed 
February 14, 2009. 
160 O'day, M. et al. "Availability of Immune Globulin Intravenous for Treatment of Immune Deficient 
Patients -- United States, 1997-19." MMWR 48, no. 8 (1999): 159–62, accessed February 14, 2009; 
available from http://www.cdc.gov/mmwr/preview/mmwrhtml/00056604.htm; Internet. 
161 Hartnell, GG. and Gates, J. "The case of Abbokinase and the FDA: the events leading to the 
suspension of Abbokinase supplies in the United States." J Vasc Interv Radiol 11, no. 7 (2000): 
841–47. 
162 Arrowsmith, JE. et al. "Shortage of isoproterenol (isoprenaline) hydrochloride." British Journal of 
Anaesthesia 89, no. 3 (2002): 528, accessed February 14, 2009; available from 
http://bja.oxfordjournals.org/cgi/content/full/89/3/528; Internet. 
163 Medicines and Healthcare products Regulatory Agency. Global shortage of acetonitrile: Advice 
to the pharmaceutical industry on changes requiring variation submissions to update Marketing 
Authorisations Internetdokument: Medicines and Healthcare products Regulatory Agency, 2009, 
January 26, 2009; available from 
http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON036276; Internet; 
accessed February 25, 2009. 
164 t'Jong, GW. et al. "A Survey of the Use of Off-Label and Unlicensed Drugs in a Dutch Children's 
Hospital." Pediatrics 108, no. 5 (2001): 1089. 
165 Nahata, MC. et al. "Lack of Pediatric Drug Formulations." Pediatrics 104, no. 3 (1999): 607–09. 
166 Pientka, L. "Krebs + Alter = keine Hoffnung." Versorgungsforschung in der Onkologie. MEK-
Forum (Gebaeude 42): Universitaetsklinik zu Köln, September 10, 2008.  
167 Wedding, U. and Höffken, K. ""Go go-slow go-no go"." Der Onkologe 8, no. 2 (2002): 111. 
168 See endnote 166 
169 Jacoby, A. "Deutschlands Gesundheitsbranche geht es blendend - noch: Pharma & Co." 
Frankfurter Allgemeine Zeitung, January 29, 2007; available from 
http://www.faz.net/s/RubB1763F30EEC64854802A79B116C9E00A/Doc~E35D75FD46FE5421BB0
14973EA1BF365C~ATpl~Ecommon~Scontent.html; Internet, accessed February 14, 2009. 
Bibliography 
150 
 
                                                                                                                                                                  
170 Plate, V. et al. "Reducing Off-Label use in paediatrics by improving drug information: 
Comparative study of approvals of children’s medicines since 2001 and a database for approved 
children’s medicines." In . DIA 19th Annual EuroMeeting. Wien, 2007. Drug Information Journal: P-
273. 
171 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Leitlinie 
Sozialpaediatrie und Jugendmedizin:: Diagnostik und Therapie bei ADHS (Aufmerksamkeits-
Defizit-Hyperaktivitaets- Störung) 2001; available from http://www.helpster.de/groups/adhs/ADHS-
Leitlinien.pdf; Internet; accessed February 16, 2009.  
172 Anonymus. Das NRF im Kurzportraet Pharmazeutische Zeitung online, 2009; available from 
http://www.pharmazeutische-zeitung.de/index.php?id=2266; Internet; accessed February 16, 2009. 
173 Nunn, AJ. et al.  "Making medicines that children can take." Archives of disease in childhood 88, 
no. 5 (2003): 369. 
174 Brion, F. et al. "Extemporaneous (magistral) preparation of oral medicines for children in 
European hospitals." Acta Paediatrica 92, no. 4 (2003): 486–90. 
175 See endnote 292 
176 Feiden, K. and Pabel, HJ. Arzneimittelrecht (for Windows XP Professional). WVGmbH, Stuttgart. 
177 Zapf, T. "Standardzulassung." Swissmedic. Pharmacopoea Helvetica – Informationen und 
Visionen. Olten, Switzerland: Swissmedic, September 28, 2006; available from 
http://www.swissmedic.ch/bewilligungen/00487/00489/00491/index.html?lang=de&download=NHzL
pZeg7t,lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDdH16fmym162epYbg2c_JjKbNoKS
n6A--; Internet; accessed February 16, 2009. 
178 Medicines and Healthcare products Regulatory Agency. " Guidance Note 14 The supply of 
unlicensed relevant medicinal products for individual patients." available from 
http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON007547&RevisionS
electionMethod=Latest accessed June 29, 2009 
179 The Department of Health. "Medicines management in NHS Trusts: hospital medicines 
management framework."; available from 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH
_4072184; Internet, accessed February 16, 2009. 
180Greenwich NHS Teaching primary care trust. "Guidance for the use of unlicensed medicinal 
products and the use of medicines outside of their licensed indications." available from 
http://www.greenwichpct.nhs.uk/publications/file.aspx?int_version_id=2091, accessed June 29, 
2009 
181 Morecambe Bay NHS Primary care trust. "Policy for Off-label use of medicines." available from 
www.mbht.nhs.uk, accessed June 29, 2009 
182 Pennine Care NHS trust. "The use of licensed medicines outside the conditions of their product 
license." available from http://www.penninecare.nhs.uk/documents/2293.pdf, accessed June 29, 
2009 
183 Somerset Partneship NHS & Social Care Trust. "Policy for the use of unlicensed medicines." 
available from http://www.sompar.nhs.uk/pdf/Medicines%20Policy%20-
%20Appendix%204%20Policy%20for%20the%20Use%20of%20Unlicensed%20Medicines.pdf, 
accessed June 29, 2009 
Bibliography 
151 
 
                                                                                                                                                                  
184 Pharmacy Services South West Yorkshire Mental Health Trust. "Request for the supply of a 
medicine for an unlicensed (“off label”) indication." available from 
www.southwestyorkshire.nhs.uk/documents/326.pdf , accessed June 29, 2009 
185 The Dudley Group of hospital NHS trust. "Use of unlicensed medicines." (2003): 1–5; available 
from http://www.dudley.nhs.uk/sections/publications/documents/FOI24383864250.pdf; Internet, 
accessed February 16, 2009. 
186 See endnote 151  
187 Brighton and Hove City NHS Teaching Primary care trust. "Policy on prescribing and supply of 
unlicensed medicines or those used off-label." (2005): 1–11; available from 
http://www.brightonandhovepct.nhs.uk/healthprofessionals/clinical-
areas/prescribing/documents/BHCPCTUnlicensedmedicinespolicy2006.pdf; Internet, accessed 
February 16, 2009. 
188 NHS Lothian. "Policy for the use of unlicensed (and off label use) medicines in NHS Lothian." 
(2004). available from http://www.ljf.scot.nhs.uk/resources/unlicensed_medicines_policy.pdf 
accessed June 29, 2009 
189 NHS Fife Board by Fife Area Drug and therapeutics committee. "Policy for the Use of 
Unlicensed (and Off-label use) Medicines." (2006). available from 
www.fifeadtc.scot.nhs.uk/Unlicensed%20medicines%20policy.doc, accessed June 29, 2009 
190 Medicines Management of the Liverpool women’s NHS foundation trust. "Prescribing, Supply 
and use of unlicensed medicines." available from www.lwh.me.uk, accessed June 29, 2009 
191 Royal Pharmaceutical Society of Great Britain. "Records of Supplies of Unlicensed medicinal 
products." (11.2007): 1–2; available from http://www.rpsgb.org/pdfs/restoolsupplyunlic.pdf; Internet, 
accessed February 16, 2009. 
192 Royal Pharmaceutical Society of Great Britain. "The Use of Unlicensed Medicines in 
Pharmacy.": 1–9; available from http://www.rpsgb.org.uk/pdfs/factsheet5.pdf; Internet, accessed 
February 16, 2009. 
193 Central and North West London NHS Foundation trust. "Unlicensed Medicines Policy.": 1–11; 
available from http://www.cnwl.nhs.uk/uploads/Unlicensed_Medicines.pdf; Internet, accessed 
February 16, 2009. 
194 NHS Fife Board by Fife Area Drug and therapeutics committee. "Fife UMP database." In . NHS 
Fife Board by Fife Area Drug and therapeutics committee 
195 Townsend, P. et al. "Developing a database to manage use of unlicensed medicines." Hospital 
Pharmacist 13, no. 8 (2006): 299–300. 
196 Health Canada. "Guidance Document for Industry and Practitioners - Special Access 
Programme for Drugs." (2008); available from http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-
drogues/sapg3_pasg3-eng.php; Internet, accessed February 16, 2009. 
197 Health Canada. Special Access Request Form A 2008; available from http://www.hc-
sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/acces/sapf1_pasf1-eng.pdf; Internet; accessed 
February 16, 2009. 
198 Health Canada. Instructions for Completing the Application Form for Custom-Made Devices and 
Medical Devices for Special Access 2007; available from http://www.hc-sc.gc.ca/dhp-
mps/acces/md-im/sapmd_pasmd_inst_v2-eng.php; Internet; accessed February 16, 2009. 
Bibliography 
152 
 
                                                                                                                                                                  
199 Health Canada. Special Access Programme - Drugs 2002; available from http://www.hc-
sc.gc.ca/dhp-mps/acces/drugs-drogues/sapfs_pasfd_2002-eng.php; Internet; accessed February 
16, 2009. 
200 Ibid.   
201 Health Canada. Single-Patient Access to Non-marketed Therapeutic Drugs 2007; available from 
http://26448.vws.magma.ca/dhp-mps/homologation-licensing/docs/exception/exception02-eng.php; 
Internet; accessed February 16, 2009. 
202 BC Cancer Agency Systemic Therapy Update 10 (7); available from 
http://www.bccancer.bc.ca/HPI/stupdate.htm; Internet; accessed February 16, 2009. 
203 "Marketing Authorization Procedures (Canada): Temporary Use authorization (compassionate 
use/emergency use)." Thomson Reuters, 02.2007. 
204 Health Canada. Health Canada’s Special Access Programme (SAP) Instructions for Making a 
Special Access Future Use Request FORM B 2008; available from http://www.coalition-nationale-
714x.com/pas_formb_en.pdf; Internet; accessed February 16, 2009. 
205 Der Institutsrat des Schweizerischen Heilmittelinstituts. "Verordnung des Schweizerischen 
Heilmittelinstituts über die vereinfachte Zulassung von Arzneimitteln und die Zulassung von 
Arzneimitteln im Meldeverfahren." AS 2006 3623; available from 
http://www.admin.ch/ch/d/sr/8/812.212.23.de.pdf; Internet, accessed February 16, 2009. 
206 Swissmedic. Erlaeuterungen zur Befristeten Zulassung von Arzneimitteln gegen 
lebensbedrohende Krankheiten* (Art. 18 – 22 VAZV) 2007; available from 
http://www.swissmedic.ch/org/00064/00067/00331/00632/index.html?lang=en&download…JjKbNoK
Sn6A; Internet; accessed February 16, 2009. 
207 Anonymus. Erlaeuterungen zur Befristeten Zulassung von Arzneimitteln gegen 
lebensbedrohende Krankheiten* (Art. 18 – 22 VAZV) Swissmedic, 2006; available from 
http://www.swissmedic.ch/org/00064/00065/00318/index.html?download=NHzLpZeg7t; Internet; 
accessed February 16, 2009. 
(http://www.swissmedic.ch/files/pdf/09_2006.pdf October 2008 
208 Anonymus. "Humanarzneimittel."; available from 
http://www.swissmedic.ch/daten/00081/index.html?lang=de&download=NHzLpZeg7t,lnp6I0NTU042
l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDdH55fGym162epYbg2c_JjKbNoKSn6A--; Internet, 
accessed February 16, 2009. 
209 Swissmedic. "Geschaeftsbericht." 2005; available from 
http://www.swissmedic.ch/org/00064/00066/00323/index.html?lang=de&download=NHzLpZeg7t,lnp
6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDdIF3f2ym162epYbg2c_JjKbNoKSn6A--; 
Internet, accessed February 19, 2009. 
210 "Regeln der Guten Herstellungspraxis in kleinen Mengen." In Ph.Helv., vol. 10 available from 
http://www.swissmedic.ch/bewilligungen/00009/00082/index.html?lang=de&download=NHzLpZeg7t
,lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCDdH9_gGym162epYbg2c_JjKbNoKSn6A-- 
accessed June 29, 2009 
211 Swissmedic. "Sonderbewilligung für einen Einsatz im Einzelfall." In ; available from 
http://www.lamprene.com/uploads/media/swissmedic_form.pdf; Internet, accessed February 16, 
2009 
Bibliography 
153 
 
                                                                                                                                                                  
212 Swissmedic. Sonderbewilligung für Compassionate Use; available from 
http://www.spitalpharmazie-
basel.ch/dienstleistungen/pdf/Formular_Sonderbewilligungen_Compassionate%20Use.pdf; Internet. 
213 Czank, A. Swissmedic Swiss Agency for Therapeutic Products. Sonderbewilligung. E-Mail to 
Vanessa Plate. Bern. May 07, 2009. 
214 Gesellschaft Schweizer Amts- und Spitalapotheker (GSASA). Voraussetzungen für die 
Zusammenarbeit unter Spitalpharmazien: Rechtsgutachten vom 6. April 2004 Bern: Pharmalex 
GmbH, 2004; available from http://files.hplus.ch/pages/HPlusDocument4622.pdf; Internet; 
accessed June 25, 2009. 
215 Nationalrat. "Arzneiwareneinfuhrgesetz." Bundesgesetzblatt für die Republik Österreich (2002); 
available from 
http://www.argepgh.at/kwpc_Downloads/Pharmarecht%20%D6sterreich/Arzneiwareneinfuhrgesetz.
pdf; Internet, accessed February 16, 2009.  
216 See endnote 159 
217 National Cancer Institute. A Manual for Participants in Clinical Trials of Investigational Agents 
Sponsored by DCTD, NCI 2002; available from 
http://ctep.cancer.gov/investigatorResources/docs/hndbk.pdf; Internet; accessed February 16, 
2009. 
218 Shoemaker, D. et al. "Access to Investigational Agents for Patients Unable to Participate in 
Clinical Trials." Workshop on Pediatric Oncology Drug Development. Advisors and Consultants 
Conference Room at 5630 Fishers Lane, Rockville, MD: FDA, July 18, 2002; available from 
www.fda.gov/cder/cancer/presentations/shoemaker.ppt; Internet; accessed February 16, 2009. 
219 See endnote 17  
220 Akbarian, GS. "Fragen zum Thema Compassionate-Use." Besuch der japanischen Delegation. 
Bonn: BfArM, January 29, 2008. 
221 Schwarz, G. "Fragen zum Thema GCP-Inspektion." Besuch der japanischen Delegation. Bonn: 
BfArM, January 29, 2008. 
222 See endnote 142 
223 Horen, B. et al. "Adverse drug reactions and off-label drug use in paediatric outpatients." British 
journal of clinical pharmacology 54, no. 6 (2002): 665. 
224 Autret-Leca, E. et al. "L'enfant et les médicaments: application à la prescription en pédiatrie." 
Archives de pédiatrie 13, no. 2 (2006): 181. 
225 See endnote 88 
226 Altenstetter, C. et al. "Regulatory Governance of Medical Devices in the European Union 
beyond Theories of European Integration." 5th European Conference on Health Economics 
London, 8-11.092004; available from 
http://158.143.192.210/collections/LSEHealth/ResearchNetworks/EHPGSEPTEMBER2004/EHPG3
Altenstetter.doc; Internet, accessed February 16, 2009. 
227 Beckmann, J. "Arzneimittelrisiken: Seminar 6 (12 h)." Weiterbildungsseminare im Gebiet 
Arzneimittelinformation. Munich: Bayerische LAK, May 11, 2007.  
228 See endnote 176 Teil A1.0 § 5 Anmerkungen zu Absatz 2 (20.) 
229 European Medicines Agency. "Regulation (EC) No 1901/2006 of the European Parliament and 
of the Council of 12 December 2006 on medicinal products for paediatric use." Official Journal of 
Bibliography 
154 
 
                                                                                                                                                                  
the European Union; available from http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-
1/reg_2006_1901/reg_2006_1901_en.pdf; Internet, accessed February 16, 2009. 
230 European Medicines Agency, "Meeting highlights from the Committee for Medicinal Products for 
Human Use, 20-23 October 2008," press statement, October 24, 2008; available from 
http://www.emea.europa.eu/pdfs/human/press/pr/55020608en.pdf; Internet, accessed February 16, 
2009. 
231 Task-force in Europe for Drug Development for the Young (TEDDY): European Paediatric 
Medicines Database (EPMD) 16.02.2009, February 16, 2009; available from 
http://www.teddyoung.org/index.php; Internet. 
232 Medicines and Healthcare products Regulatory Agency. The Blue Guide Norwich, 2005; 
available from http://www.mhra.gov.uk/home/groups/pl-
a/documents/websiteresources/con007552.pdf; Internet; accessed February 16, 2009. 
233 Medicines and Healthcare products Regulatory Agency. Paediatric Medicines Expert Advisory 
Group of the Commission on Human Medicines 2009, February 16, 2009; available from 
http://www.mhra.gov.uk/Committees/Medicinesadvisorybodies/CommissiononHumanMedicines/Ex
pertAdvisoryGroups/PaediatricMedicines/index.htm; Internet. 
234 Yeates, N. et al. "Health Canada's Progressive Licensing Framework." CMAJ 176, no. 13 
(2007): 1845. 
235 See endnote 196 
236 Japan Pharmaceutical Manufacturers Association. "Pharmaceutical Administration and 
Regulations in Japan." Tokyo, 11.2005: 23, 29; available from 
http://www.jpma.or.jp/english/parj/pdf/2006.pdf; Internet, accessed February 16, 2009. 
237 Schweizerische Gesellschaft der Vertrauens- und Versicherungsaerzte. Empfehlungen im off-
label-use 16.02.2009, February 16, 2009; available from 
http://www.vertrauensaerzte.ch/expertcom/oncology/recommendations.html; Internet.  
238 Österreichische Gesellschaft für Dermatologie und Venerologie. BidDbase: Biologicals in der 
Dermatologie off-label 16.02.2009, February 16, 2009; available from http://www.biddbase.at/; 
Internet. 
239 Bélorgey, C. "Temporary Authorisations for Use (ATU)." 06.2001. 
240 FDA. Early/Expanded Access 2003; available from 
http://www.fda.gov/CDRH/devadvice/ide/early.shtml; Internet; accessed February 16, 2009. 
241 Dickenson, JG. "FDA's off-label guidance may be up for review." Washington insider, March 13, 
2009; available from http://www.mmm-online.com/FDAs-off-label-guidance-may-be-up-for-
review/article/129910/; Internet, accessed June 16, 2009. 
242 "Medicare expands coverage of off-label cancer treatments." DIA communications 27.01.2009. 
243 See endnote 15 
244 See endnote 16 
245 AOK. Aktuelle Informationen zum Thema Onkologie: 9/06 Anlage 9 (off-label-use) des 
Abschnitts H der Arzneimittelrichtlinien im Bundesanzeiger veröffentlicht; available from 
http://www.aok-beratungsapotheker.de/redirect.html?http://www.aok-
beratungsapotheker.de/11_aktuelles/OnkologieAktArchiv.htm; Internet; accessed February 16, 
2009. 
246 Deutsche Gesellschaft für Gynaekologie und Geburtshilfe. Anwendung von Prostaglandinen in 
Geburtshilfe und Gynaekologie: AWMF 015/031 (SI) 08.2008; available from 
Bibliography 
155 
 
                                                                                                                                                                  
http://neu.dggg.de/_download/unprotected/g_03_03_02_anwendung_prostaglandinen_geburtshilfe_
gynaekologie.pdf; Internet; accessed February 16, 2009.  
247 Straeter, B. "Haftung und Verantwortung nach dem AMG." Spezielle Rechtsgebiete für 
Apotheker. Bonn: Rheinische Friedrich-Wilhelms-Universitaet Bonn; available from 
http://www.pharma.uni-bonn.de/fachgruppe/html/skripte.php; Internet; accessed February 16, 2009. 
248 See endnote 176  
249 See endnote 176 
250 See endnote 176 
251 Völler, R. "Off-label Use und Compassionate Use in der Dermatologie." Dermotopics, no. 03 
(2001).  
252 Bundesministerium für Gesundheit. "Gesetz zur AEnderung des Arzneimittelgesetzes und 
anderer Vorschriften." (2008); available from 
http://www.bmg.bund.de/cln_110/nn_1168258/sid_30F8EF599792099FB36F61F824A24DDB/nsc_t
rue/SharedDocs/Downloads/DE/GV/GT/Entwuerfe/publizierte-
Entwuerfe/Referentenentwurf__15.AMG__Novelle.html?__nnn=true; Internet, accessed February 
16, 2009. 
253 See endnote 176 
254 Namjoshi, S. et al. "A Primer om: Off-label marketing of pharmaceuticals." American Medical 
Student Association (2005). 
255 Fugh-Berman, A. and Melnick, D. "Off-Label Promotion, On-Target Sales." PLoS medicine 5, no. 
10 (2008): e210. 
256 Graves, DA. and Baker, RP. "The core curriculum for medical communications professionals 
practicing in the pharmaceutical industry." Drug Information Journal, no. 34 (2000): 995–1000. 
257 Iserson, KV. et al. "Politely Refuse the Pen and Note Pad: Gifts From Industry to Physicians 
Harm Patients." The Annals of thoracic surgery 84, no. 4 (2007): 1077. 
258 Steinman, MA. et al. "Characteristics and Impact of Drug Detailing for Gabapentin." PLoS 
medicine 4, no. 4 (2007): e134. 
259 Anderson, GM. et al. "Newly Approved Does Not Always Mean New and Improved." JAMA 299, 
no. 13 (2008): 1598. 
260 Rising, K. et al. "Reporting bias in drug trials submitted to the Food and Drug Administration: A 
review of publication and presentation." PLoS medicine 5, no. 11 (2008): e217. 
261 Sheldon, T. et al. "Focus on the Funding and Production of Evidence Rather Than Its 
Publication." PLoS medicine 2, no. 7 (2005): e222. 
262 See endnote 43 
263 Drug Information Association, "MSLs help drug companies legally discuss off-label uses.," June 
26, 2009; available from DIA.custombriefings.com; Internet, accessed June 26, 2009. 
264 Helm, KA. Protecting Public Health from Outside the Physician’s Office: A Century of FDA 
Regulation from Drug Safety Labeling to Off-Label Drug Promotion Fordham University, 2007; 
available from http://law.fordham.edu/publications/article.ihtml?pubID=200&id=2578; Internet; 
accessed February 16, 2009.  
265 Rowley, BR. and Van Harrison, R. "Professionalism and Gifts to Physicians from Industry." 
American Medical Association (2003): 2, accessed February 16, 2009; available from 
http://www.ama-assn.org/ama1/pub/upload/mm/437/ama_m3_pg.pdf; Internet. 
266 Ratner, M. and Gura, T. "Off-label or off-limits?". Nature biotechnology 26, no. 8 (2008): 867. 
Bibliography 
156 
 
                                                                                                                                                                  
267 Bratulic, A. "Proposed U.S. bill would require drugmakers to disclose payments to doctors of 
$100 or more." FirstWord, 2009; available from 
http://www.firstwordplus.com/Fws.do?articleid=FA2C4D75CEE04D7EAA3A9B566332BB06; 
Internet, accessed February 16, 2009.  
268 See endnote 266 
269 "Corporate integrity agreement between the office of inspector general of the department of 
health and human services and Bristol-Myers Sqibb company.": 10, 25ff, 29ff, 43, 68 
270 DIA Communications, "Lawmakers may take action to reverse FDA guidelines on off-label drug 
use," press statement, February 02, 2009. 
271 Schweim, HG. "Praeklinische Studien in der Entwicklung und Zulassung von Arzneimitteln." 
Rheinische Friedrich-Wilhelms-Universitaet Bonn. Drug Regulatory Affairs, Masterstudiengang 
Drug Research. Bonn: Pharmazeutisches Institut Bonn, June 10, 2009. 
272 See endnote 129 
273 Heijmans, T. Aut idem Substitution. E-Mail to V. Plate. Starnberg. November 06, 2006. 
274 "Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine 
AEnderung der Arzneimittel-Richtlinie: Aktualisierung von Festbetragsgruppen Makrolide, neuere, 
Gruppe 1, in Stufe 2." 16.08.2007; available from http://www.g-ba.de/downloads/40-268-438/2007-
08-16-AMR2-Makrolide1_TrGr.pdf; Internet, accessed February 16, 2009. 
275 Medicines and Healthcare products Regulatory Agency. Delivering High Standards in Medicines 
Advertising Regulation - Annual Report September 2007 – August 2008 2008; available from 
http://www.mhra.gov.uk/Howweregulate/Medicines/Advertisingofmedicines/index.htm; Internet; 
accessed February 16, 2009. 
276 Gerver, K. "U.K. Medical experts to recommend gift ban for pharmaceutical companies." 
FirstWord, January 30, 2009. 
277 DeMonaco, HJ. Innovative Diagnostics and Therapeutics Committee. E-Mail to V. Plate. Boston. 
January 20, 2009. 
278 IDIS: managing named-patient medicines; available from www.idispharma.com; Internet; 
accessed February 16, 2009. 
279 Orphanet: The portal for rare disease and orphan drugs. Orphanet database of orphan drugs; 
available from http://www.orpha.net; Internet; accessed February 16, 2009. 
280 National Organization for Rare Disorders. NORD: Orphan Drug database; available from 
www.rarediseases.org; Internet; accessed February 16, 2009. 
281 See endnote 237 
282 See endnote 208 
283 See endnote 238 
284 U.S. Food and Drug Administration. Treatment Investigational New Drugs (IND) Allowed to 
Proceed 2001; available from http://www.fda.gov/oashi/patrep/treatind.html; Internet; accessed 
February 16, 2009. 
285 U.S. Food and Drug Administration. List of Orphan Designations and Approvals 2008; available 
from http://www.fda.gov/orphan/designat/list.htm; Internet; accessed February 16, 2009. 
286 See endnote 231 
287 European Commission. Register of designated Orphan Medicinal Products (by number); 
available from http://ec.europa.eu/enterprise/pharmaceuticals/register/orphreg.htm; Internet; 
accessed February 16, 2009. 
Bibliography 
157 
 
                                                                                                                                                                  
288 Hexal- Initiative Kinderarzneimittel. Zugelassene Arzneimittel für Kinder ZAK(R); available from 
http://www.zak-kinderarzneimittel.de/; Internet; accessed February 16, 2009. 
289 Fritze, J. and Schmauß, M. "Off-Label-Use in der Psychopharmakotherapie." Psychoneuro 28, 
no. 8 (2002): 431–39. 
290 "Richtlinien des Bundesausschusses der AErzte und Krankenkassen über die Verordnung von 
Arzneimitteln in der vertragsaerztlichen Versorgung („Arzneimittel-Richtlinien“)." Bundesanzeiger, 
no. 181 (2008): 4261; available from http://www.g-ba.de/downloads/62-492-305/RL-AMR-2008-10-
16.pdf; Internet, accessed April 30, 2009. 
291 Verband Forschender Arzneimittelhersteller e.V. Orphan-Arzneimittel nach Indikationen; 
available from http://www.vfa.de/download/SHOW/de/politik/positionen/orphan-drugs.html/orphan-
drugs-list.pdf; Internet; accessed February 16, 2009. 
292 Enzmann, H. "Klinische Studien/Zulassung." Symposium des Pharma Zentrums Bonn: 
Bundesinstitut für Arzneimittel und Medizinprodukte, August 14, 2008; available from 
http://www.uni-bonn.tv/search?Subject_usage:ignore_empty=operator:and&Subject:list=Pharma-
Zentrum; Internet; accessed February 19, 2009. 
293 Laeer, S. "Europa und die Chancen für eine Kindgerechte Arzneimitteltherapie." 
Pharmazeutisches Kolloquium. Bonn: Rheinische Friedrich-Wilhelms-Universitaet Bonn, June 30, 
2008. 
294 "Losartan künftig auch für Kinder zugelassen." @rzneimittelnews, November 15, 2008. 
295 Elbers, R. "Orphan Drugs BfArM im Dialog: Wir in Europa.": Bundesinstitut für Arzneimittel und 
Medizinprodukte, October 09, 2001; available from 
http://www.bfarm.de/cln_029/nn_1232318/SharedDocs/Publikationen/DE/BfArM/publ/praesent/dialo
g__2001-2005/dialog-
011009/elbers__dialog,templateId=raw,property=publicationFile.pdf/elbers_dialog.pdf; Internet; 
accessed February 16, 2009. 
296 Laeer, S. et al. "Termination of automatic atrial tachycardia in an infant by adequate sotalol 
dosing. Indication of clinically relevant age-dependent pharmacokinetics of sotalol." European 
journal of clinical pharmacology 57, no. 2 (2001): 181–82. 
297 Laer, S. et al. "Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based 
on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular 
Tachycardia." Journal of the American College of Cardiology 46, no. 7 (2005): 1322. 
298 Aut-idem-Regelung: BMG haelt an extensiver Auslegung fest 2009; available from 
http://www.deutscher-apotheker-
verlag.de/daz_neu/public/tagesnews/Mai/tagesnews20090513a.html; Internet; accessed May 22, 
2009. 
299 Süverkrüp, R. "Rezeptur und Defektur: Möglichkeiten und Grenzen." Abteilung "Aus- und 
Fortbildung" AKNR. Bonn: Rheinische Friedrich-Wilhelms-Universitaet Bonn, September 09, 2008. 
300 Sickmüller, B. "Das BfArM im Dialog: Wir in Europa." Das BfArM im Dialog: Wir in Europa. Bonn: 
Bundesinstitut für Arzneimittel und Medizinprodukte, October 09, 2001; available from 
http://www.bfarm.de/cln_029/nn_1232318/SharedDocs/Publikationen/DE/BfArM/publ/praesent/dialo
g__2001-2005/dialog-
011009/sickmueller__dialog,templateId=raw,property=publicationFile.pdf/sickmueller_dialog.pdf; 
Internet; accessed February 16, 2009. 
Bibliography 
158 
 
                                                                                                                                                                  
301 Straeter, B. "Klinische Prüfung von Arzneimittel." Spezielle Rechtsgebiete für Apotheker. Bonn: 
Rheinische Friedrich-Wilhelms-Universitaet Bonn; available from http://www.pharma.uni-
bonn.de/fachgruppe/html/skripte.php; Internet; accessed February 16, 2009. 
302 See endnote 177 
303 "Marketing Authorisation Procedures (U.K.) Procedure for variation/changes/supplements." 
IDRAC(R), 03.2007. 
304 Shaddy, R. E. et al. "Carvedilol for Children and Adolescents With Heart Failure: A Randomized 
Controlled Trial." JAMA 298, no. 10 (2007): 1171. 
305 Laer, S. et al. "Carvedilol therapy in pediatric patients with congestive heart failure: A study 
investigating clinical and pharmacokinetic parameters." The American Heart Journal 143, no. 5 
(2002): 916. 
306 Albers, S. et al. "Population pharmacokinetics and dose simulation of carvedilol in paediatric 
patients with congestive heart failure." British Journal of Cinical Pharmacology 65, no. 4 (2008): 
511. 
307 See endnote 293 
308 Adebare, A. "Data Exclusivity: The Implications for India." (2005); available from 
http://www.articlealley.com/article_16562_18.html; Internet. 
309 Bücheler, R. et al. "Off-Label-Verordnungen in der Paediatrie." Bundesgesundheitsblatt, 
Gesundheitsforschung, Gesundheitsschutz 46, no. 6 (2003): 467. 
310 Bundesverband Niedergelassener Diabetologen e.V. Bericht des Hauptgeschaeftsführers über 
seine Taetigkeit im Zeitraum vom 09.Februar bis 09. Mai 2002 Bundesverband Niedergelassener 
Diabetologen e.V; available from http://www.bvnd.de/download/taetigkeitsbericht052002.pdf; 
Internet; accessed November 17, 2008. 
311 Deitermann, B. et al. "Mehr Qualitaet in der Arzneimitteltherapie." Gesellschaft für 
Arzneimittelanwendungsforschung und Arzneimittelepidemiologie e.V., October 17, 2003. 
312 The European Parliament and the Council of the European Union. "Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004." Official Journal of the 
European Union (2004); available from http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf; Internet, accessed February 13, 2009. 
313 The European Parliament and the Council of the European Union. "Directive 2001/83/EC of the 
European Parliament and of the Council 6 November 2001." Official Journal of the European Union 
(2001); available from http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-
1/dir_2001_83_cons/dir2001_83_cons_en.pdf; Internet, accessed February 13, 2009. 
314 Schwarz, JA. et al. "Therapieversuche mit nicht zugelassenen Prüfsubstanzen 
(Compassassionate use) and zugelassenen Arzneimitteln (Off-label Use)." Pharm. Ind. 61, no. 4 
(1999): 309. 
315 Barnscheid, L. et al. "Kindgerechte Arzneizubereitungen mit diuretischen Wirkstoffen." 
Dissertation, Heinrich-Heine-Universitaet Düsseldorf, Düsseldorf, 11.2007; available from 
http://docserv.uni-duesseldorf.de/servlets/DerivateServlet/Derivate-6929/Barnscheid-Diss.pdf; 
Internet, accessed February 13, 2009. 
316 Thaler, M. and Plank, M-L. Heilmittel und Komplementaermedizin in der Krankenversicherung. 
Wien: Manz, 2005. 
Bibliography 
159 
 
                                                                                                                                                                  
317 "Compassionate Use." AGES. Anwendungsbeobachtung und Compassionate Use: AGES, 
November 29, 2007; available from 
http://www.basg.at/web/ages/content.nsf/73b5f92ac245b957c1256a9a004e1676/c79a7cc9ba97cb0
6c1257367003d0a5e/$FILE/Compassionate%20Use.pdf; Internet; accessed February 13, 2009. 
318 Anonymus. Référentiels nationaux pour un bon usage des médicaments onéreux et innovants 
Afssaps, 2007; available from http://www.e-
cancer.fr/v1/fichiers/public/dp_medicaments_innovants_260307.pdf; Internet; accessed February 
13, 2009. 
319 Chalumeau, M. et al. "Off label and unlicensed drug use among French office based 
paediatricians." Archives of disease in childhood 83, no. 6 (2000): 502. 
320 See endnote 7 
321 Anonymus. Your medicines – useful sources of information BMA, 2007; available from 
http://www.bma.org.uk/ap.nsf/Content/Youmedicinesusefulsourcesofinformation.jsp; Internet; 
accessed February 13, 2009. 
322 Royal Pharmaceutical Society of Great Britain. Standards and Guidance Documents to support 
the revised Code of Ethics Royal Pharmaceutical Society of Great Britain, 2007; available from 
http://www.rpsgb.org.uk/pdfs/coun0706-C-54.pdf; Internet; accessed February 13, 2009. 
323 Nunn, T. et al. Medicines: Tried And Tested - In Children? The Association of the British 
Pharmaceutical Industry; available from 
http://www.abpi.org.uk/publications/publication_details/mttur/mttur_children.asp; Internet; accessed 
February 13, 2009. 
324 Ibid. 
325 Moremcambe Bay NHS Primary care trust. "Policy for the Off-label use of medicines." 
Moremcambe Bay NHS Primary care trust, 06.2004. 
326 See endnote 7 
327 Medicines and Healthcare products Regulatory Agency. Medicines that do not need a licence 
(Exemptions from licensing) Medicines and Healthcare products Regulatory Agency; available from 
http://www.mhra.gov.uk/Howweregulate/Medicines/Doesmyproductneedalicence/Medicinesthatdon
otneedalicence/index.htm; Internet; accessed February 13, 2009. 
328 National Institute for Health and Clinical Excellence. Ranibizumab and pegaptanib for the 
treatment of age-related macular degeneration: a systematic review and economic evaluation 
National Institute for Health and Clinical Excellence, 2006; available from 
http://www.nice.org.uk/nicemedia/pdf/PegaptanibRanbizumabAssessmentReport.pdf; Internet; 
accessed February 13, 2009. 
329 Lamb, L. and Biffignande, PM. "Review 2001:The future of European pharmaceutical 
legislation." Drug Information Journal, no. 36 (2002): 899–907. 
330 See endnote 88 
331 Collier, J. et al. "Paediatric prescribing: using unlicensed drugs and medicines outside their 
licensed indications." British journal of clinical pharmacology 48, no. 1 (1999): 5. 
332 European Medicines Agency. "Guideline on conduct of Pharmacovigilance for medicines used 
by the paediatric population." Official Journal of the European Union (2007); available from 
http://www.emea.europa.eu/pdfs/human/phvwp/23591005enfinal.pdf; Internet, accessed February 
13, 2009. 
Bibliography 
160 
 
                                                                                                                                                                  
333 Behles C. "Off-label use und Arzneimittelzulassung." Colloquium Pharmaceuticum GmbH. Off-
label/no-label-use und Studien in der GKV. Bonn, April 19, 2007. 
334 Steurer, M. et al. "Low-Dose Thalidomide for Multiple Myeloma: Interim Analysis of a 
Compassionate Use Program." Onkologie 27, no. 2 (2004): 150. 
335 See endnote 332 
336 See endnote 50 
337 Die Bundesbehörden der Schweizerischen Eidgenossenschaft. "Bundesgesetz vom 15. 
Dezember 2000 über Arzneimittel und Medizinprodukte." Art. 9 Abs. 2; available from 
http://www.admin.ch/ch/d/sr/8/812.21.de.pdf; Internet, accessed February 13, 2009. 
338 BGE 130 V 532 Erw. 6  
339 BGE 131 V 349 Erw. 3 
340 Swissmedic. Faktenblatt: Kinder und Arzneimittel: Situation heute Swissmedic, 2005; available 
from http://www.swissmedic.ch/files/pdf/Merkblatt_Arzneimittel_fuer_Kinder.pdf; Internet; accessed 
December 15, 2008. 
341 Ibid. 
342 Jagger, S. F., and U.S. Prescription drugs: implications of drug labeling and off-label use: 
Statement of Sarah F. Jagger, Director of Health Services Quality and Public Health Issues, Health, 
Education, and Human Services Division before the Subcommittee on Human Resources and 
Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of 
Representatives / United States General Accounting Office GAO, 1996; available from 
<http://purl.access.gpo.gov/GPO/LPS12207>; Internet; accessed February 13, 2009. 
343 Former, M. J. et al. "The Ins & Outs of Compassionate Use Programs." Oncology Times (2005): 
10, 12-14. 
344 Mintzes, B. et al. Drug regulatory failure in Canada: The case of Diane-35 Canada: Women and 
Health Protection, 2004; available from http://www.whp-apsf.ca/pdf/diane35.pdf; Internet; accessed 
February 13, 2009. 
345 PMSB/ELD. "Notification Nr. 104." PMSB/ELD, February 01, 1999. 
